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Abstract 
Deletions of the long arm of chromosome 6 are a recognised recurrent cytogenetic 
abnormality associated with ALL. Balanced rearrangements of 6q are less common but occur 
in leukaemias of both lymphoid and myeloid origin. With the aim of identifying genes that 
contribute to leukaemia through loss or rearrangement the breakpoints of translocations and 
deletions of 6q were mapped by FISH. Comparison between the mapped deletions led to the 
identification of a 4.8 Mb CDR and candidate tumour suppressor gene (GluR-6). Expression 
of GluR-6 was demonstrated to occur in haernatologic tissues and mutation analysis was 
performed on leukaemic samples with clonal deletions of the region. In one of 14 cases a 
base pair substitution that led to a change in amino acid sequence was found. The base pair 
substitution was also present in the patients' remission sample but was not seen in any of 20 
other normal bone marrow samples analysed. Analysis of the translocations identified a 
variety of breakpoints between 6q15 and 6q27, with none positioned within the CDR. In 
seven cases breakpoints clustered within a 14 Mb region of 6q22-q23 but different sub- 
regions were defined for five analysed in detail. Complex rearrangements in one case of ALL 
appeared to result in translocation of one homologue of 6q and deletion of the second. 
Detailed FISH analysis defined a translocation breakpoint falling between two PACs that 
contained exons of a known tumour suppressor gene, the IGF2-R. Southern blot analysis 
failed to confirm disruption of the IGF2-R, but an IGF2-R-Afl? P8 fusion transcript was 
cloned by RACE PCR from the patients' c-DNA. Involvement of MRP8 in the translocation 
remains in doubt because attempts to confirm the presence of the fusion transcript were 
unsuccessful. 
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Chapter I (Introduction) 
Cytogenetic rearrangements of the long arm of chromosome 6 frequently accompany 
malignant transformation of a number of tissues including breast, liver, and the urinogenital, 
nervous, endocrine and haematopoietic systems. Four genes on 6q have been cloned from 
leukaemia- associated translocations, while other balanced rearrangements are as yet 
uncharacterised. Among malignancies of lymphoid origin, deletions of 6q are common and it 
is widely assumed that loss of one or more tumour suppressor genes underlie these 
abnormalities. The principle aim of this study is to identify genes on 6q that contribute to 
haematopoietic malignancy through loss or rearrangement. 
Section 1.1 of this chapter provides a broad overview of the genetic changes that accompany 
malignancy, concentrating on common features rather than details of specific diseases. Next, 
normal blood cell development, with emphasis placed on the lymphoid and myeloid lineages, 
has been briefly described (1.2). The classification of leukaemia is dealt with in section 1.3 
and associated cytogenetic changes are described in section 1.4. Taking specific, well 
researched examples to illustrate important general principles, the molecular consequences of 
the cytogenetic rearrangements are also discussed. In section 1.5 the classical tumour 
suppressor gene model and related concepts are described. Cytogenetic and molecular 
investigations of 6q that form the background to this project are covered in 1.6 and 1.7. 
1.1 The Genetic Basis of Malignancy. 
It is now widely accepted that progression from a normal cell to a malignant clone is 
accompanied by the accumulation of genetic changes. That alterations to DNA played a 
significant role in carcinogenesis was long suspected because exposure to mutagenic 
chemicals also resulted in tumour formation in animals and man. Further support for the 
hypothesis came from the demonstration that a single gene from the rous sarcoma virus (src) 
could transform cells in vitro'. Subsequently it was demonstrated that fragments of DNA 
13 
from a human cancer, transfected into mouse NIH-3T3 cells, also induced the phenotypic 
changes associated with malignancy. The recovered transforming DNA was found to encode 
a mutated form of the HA-ras gene 2. In the same fashion, other genes were implicated in 
malignancy and in their mutated and non-mutated forms respectively were termed oncogenes 
and proto-onco genes. 
A second line of evidence supporting the involvement of specific genes in the development 
of malignancy came from the analysis of banded metaphase chromosomes from human 
cancers. The Philadelphia (Ph) translocation [t(9; 22)(q34; ql 1)] was found consistently in 
bone marrow cells from chronic myeloid leukaemia patients 3,4 . Following this discovery, 
other translocations have been associated with a wide range of different malignancies5. 
Molecular analysis of the break points of translocations lead to the identification of new 
proto-oncogenes that were activated through two basic mechanisms. First, ectopic or up- 
regulated gene expression could result from the replacement of wild type with novel 
regulatory sequences. Secondly, fusion of coding sequence from two different genes resulted 
in production of chimeric proteins with transforming propertieS6. 
Oncogenic proteins resulting from mutation or chromosomal rearrangements can be thought 
of as possessing dominantly acting gain of function properties. Because a single change of 
this type transformed NIH 3T3 cells, it was at first thought that just one mutation could cause 
human cancer. However, non-transfected NIH 3T3 cells are now thought to harbor mutations 
that contribute to a pre-malignant state. Etiological studies and evidence from animal models 
suggest that at least 4 to 6 different mutations are required for the development of most 
cancers 7. Full malignant transformation depends on the acquisition of an appropriate 
combination of gain of function but also loss of function genetic changes. Loss of function 
mutations affect tumour suppressor genes (tsgs) that in the wild type form encode proteins 
that constrain neoplastic expansion. Tsgs were first recognised when inherited inactivating 
mutations of the Rb gene were found to be unmasked by tumour-associated deletions of 
chromosome 13 in cases of familial retinoblastoma 8. 
14 
Although certain translocations or mutations are strongly associated with or even diagnostic 
for a specific disease, apparently identical malignancies often have very different profiles of 
underlying genetic abnormalities. The range of known cancer related abnormalities at the 
cytogenetic and DNA sequence level is now huge. Paradoxically with growing appreciation 
of this genetic heterogeneity has come the realization that the functional consequences of the 
mutations involve the acquisition of only a small number of changes in cellular physiology 
(reviwed by Hanahan D. and Weinberg R. A. 9). 
It has been suggested that malignant cell growth is associated with disruption to a relatively 
small number of regulatory circuits governing the acquisition of only the six following 
essential cellular characteristics: 1) self-sufficiency in growth signals; 2) insensitivity to 
growth inhibitory signals; 3) evasion of apoptosis; 4) limitless replicative potential; 5) 
sustained angiogenesis and 6) tissue invasion and metastasis. 
Of the six characteristics listed above two, (sustained angiogenesis and tissue invasion and 
metastasis), are of less relevance to leukaemias than to solid turnours and will not be covered 
in this thesis. Although signaling pathways contributing to the remaining characteristics are 
often difficult to place within one of the categories alone, the above classification will be 
used as a framework for a general discussion of malignancy. An additional type of mutation, 
that increases the rate of acquisition of the six types of change, will also be considered 
(1.1.5). 
1.1.1 Self-sufficiency in growth signals. 
Normal cells require mitogenic growth signals for active proliferation to occur. The signals 
are transmitted into the cell by transmernbrane receptors that are, either tyrosine kinases or 
coupled to G-proteinslo. The signalling molecules may be diffusible growth factors, 
extracellular matrix components or cell-to-cell interaction molecules. Neoplastic cells 
circumvent dependence on exogenous growth signals in a number of ways. Some turnours 
secrete their own growth factors, others upregulate or switch the type of transmembrane 
receptors produced making them hyper-responsive to low levels of growth factor' 1,12 
Structurally altered receptors that are Constitutively activated, have also been reported 13 . 
15 
Independence from growth factor control can also result from disruption of the complex 
signalling pathways that lie downstream of ligand activated growth factor receptors. A 
central component of these regulatory pathways is the SOS-Ras-Raf-MAPK cascade. 
Approximately 25% of tumours express structurally altered Ras proteins that release 
mitogenic signals in the absence of stimulation by their upstream regulators 14 .A second 
important growth factor regulated pathway involves activation of phosphatidylinositol 3- 
kinase (P13K). PUK, is activated not only by growth factors but also by Ras, and plays an 
anti-apoptotic role (see 1.1.3) 
15 
. 
Activation of the growth factor regulated signal transduction pathways ultimately leads to the 
nuclear translocation of mitogen activated protein kinases (MAPKs) that phosphorylate and 
activate transcription factors governing growth and differentiation. The target genes may be 
general factors required for transition through the cell cycle such as the cellular cyclins and 
cyclin dependent kinases (detailed in 1.1.2) or may code for proteins that drive differentiation 
of a specific lineage. As it might be expected, autonomy from growth factor regulation can 
also result from mutations occurring at the transcription factor level. Translocations that 
generate oncogenes from lineage specific transcription factors, play a particularly prominent 
role among the acute leukaemias and will be discussed further in section 1.4. 
1.1.2 Insensitivity to growth inhibitory signals. 
The important growth and apoptotic pathways discussed in this section and in 1.1.3, are 
represented diagrammatically in Fig 1.1. 
Normal cell proliferation is regulated not only by positively acting growth factors but also by 
multiple growth inhibitory signals. Antigrowth signals block proliferation by two distinct 
mechanisms. Firstly, cells may be forced into a quiescent (Go) state from which they can 
reemerge and continue cycling upon stimulation by appropriate factors and secondly they can 
enter a state of terminal differentiation or senescence in which proliferative potential has 
been lost. 
16 
Pathways that allow normal cells to respond to anti-growth signals are centered on factors 
governing transition through the GI phase of the cell cycle. Most studied antiproliferative 
pathways are funneled through the retinoblastoma, protein (pRB) which when 
hypophosphorylated blocks proliferation by binding E2F transcription factors. The E2Fs 
regulate transcription of a variety of genes needed for GI to S phase transition. When bound 
to the E2Fs, pRB blocks transcription of their target genes by recruiting a histone de- 
acetylase. On phosphorylation, pRB is released from the E2Fs which then become positive 
16,17 regulator of cell cycle transition 
Phosphorylation of pRB is positively regulated by complexes of cyclin-D with cyclin 
dependent kinases 4 and 6 (CDK 4/6), and cyclin-E with CDK2. The ability of the cyclin- 
CDK complexes to form and phosphorylate pRB is antagonized by a series of CDK 
inhibitors known as INKs. Two of the best known INKs are p 15 
INK4B 
and p16 
INMA both of 
which perform a tumour suppressor function in a number of tissues 18,1 9. The cyclin E/CDK2 
complex is inhibited by WAF I (also known as p2 1) that is transcribed under the influence of 
p53, a well characterised tsg. p53 is also a critical regulator of genes involved in the 
induction of apoptosis (see 1.1.3), and the factors that cause p53 to induce cell cycle arrest in 
favor of apoptosis are at present uncertain. 
The RB gene itself was identified as a tsg in families that carried a point mutation of one 
allele and developed bilateral retinoblastomas in which loss of the second allele resulted from 
cytogenetically detectable deletions of chromosome 13 (see also 1.5). Mutations of RB have 
been found in some but not all other types of sporadic tumours and mice heterozygously 
inactivated for Rb develop pituitary adenomas 20 . The restricted range of tumours associated 
with RB mutations may in part be explained by a degree of functional redundancy between 
pRB and two related proteins, p 107 and p 13021. Cancer related inactivating mutations have 
been reported to occur in both additional RB family proteinS22. 
As mentioned in 1.1, exposure to growth factors prompts cells to enter S phase of the cell 
cycle in part by upregulating transcription of cyclins and CDKs- A second type of 
extracellular effector negatively regulates cell growth. Best studied of the antiproliferative 
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ligands that lead to pRB dephosphorylation is the transforming growth factor P (TGFP). 
TGFP causes synthesis of the p15 INK4B and p2l. proteins that block formation of the 
cyclin/CDK complexes responsible for pRb phosphorylation. Loss of function mutations of 
many genes in the TGFP signalling pathway, including the TGFP receptor, lead to human 
23,24 malignancies 
The pathways that lead to terminal differentiation are more diverse, tissue-specific and 
presently less well studied. One important mechanism for avoiding differentiation involves 
upregulation of the proto-oncogene c-myc that disrupts the balance between MYC-MAX and 
MAD-MAX protein complexes that in turn regulate the expression of differentiation 
signalS25 . The importance of disruption to lineage specific differentiation programs 
in 
leukemia is discussed in 1.4. 
1.1.3 Evasion of Apoptosis. 
Programmed cell death or apoptosis occurs in normal cells in response both to the balance 
between external death and survival signals and to intracellular factors which sense DNA 
damage, signal imbalance and other changes such as hypoxia. Cells bearing oncogenic 
mutations are routinely destroyed through apoptosis and the disruption of apoptotic pathways 
probably occurs in all malignancies. The majority, though not all, of known apoptotic signals 
are transduced by the important tsg p53. 
Loss of or inactivating mutations of p53 occur in about 70% of human malignancies and the 
remainder probably all have defects in genes functionally up or downstream of p53 26 . The 
high rate of cancer-associated mutation of p53 reflects its central role in eliminating the 
genetic damage that underlies malignant transformation. Either of two routes may be 
activated by p53 on sensing potentially oncogenic lesions to DNA. In the first, cell cycle 
arrest occurs (see 1.1.2) while DNA repair pathways are activated (see 1.1.5). In the second 
pathway, caspase activation and apoptosis are initiated. 
Central to the p53 pathway is a core regulatory circuit consisting of p53 itself, the 
ubiquitinating enzyme Mdm2, p14 
ARF 
and the E2FS27,28. Under normal circumstances 
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ubiquitination by Mdm2, maintains p53 at low levels by targeting it to the lysosomes for 
degradation. In turn, p53 exerts transcriptional control over the level of Mdm2. In a second 
feedback loop, the E2Fs activate p14ARF transcription and p14 ARF facilitates proteolytic 
degradation of the E2Fs. The two feedback loops are connected because p14 ARF inhibits 
Mdm2 mediated ubiquitination of p53 and p53 is a negative regulator of p14 ARF expression. 
Activation of a range of upstream sensors of DNA damage and some other pro-apoptotic 
signaling molecules, leads to post-translational modifications of p53 and/or Mdm2 that block 
ubiquitination of p53 and target it to the nucleus. Other pro-apoptotic signals, such as those 
transduced by activated oncogenes, indirectly regulate p53 through effects on transcription or 
ARF activity of p14 
The ultimate effectors of apoptosis are the caspases that selectively destroy subcellular 
structures, organelles and DNA. Many signals that cause apoptosis converge on the 
mitochondria inducing cytochrome C release and caspase 9 activation29. Both pro-apoptotic 
(Bax, Bak, Bid, Bim) and anti-apoptotic (Bcl-2, Bcl-XL, Bcl-W) members of the Bcl-2 
family of proteins, act by controlling cytochrome-C release. p53 upregulates Bax in response 
to DNA damage and other intracellular abnormalities. Cytochrome-C release can also occur 
independently of p53 activation upon binding of the FAS and TNF(X receptors by their 
ligands. Death signals are transduced by caspase-8 after the activated TNF-RI and FAS 
receptors complexed with FADD cleave pro-caspase 8. Caspase 8 itself, has been reported to 
be silenced in cases of childhood neuroblastoma 30 . 
Examples of extracellular ligands, that induce antiapoptotic (survival) signals are IGF- I and 
IGF-2, through the IGF-1 receptor, and IL-3 through the IL-3 receptor. Both these ligands 
and some intracellular signals via Ras stimulate the anti apoptotic P13 kinase-AKT/PKB 
pathway. Recently AKT has been shown to both activate Mdm2 and to prevent nuclear 
localization of p2l, linking it to both the core p53 regulatory circuit and to pRb mediated 
control of the cell cycle 31,32 . This pathway is also modified in many cancers and the multi- 
lineage tsg pTEN negatively regulates AKT survival signals 33 . 
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It should be emphasized that only selected, relatively well understood, aspects of the control 
of growth and apoptosis are presented here. Although much of the detailed circuitry of the 
apoptotic pathways remains to be elucidated, it is becoming increasingly clear that a high 
degree of functional redundancy exists between both regulatory and effector components. 
One expected consequence of this redundancy is that successive mutations affecting the 
components of apoptotic pathways will have additive tumourigenic effects. 
1.1.4 Limitless replicative potential. 
All of the acquired characteristics so far described lead to evasion of limitations on growth 
placed by external factors. However, almost all normal cells are also intrinsically limited in 
their replicative potential. This limitation arises because with each successive round of 
replication 50-100 base pairs of DNA are lost from the ends (telomeres) of each 
chromosome. Each telomere is capped by several thousand hexanucleotide repeats that form 
a looped structure protecting the chromosome end from degradation and recombination. 
Telomeric repeats are completely eroded after about 60-70 rounds of replication leading to 
recombination between chromosome ends and the formation of genetically unstable dicentric 
chromosomes. The consequent disruption to the genome normally results in cell death. 
Therefore, in order to replicate beyond a finite cell number, malignant clones have to evolve 
mechanisms that restore telomere stability. In most turnours the enzyme telomerase, which 
adds hexanucleotide repeats to telomeres, is upregulated 34 . 
1.1.5 Loss of DNA maintenance mechanisms. 
The pathways described in 1.1.1-1.1.4 include several tsgs that lie directly in the pathway of 
full malignant transformation and for this reason have been termed "gate keepers 99 35 . Loss of 
function of a second group of genes, sometimes known as "caretakers", accelerates the rate 
of acquisition of mutations, including those that represent steps towards a cancer phenotype. 
The caretakers consist of genes involved in genome surveillance and the repair of DNA 
damager (reviewed by Hoeijmakers 2001 and Khanna and Jackson 2001 
36,37). 
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Several different classes of DNA damage are recognized and repaired by distinct sets of 
enzymes. Bulky DNA adducts and double strand breaks that cause major distortions to the 
double helix are sensed by general surveillance mechanisms. Smaller lesions are recognised 
because they stall transcription or replication. On sensing DNA damage two types of signals 
are transduced, those leading to the recruitment of repair apparatus to the site of damage and 
those preventing entry into S phase of the cell cycle. Much of the known repair signaling 
circuitry is centred on p53 (see 1.1.3) which, depending on the nature of the detected damage 
and cell type involved, may trigger apoptosis rather than replication block. 
Repair systems are of three main types, excision repair, double strand break repair (DSBR), 
and mismatch repair. In the first of these a damaged nucleotide, or patch of nucleotides 
surrounding the lesion, are excised by repair specific enzymes such as the Xeroderma 
Pigmentosa (XP) proteins. The resulting gap is then filled by the cells regular replication 
38,39 machinery using the complementary strand as a template 
DSBR is initiated when the ataxia telangiectasia mutated (ATM) protein detects a double 
strand break4o. Two other proteins, ataxia telangiectasia related (ATR) and DNA protein 
kinase (DNA-PK), are then recruited to the broken end where they phosphorylate histones 
over a region of approximately one Mb 41. If the break has occurred post-S phase the 
relatively error free process of homologous recombination, in which the sister chromatid is 
used as a template, takes place. A number of repair specific enzymes including NBS- I 
BRCAI and BRCA2 are involved in homologous recombination 42 . Double strand breaks 
arising prior to S phase, have no easily available template and are repaired through the error- 
prone process of end joining. Several proteins involved in antibody and T-cell receptor 
rearrangement (see 1.2) are also used in the process of end joining. These include the 
KU70/80 end binding complex DNA-PK and XRCC4 DNA ligase 43 . End joining not only 
leads to the risk of recombination taking place between different chromosomes, particularly 
in cells that are actively rearranging antigens, but also to loss or gain of nucleotides. 
Mismatch repair involves a number of proteins that recognize and rectify mismatch, insertion 
and deletion mutations introduced by DNA polymerase 11. The process is tightly linked to 
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replication and involves protein complexes of the human homologues of Drosophila MutS 
and MutL (hMSH2/6 and hMLH/hPMS) that distinguish parent from daughter strand and 
recognize mutations. Excision of nucleotides in the daughter strand and re-synthesis of DNA 
is performed by specialized exonucleases and polymeraseS44. 
The important role of DNA repair systems in protecting against malignancy is highlighted by 
the existence of cancer prone syndromes in which germline mutation in a caretaker gene has 
occurred. Patients with Xeroderma Pigmentosum (XP) carry mutations affecting one of 7 
different proteins (XPA-XPG) required for excision repair, are sun-sensitive and develop 
skin cancer 45 . Germ line mutations in the ATM gene lead to the condition of ataxia 
telangiectasia, an X-ray sensitive cancer-prone syndrome 40 . Other genes coding 
for proteins 
involved in DSBR that are known to be mutated in familial cancers include; NBS-I causing 
Nijimegen breakage syndrome, and BRCAI and BRCA2 in breast cancer 42,46 . The hAff. H I 
and 2 and hMSH6 genes, essential to mismatch repair, bear germ line mutations in more than 
half of hereditary non-polyposis colorectal cancer (HNPCC) patients. A range of sporadic 
tumours have also been associated with defects in mismatch repait47. 
Animal models also demonstrate that the DNA repair systems protect against the 
development of malignancy. Ku80-1- mice displayed a marked increase in chromosomal 
aberrations and slightly earlier onset of cancer. Double knock out Ku80-1- p53-1- mice 
developed lymphomas at an early age that, mirroring the situation in human lymphomas, 
C_M C48 were characterized by chromosomal rearrangements involving IgH and Y. Loss of Ku 
protein fimction also impaired the immune system and inactivation of DNA-Pk produces a 
similar but milder (skid) phenotype 
1.2. Normal blood cell development. 
Unless otherwise indicated the information in this section and section 1.3 is summarized 
from standard haernatology textS49. 
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Normal adult haemopoietic marrow is confined to the central skeleton and proximal ends of 
femurs and humeri. Stem cells committed to the myeloid and lymphoid lineages originate 
from a common (pluripotent) stem cell. After successive divisions a common myeloid 
progenitor gives rise to the erythroid, megakaryocytic, granulocyte/monocyte, eosinophilic 
and basophilic lineages. Two lineages, monocytes and neutrophils are derived from the 
granulocyte/monocyte line. The common lymphoid stem cell gives rise to T and B- 
lymphocytes. Pluripotent stem cells have the capacity for self-renewal and each can give rise 
to about 106 mature blood cells. 
The bone marrow stroma, is composed of a microvascular network and stromal cells which 
secrete a complex matrix of collagen and adhesive proteins. The adhesive proteins bind stem 
cells where they are presented with growth factors (often referred to as cytokines) produced 
by the stromal cells. Cytokines are also produced by T-lymphocytes, monocytes and 
macrophages and may circulate in the plasma or act through cell-to-cell adhesion. The 
direction in which stem and progenitor cells differentiate depends largely on the spectrum of 
growth factors to which they are exposed and the growth factor receptors they express. 
Cytokines may stimulate production of other growth factors or growth factor receptors. Other 
ligands play an inhibitory role, for example, TGFP attenuates growth in a variety of 
haematopoietic cells. Although extracellular growth and inhibitory factors sustain 
haematopoiesis they are thought not usually to be instructive for lineage differentiation, but 
rather permissive for cell viability and proliferation (reviewed by Orkin 200050) . That is to 
say, in the absence of specific cytokines cells of a particular phenotype are blocked from 
entering the cell cycle or initiate apoptotic programs. As discussed in 1.2 and 1.3 the 
pathways that lie downstream of growth and inhibitory factor receptors have been linked to 
the core pRb and p53 pathways controlling cellular growth and survival. In the presence of 
appropriate permissive cytokines, cells bearing the right receptors are permitted to grow but 
differentiate under the control of intrinsic regulators of transcription. The transcription 
factors controlling haematopoietic differentiation have frequently been first identified 
through cloning break points of chromosomal translocations recurrent in leukaemia. 
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Transcription factors modulate expression of their target genes in a number of ways, some 
remodel DNA locally by ATP dependent mechanisms, others modify histones or interact 
with DNA polymerase 11 (reviewed by Lemon and Tjian 20005 1). Frequently a number of 
proteins form multimeric complexes, that depending on the presence of co-activators or co- 
repressors can either be positive or negative regulators of transcription. Transcription factors 
are often classified according to their DNA binding domains. A group of helix-tum-helix 
containing transcription factors, known as the class I homeobox or HOX genes, play a critical 
role in embryonic development as well as in human haemopoiesis. The 39 HOX genes are 
organised into four groups A-D each one sharing common regulator sequences and 
occupying different chromosomal locations. Expression of genes within each cluster has a 
spatially/temporal relationship with the more 5' being expressed at early stages of 
development/haemopoiesis. The down stream targets of HOX genes remain largely 
speculative but it is clear that members of the HOX family regulate each other and related 
class 11 homeobox genes in a complex homeotic network (reviewed by van Oostveen and Bijl 
9952) . Regulatory sequences positioned upstream of HOX genes include TAAT and retinoic 
acid response elements. In Drosophila the HOX genes are regulated negatively by polycomb 
(Pc-G) and positively by trithorax (Trx-G) master transcription factors. In humans a single 
Trx-G homologue, the promiscuous proto-oncogene mixed-lineage leukaemia (Alff-, L) has 
been cloned. Various HOX and also class 11 homeobox genes have themselves been shown to 
participate in chimeric fusion-oncogene formation or to be deregulated as the result of 
translocations in leukaemia. 
In addition to MLL and the HOX family members, genes coding for several other 
transcription factors controlling blood cell development are recurrently interrupted or 
deregulated by leukaemia related chromosomal rearrangements. Proteins encoded by known 
oncogenes that also regulate transcription in the haematopoietic stem cell include TALI, 
LM02, HLXB9, GATA-2, CBFA2 and CBFP. Development of the myeloid lineage is 
accompanied by expression of RARcc, Myb and PU. 1 and lymphoid restricted oncogene/ 
transcription factors include IKAROS, E2A and PAX 5 (for further discussion of the role of 
transcription factors in leukaemia see 1.4). 
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1.2.1 Myeloid Development 
The leukaemias dealt with in this study originate from the granulocytic and lymphocytic 
lineages, so development of red blood cells and megakaryocytes are not discussed further. 
Under the influence of growth factors SCF, IL-3, GM-CSF, G-CSF, M-CSF and IL5 bone 
marrow stem cells are induced to differentiate into mature granulocytes (neutrophils, 
basophils and eosinophils) and monocytes. 
Morphologically recognisable immature forms of the neutrophil lineage found in the bone 
marrow include promyelocytes, myelocytes, metamyelocytes and band neutrophils. Only 
mature neutrophils are found in normal blood and tissues where they perform a phagocytic 
function. Of the other granulocytic lineages eosinophil and basophil precursors are 
indistinguishable from those of the neutrophil lineage. Mature eosinophils perform specific 
roles in allergic response, defence against parasites and fibrin removal. Basophils mature into 
mast cells in the tissues. Immature forms of monocytes (promonocytes) can be recognised in 
the bone marrow. After migration to the tissues monocytes undergo further maturation into 
macrophages. Like neutrophils, monocytes and macrophages have a phagocytic function but 
also secrete growth factors (IL-1, TNF, IL-3, GM-CSF, G-CSF, M-CSF, IL-4 and IL-6) some 
of which may be targeted to tissues outside the haematopoietic system such as brain and 
liver. Specialised macrophages also act as antigen presenting cells to T-lymphocytes. 
1.2.2 Lymphoid development. 
Undifferentiated lymphoid cell expansion occurs in the bone marrow under the influence of 
cytokines: IL-1, IL-4, IL-6, TNF and IL-3. Growth of the B-cell lineage is under the control 
of IL- 19 IL-4, IL-6, IL-7, IL- 10, TNF, IL-2 andyIFN. T cells are stimulated to divide by IL- 1, 
IL-2, IL-4, IL-6, IL-7 and IL-9 with later maturation occurring in the thymus. Both mature B 
and T cells express antigen recognising receptors on their cell surface, immunoglobulins (that 
are also the secreted antibodies) in the case B-cells and T cell receptors (TCRs) in the case of 
T cells. Antigen specificity results from rearrangement of genes that code for 
immunoglobulin and T cell receptor proteins during lymphocyte development. 
Immunoglobulins are composed of two heavy chains (IGH) encoded by a series of gene 
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segments on chromosome 14 band q32 and two light chains (IGL) either ic (chromosome 
band 2p 11) or X (chromosome band 22q2 1). In the germ line configuration the IGH and IGL 
consist of Variable (Y) diversity (D), joining (. ý and constant (C) regions each containing a 
number of different segments. During early B-cell development, under the influence of 
sequence specific recombinases, one of the D segments becomes joined with aJ segment (in 
the IGH) and then to one of the V segments to form an actively transcribed IGH gene. 
Variations in the joining of V, D and J segments used and insertion of additional sequences 
by terminal deoxynucleotidyl transferase (TdT) at the DJ and VD junctions introduce 
additional diversity in the IGH repertoire. Similar rearrangements of ic and A IGL genes take 
place slightly later in B-cell development. No D segments are present in the IGL genes. 
T cell receptors are composed of heterodimers, most commonly composed of (x and P chains 
or less frequently y and 8 chains. The genes encoding TCR (x, P, y and 8 chains are composed 
of V, D, J and C regions and become rearranged during thymic T-cell development in a 
manner analogous to IGH and IGL rearrangement in B-cells. 
Immature forms of B-cell present in the bone marrow include pre pro-B cells, pre-B cells, 
early B cells and mature B-cells. The most immature form of T cell found in the thymus is 
the Pre-T cell which gives rise to large cortical thymocytes, small cortical thymocytes and 
mature medullary thymocytes. Mature B and T cells leave the bone marrow and thymus and 
migrate to the lymphoid tissues where they are exposed to antigens by antigen presenting 
cells (APCs) in the lymphoid tissues, and at this point they are transformed into T or B 
immunoblasts. Some T immunoblasts go on to perform an immunocytotoxic function and 
then die. Others develop into memory T-cells capable of reacting more rapidly and intensely 
upon further exposure to antigens. B immunoblasts develop into lymphoplasmacytoid cells 
then immunoglobulin secreting plasma cells or alternatively develop into memory B cells. 
Two forms of lymphocyte, natural killer (NK) cells and lymphokine activated killer (LAK) 
cells recognise and destroy foreign cells without producing antigen recognising receptors. 
NK cells recognise other structures on the target cell that in some cases are bound antibodies. 
LAK cells perform the same function but require activation by cytokines. 
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1.3 Classification of haernatological malignancies. 
The leukaemias can be broadly divided into those of myeloid and lymphoid origin. Diseases 
arising in the lymphatic system are categorised into Hodgkins and non-Hodgkins 
lymphomas. Chronic and acute forms of the leukaemias and lymphomas exist while the 
myelodysplastic syndromes (MDSs), polycythaemia rubra vera (PRV), essential 
thrombocytopaenia (ET) and myelofibrosis are usually classed as pre-leukaemias or 
smoldering leukaemias. The precise cell of origin of haematological malignancies is often 
uncertain and placing diseases into the above categories is not always straightforward. Rare 
cases of mixed-lineage leukaemia express immunological markers of both myeloid and 
lymphoid type and in leukaemia/lymphoma syndromes, disease of both the haematopoietic 
and lymphopoietic systems are manifest. Diagnosis of haematological malignancies is made 
on the basis of morphology, immunology and genotype as determined both by cytogenetic 
and molecular techniques. 
1.3.1 Acute Myeloid leukemia (AML). 
AML is usually classified according to the French, American, British (FAB) system into 7 
morphologic sub-types (Table 1.1). The sub-types correspond to the lineage and stage of 
differentiation of the leukaemic clone. Several sub-types are associated with specific 
cytogenetic rearrangements (see 1.4.1), further diagnostic and prognostic information can be 
derived from genotypic and immunological data. 
1.3.2 Chronic myeloid leukemia (CML). 
While the acute myeloid leukaemias generally result from maturation block of one or more of 
the myeloid lineages, CML involves the relatively indolent clonal expansion of mature or 
near mature granulocytes. If left untreated, the disease progresses to a more aggressive acute 
phase and finally blast crisis. Blast crisis of CML resembles acute leukemia of either 
lymphoid or myeloid lineage supporting the widely accepted belief that the disease arises in 
the pluripotent stem cell compartment. The BCR-ABL fusion gene resulting from the 
28 
Philadelphia (Ph) translocation [t(9; 22)(q34; ql 1)] is considered diagnostic for CML and 
transformation to blast crisis is frequently accompanied by the acquisition of further 
cytogenetic abnormalities. Rare cases of BCR-ABL negative 'variant CML' have been 
described but are distinguished from CML by a somewhat different clinical course. 
FAB Sub-Type Lineage/ Stage of differentiation 
MO Undifferentiated common myeloid progenitor cells 
ml Myeloblasts without differentiation 
M2 Myeloblasts with differentiation 
M3 Promyelocytes 
M4 and VM4 Myeloblasts and Monoblasts [variant(v) has eosinophilia] 
M5 Monocytes 
M6 Erythroblasts 
M7 Megakaryoblasts 
Table 1.1. French American British (FAB) classification of AML. 
1.3.3 Myeloproliferative Disorders (MPDs) other than CML. 
The MPDs, PRV, ET and myelofibrosis are considered non-leukaemic although they may 
occasionally transform into AML. All forms involve clonal expansion of the stem cells but in 
PRV the erythroid lineage is dominant, in ET there is excessive production of 
megakaryocytes and platelets while myelofibrosis results in a reactive fibrosis of the bone 
marrow. The three conditions are closely related and frequently one will transform into 
another. 
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1.3.4 Myelodysplastic syndromes (MDSs). 
The MDSs comprise a spectrum of clonal disorders arising in the multipotent stem cell and 
leading to maturation defects and cytopaenias of all three myeloid lineages. There are 5 FAB 
sub-classes of MDS based upon numbers of blast cells in the bone marrow or peripheral 
blood, presence or absence of ring sideroblasts and the occurrence of monocytosis. The FAB 
sub-types are 1) Refractory anaemia (RA) 2) RA with ring sideroblasts (RARS) 3) RA with 
excess blasts (RAEB) 4) RA with excess of blasts in transformation (RAEB-t) and 5) 
Chronic myelomonocytic leukemia (CMML). The MDSs frequently transform into AML 
with an arbitrary level of 20% bone marrow blasts used to distinguish between the two 
diseases. 
1.3.5 Acute Lymphocytic leukemia (ALL). 
On the basis of morphology ALL can be classified into 3 FAB sub-types; LI: blasts are small 
and uniform with a high nuclear to cytoplasmic ratio. L2: large non-uniform blasts with a 
lower nuclear to cytoplasmic ratio irregular shaped nuclei and prominent nucleoli. U: Large 
uniform vacuolated blasts with basophilia, regular nuclei and prominent nucleoli. The three 
sub-types show distinct age distributions with LI accounting for 85% of childhood ALL and 
L3 only 1%. 
ALL can also be classified according to lineage and stage of differentiation by using 
immunological markers. Immunological sub-types include common or early pre-B, pre-B, B 
and T ALL. The majority of childhood ALL are of the early pre-B immunological sub-type. 
ALL is associated with a number of characteristic numerical and structural cytogenetic 
abnormalities that provide the most important prognostic tool in this disease (see 1.4). The 
stage of Immunoglobulin/T cell receptor rearrangement and segment usage has also been 
investigated in ALL and may provide additional prognostic information as well as a sensitive 
means of detecting relapse after treatment. 
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1.3.6 Chronic lymphocytic leukemia (CLL). 
CLL is the commonest adult leukemia in western society. it is characterised by the 
accumulation of small mature lymphocytes in the blood, bone marrow and lymph nodes. 
Over 90% of CLL cases express surface immunoglobulin and 98% express B lineage 
markers the remaining 2% are of T cell origin. 50% of cases have cytogenetic abnormalities 
that together with presence or absence of specific immunological markers can aid in 
prognosis (see 1.4) 
1.3.7 Lymphomas. 
The lymphomas result in malignant overgrowth of normal lymphoid tissue by abnormal cells 
that are usually of B or T lymphocyte origin, in later stages other tissues including the bone 
marrow may be infiltrated. The disease is usually divided into Hodgkin's disease (HD) and 
non-Hodgkin's (NHL) types. HD is characterised by the presence of large, multi-nucleated, 
Reed Stemberg cells that have been shown to be of B cell origin. Classification of NHL is 
complex and in a state of flux. The precise cell of origin is often unclear though most are 
rearranged either for the IGH and IGL or TCR genes. Since cases of lymphoma are not 
included in this study the classification of NHL will not be covered in detail in this thesis. 
The lymphomas are characterised by complex cytogenetic rearrangements with 
translocations frequently resulting from illegitimate IG or TCR gene rearrangements. The 
presence of specific cytogenetic abnormalities, immunological markers and viral infection 
are all used to guide the clinical management of lymphomas. Recently, morphologically 
indistinguishable, diffuse large cell lymphomas, were classed into prognostic sub-groups on 
the basis of expression microarray data 53 . The microarray approach to characterising 
malignancies seems likely to gain in importance as the relevant technology becomes more 
accessible. 
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1.3.8 Multiple Myeloma. 
Multiple myeloma (MM) results from a monoclonal bone marrow proliferation of mature, 
dysmorphic plasma cells. At present it remains uncertain whether the plasma cells develop in 
the bone marrow or are post germinal centre and later infiltrate the marrow. TNF and IL-I 
secreted by the multiple myeloma cells lead to osteolytic lesions. The neoplastic cells express 
clonally rearranged Ig proteins on their cell surface that are secreted in the plasma 
(paraprotein) and urine (Bence-Jones protein). Multiple myeloma is characterised 
cytogenetically by translocations of the IGH and IGL geneS54. 
1.4 Cytogenetic Abnormalities of Haernatological malignancies. 
Conventional G-banded analysis of haematological malignancies has revealed many lineage- 
specific as well as non-specific cytogenetic abnormalities. If the same abnormality is 
identified repeatedly in a disease it is described as recurrent, while previously unreported 
changes are termed sporadic. Molecular cloning of genes affected by recurrent changes has 
resulted in the identification of many oncogenes and tsgs contributing greatly to the 
understanding of the biology of malignancy. As karyotypic data for the haematological 
malignancies accumulates, cytogenetics has come to play an increasingly important role in 
diagnosis, prognosis and monitoring of residual disease. Fluorescence in-situ hybridisation 
(FISH) and the related techniques of comparative genomic hybridisation (CGH) and 
multicolour FISH (M-FISH) or spectral karyotyping (SKY) have increased the accuracy and 
sensitivity of cytogenetic techniques (reviewed by Kearney 99 55) . For the purpose of this 
thesis recurrent cytogenetic abnormalities will be divided into myeloid specific, multilineage 
and lymphoid specific. 
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1.4.1 Recurrent cytogenetic abnormalities restricted to myeloid malignancies. 
AML karyotypes are typically characterised by balanced translocations and the formation of 
chimeric oncogenes (reviewed by Hayashi 200056) . The MDSs and MPDs are by contrast, 
more often associated with monosomy or deletion of specific chromosomes. The most 
important recurrent chromosomal abnormalities with their associated underlying molecular 
lesions (where known) are presented in table 1.2. The Philadelphia translocation and 
translocations of II q23 will be considered in section 1.4.2 since they are common to both 
myeloid and lymphoid disease. The mechanisms by which the various chimeric oncogenes 
contribute to development of the common neoplastic characteristics, discussed in 1.1-1.5, 
have been the subject of intensive research in recent years and are becoming increasingly 
well understood. A detailed review of published work exploring downstream effects of 
leukaemic translocations is beyond the scope of this thesis as is a description of the incidence 
and clinical implications of each rearrangement. However, some of the numerically most 
important and well understood, rearrangements will be discussed. 
The translocations associated with AML, unlike many seen in lymphoid malignancies, result 
in the formation of chimeric fusion-proteins with oncogenic activity rather than deregulation 
of wild type genes. The t(3; 3)/inv(3)(q2l; q26) is an exception to this rule since the 
rearrangements cause the Ribophorin I promoter to drive ectopic expression of EVIL One or 
both of the partners of most of the fusion genes is a transcription factor (or co-factor) 
involved in the regulation of normal myeloid development. The role of some of these 
transcription factors in normal haemopoiesis was described briefly in 1.2, their contributions 
to leukaemogenesis will be discussed further in this section. 
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Cytogenetic Abnormality Fusion Gene references Disease sub-types 
t(6; 9)(p23; q34) 
t(I 6; 2 1)(p 11; q22) 
t(8; 21)(q22; q22) 
t(16; 21)(q24; q22) 
t(3; 21)(q26; q22) 
t(3; 3)/inv(3)(q2 I; q26) 
t(I 6; 16)/inv(I 6)(p I 3q22) 
t(15; 17)(q22; ql2) 
t(I 1; 17)(q23; q 12) 
t(7; I 1)(p I 5; p 15) 
inv(I 1)(p I 5q22) 
t(l; I 1)(q2 3; p 15) 
t(2; 1 1)(q3 I; p 15) 
t(I 1; 20)(p 15; q 11) 
t(12; 22)(pl3; ql3) 
t(12; 15)(pl3; q25) 
t(l; 12)(q25; p 13) 
t(9; 12)(q34; p 13) 
t(7; 12)(q36; pl3) 
t(8; 16)(p I I; p 13) 
inv(8)(p IIq 13) 
t(8; 22)(p I I; p 13) 
-5/del 5q 
-7/del 7q 
del 20q 
)57 DEK-CAN(NUP214 
TLS(FUS)-ERG 58 
AAIILI-ET059 
AMLI-AITG. J 6 
AAff, ]-EV, 161 
EVII-Ribophorin 162 
CBFfl-MYHII 63 
P]Vff, -IMRA64 
PLZF-RARA 65 
NUP98-HOXA966 
NUP98-DDX]067 
NUP98-PAllyl 68 
NUP98-HOXD13 69 
NUP98-TOP170 
TEL-Nmi 71 
TEL _ TRKC2 
TEL-ARG 73 
TEL-ABL 74 
TEL_HL. XB975 
MOZ_CBp76 
MOZ I _T 
F277 
MOZ-p30078 
? 5NcA79 
AML-Ml, M2, M4, M5 
AML, CML-bc 
AML-M2 
t-AML, MDS 
AML, CML-bc 
AML-M7, 
AML-M4Eo 
AML-M3 
Atypical AML-M3 
AML-M2, M4, CML, MDS 
t-AML, t-MDS 
AML-M2 
t-MDS 
t-MDS 
AML-M4 
AML-M2 
AML-M3 
AML- 
AML-M I, M3 
AML-M4, M5 
AML-MO, M I, M5 
AML-M5 
AML, MDS 
AML, MDS 
MDS, MPD 
Table 1.2. Recurrent cytogenetic abnormalities of myeloid malignancies with cloned 
oncogenes and disease associations. 
1.4.1.1 Translocations affecting CBF- 
A critical step in the regulation of the transcription of myeloid genes involves the reversible 
remodelling of chromatin from an inactive to an active configuration by changing the 
acetylation status of core histones8o. Activating proteins bind specific DNA sequences and 
recruit histone acetyl transferases (HATs) that are responsible for the acetylation of histones 
and the conversion of DNA to a transcriptionally open form. Conversely, histone 
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deacetylases (HDACs) repress transcription. One of the most important activators of genes 
involved in haernatological development is the core binding factor (CBF). CBF consists of a 
complex of an a subunit that binds DNA through a runt homology domain and the 0 subunit 
(CBFP) which facilitates DNA binding. The oc subunit can vary but in haernatological tissues 
the protein is called AMLI (also referred to as CBFA2 or RUNXI). CBF recruits the HATs, 
p300 and CREB-binding protein (CBP) that in turn acetylate histones and activate master 
gene involved in myeloid development. Several common translocations seen in AML involve 
CBF, p300 or CBP. The AML M2 associated t(8; 21) underlies a fusion gene consisting of 
the runt domain of AA1ILI and most of the gene eight twenty one or ETO (also known as 
MTG8). ETO is able to recruit an HDAC complex and as a consequence of the AIEI-ETO 
fusion, CBF is converted to a repressor rather than an activator of myeloid development 
(reviewed by Downing 1999, Licht 2001 81,82) . AIE I is also recurrently involved in 
translocation with other genes and the partner gene can dramatically influence the type of 
leukaemia which develops, for example TEL-AIE] is most commonly seen in 20-25% of 
childhood ALL (see 1.4.3). 
As a result of the inv(16)(pl3q22) CBF, 8 becomes fused with the myosin heavy chain gene 
MYHII a rearrangement that is associated particularly with FAB subtype M4-Eo. CBFP- 
MYH II is thought to sequester AMLI into multimeric complexes where it is unable to 
perform its function as a transcription regulator 
83,84 
. The two HATs p300 and CBP are both 
fusion partners of MLL (see 1.4.2) and MOZ which its self stimulates AML-I mediated 
transcription. The MOZ-CBP fusion protein has been shown to impair the ability of AML-I 
85 
to induce differentiation 
It is thought that the protein products of several of the CBF related translocations act in a 
dominant negative fashion, effectively resulting in functional inactivation of both alleles. 
Dominant negative effects could be mediated through several mechanisms. For example if 
an abnormal transcription factor complex binds DNA in a more stable fashion than its wild 
type counterpart, expression of target genes would be competitively inhibited. Alternatively 
formation of dimeric or oligomeric complexes could result in trafficking of both normal and 
abnormal proteins to an inappropriate cellular compartment. Dominant negative effects can 
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mimic homozygous loss of a classical tsg. Accordingly CBF genes have been investigated for 
evidence of leukaemia related inactivating mutations. As a result of these investigations 
mutations resulting in either homozygous or heterozygous inactivation of AMLI have been 
described in cases of AML (discussed further in 1.5)86,87. 
1.4.1.2 translocations affecting RARA. 
A second important group of chimeric genes that interfere with the balance of HAT/HDAC 
modulated transcription of myeloid differentiation involve the Retinoic acid receptor Cr 
(RARA). To date five RARA partners have been cloned; promyelocytic leukaemia (PA1L), 
promyelocytic zinc finger (PLZF), nucleophosmin (NPM, the nuclear mitotic apparatus 
(NuA, M) gene and STAM. Of the five fusion transcripts, which have been studied 
intensively in mouse models (reviewed by Pandolfi 200 188) , by far the most common is 
PAIIL-RARA. Like other RARA translocations, t(15; 17)(q22; ql2) producing PML-RARA, is 
associated with APL (AML-M3). However, PA1, M-RARA is distinguished from the four 
variant fusion genes in that it is thought not only to block differentiation through effects on 
RARA mediated transcription but also to have a tumour suppressor like effect resulting from 
interference with normal PML function (reviewed by Salomoni and Pandolfi 200289). This 
dual contribution to tumourigenesis perhaps explains the frequency of PAIIL-RARA when 
compared to the other RARA fusion genes. 
The normal RARA protein forms a heterodimer with a Retinoid-X -Receptor (RXR-RA) that 
in the absence of retinoic acid (RA) forms a complex with transcriptional co-repressors. 
These, in turn, are able to recruit HDACs and repress transcription of RA responsive genes. 
In the presence of physiological concentrations of RA the RARA-RXR-RA complex binds 
transcriptional co-activators, in place of the co-repressors, leading to recruitment of HATs 
and activation of RA responsive genes that include some involved in the terminal 
differentiation and growth arrest of myeloid cells. PML-RARA-RXR-RA heterodimers, 
remain complexed with the co-repressors at normal levels of RA resulting in maturation 
arrest of the myeloid lineage at the promyelocyte stage9o. The dominant negative effect on 
transcription mediated by PML-RARA however, appears to be only partly responsible for the 
contribution of the t(15; 17)(q22; ql2) to leukemia because mice expressing the PAff, -RARA 
and RARA-PAff, fusion transcripts develop leukaemia more quickly than those expressing 
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PAE-RARA alone9l. The mechanism by which RARA-PML contributes to the malignant 
process is presently unclear but may be related to disruption of normal PML function. 
Using immunofluoresence the PML protein was demonstrated to be concentrated in distinct 
microscopically visible sub-nuclear structures, sometimes known as PML nuclear bodies 
(PML-NBS)92 
. Typically 10-30 of these structures are found in the inter-chromatin domain 
with some variation in both number and size during the cell cycle 93 . Formation of the PML- 
NBs is dependent on the presence of PML but more than 30 other proteins, including p53, 
pRb, CBP and p300, have also been found to associate with the PML-NBs. In APL blasts, 
PML-RARA causes the PML-NBs to be disrupted and also to block pRb mediated 
transcriptional repression of the E2Fs 94. As discussed in section 1.2 GI -S transition is held in 
check when hypophosphorylated pRb binds the E2Fs and recruits HDAC complexes, so 
PML-RARA and or RARA-PML appear not only to block myeloid differentiation but also to 
remove constraints on cell growth through a second route. Furthermore, UV induced pro- 
apoptotic post-translational modifications of p53 have been shown to depend on its 
association with homeodomain interacting protein kinase-2 (HIPK2) and CBP within PML- 
NBs 95 . Normal PML is also thought to be required for some p53 independent apoptotic 
pathways such as those stimulated by FAS and TGFp341. It seems likely therefore, that PML 
has a tumour suppressor (or caretaker) like function that is lost or abrogated as a result of 
fusion to RARA. 
Addition of the drug all-trans retinoic acid (ATRA) to cultured PML-RARA positive blasts 
leads to the reappearance of PML NBs and dissociation of the PML-RARA-RXR co- 
repressor. Administration of ATRA also restores normal myeloid differentiation in cases of 
PML. Interestingly inhibitors of HDACs can mimic the effects of ATRA in PML and are 
being considered a potential treatment option in other cases of AML with maturation block 
resulting from abnormal HDAC activity 
96 
. 
1.4.1.3 Translocations affecting homeobox genes. 
The translocations so far discussed modify fimction of two master regulators of myeloid 
development, AMLI and RARA. The full complement of AMLI and RARA responsive 
genes is presently unknown but undoubtedly includes HOX and class 11 homeobox 
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transcription factors that operate in a network to maintain blood cell homeostasiS52. It is 
therefore unsurprising that several homeobox genes have been found at the break points of 
leukaemia related translocations. In cases of AML (or CML myeloid blast crisis) HOX, 49, 
HOX411, HOXD11 and HOXD13 have been found fused to the nucleoporin gene (NUP98). 
The fusions all produced an in-frame chimeric gene consisting of an intact DNA binding 
homeodomain. fused to the 5' part of NUP98 under the control of its strong transcriptional 
activation domain 66,69,97,98 .A similar fusion gene results from t(1; 11)(q23; pl5) involving 
NUP98 and the class 11 homeobox gene pAM168 . Another class 11 homeobox gene HLXB9 is 
recurrently involved in translocation with TEL (ETN in cases of infant AML 75. The ETV6- 
HLXB9 translocation produces an in-frame fusion transcript but wild type GSH2, also a class 
11 homeobox gene, was expressed ectopically, as the result of a translocation that interrupted 
ETV6. A similar position effect was reported by the same authors to result in expression of 
the cytokine IL399. HOX and related homeobox genes have also been involved in 
rearrangements with MLL or in ALL associated translocations (see 1.4.2 and 1.4.3). 
1.4.1.4 deletions. 
Deletions of the long arm of chromosomes 5 and 7 are relatively frequent in cases of MDS 
and AML and deletions of 20q associated with MDS and the MPDs. The techniques of FISH, 
southern blot and microsatellite analysis have been used, in successive studies, to narrow 
100-103 down common deleted regions (CDRs) on all three chromosomes . In each case more 
than a single CDR has been defined and mutation or expression analysis of candidate tumour 
suppressor genes performed on patients carrying deletion of one homologue. 
Although a promising candidate tsg, because of its involvement in the regulation of the cell 
cycle and transcription, no mutations were found in the ORC5L gene, mapping to 
chromosome 7 band q22 and in any of 9 patients tested' 04 . The PIK3CG gene, encoding a 
subunit of P13K gamma, also maps to 7q22 and was considered a good candidate because 
mice mutated for Pi3k developed haematologic defects. Of 40 patients with leukaemia and 
deletions of chromosome 7 two were shown to carry an identical missense variation in the N 
terminal domain of the protein. However, unaffected parents of the two patients and one of 
60 control alleles also carried the variant sequence which was therefore considered unlikely 
to be leukaemia related' 05 .A third gene, H77FIa was investigated because its encoded 
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protein was shown to interact with both RARA and PM L. Although HTIFIa was deleted in 
all patients with myeloid malignancy and deletion or translocation of 7q32, its expression 
was elevated in leukaemias and particularly in those of an immature FAB sub type' 06 
Mutation analysis of several candidate tsgs on 5q3I has also been performed. These include 
5qNCA, ETFI, CDC23, TTID, RAB6K[FL, PURA and KLHL3 79,107-112 . Among the tested 
candidate genes, evidence for mutation of the second allele was found only in 5qNCA which 
displayed a THR to ALA change in one cell line bearing a 5q deletion. The potential 
mutation was not seen in any of 60 normal alleles and furthermore expression of 5qNCA in a 
del (5q) cell line resulted in suppression of clonogenic growth. The function of the 5qNCA 
protein is uncertain but it contained a domain often seen in proteins that regulate chromatin 
remodelling. Hemizygous loss of PURA and PURB (located on 7p) have been suggested to 
have a synergistic tumour suppressor effect because loss of one allele of both genes occurred 
at a higher rate than would be expected by chance in cases of MDS transformed to AML. The 
two PUR genes are known to form heterodimers and to affect cell cycle control through 
interaction with Rb. 
No data has yet been presented in support of the candidacy of individual genes on 20q 
03,113,114 
although narrow CDRs containing relatively few genes have been published' 
Although little evidence for the existence of recessive tsgs (with the possible exception of 
5qNCA) on chromosomes 5,7 or 20 has emerged from the extensive studies discussed, 
heterozygous loss of any of the candidate tsgs might contribute to myeloid malignancy (see 
1.5). 
1.4.2 Recurrent cytogenetic abnormalities associated with both myeloid and lymphoid 
malignancies. 
1.4. ZI The Philadelphia and related Translocations. 
The Philadelphia (Ph) translocation [t(9; 22)(q34; q2l)] as well as being numerically and 
clinically one of the most important leukemia associated translocations was also the first to 
be described and so has been studied in depth. At the molecular level several fusion 
oncogenes result from breaks in different introns of the BCR and ABL genes (Reviewed by 
Melo 19961 15) . The most common 
fusion transcript results from breaks occurring in a 5.8Kb 
39 
[major breakpoint cluster region (M-BCR)] between exons 12 and 16 of the BCR gene and 
result in production of a p2 10 fusion protein. Rearrangements of M-BCR occur in all cases of 
CML although in approximately 5% the Ph translocation is not detectable by conventional 
cytogenetic techniques. The Ph translocation is also the commonest rearrangement seen in 
adult ALL, in some cases breaks occur in M-BCR but more commonly between exons I and 
2 [the minor breakpoint cluster region (m-BCR)] producing the smaller p190 fusion protein. 
Both M-BCR and m-BCR translocations are associated with poor outcome in ALL. 
Alternative rare BCR-ABL fusions have been reported; cases of chronic neutrophilic 
leukaemia have been associated with breakpoints downstream of exon 19 of BCR and a 230 
Kd fusion protein. Recently cases of CML with breakpoints falling within exon 8 leading to 
production of a p200 protein have also been characterised' 16 . 
By contrast with the majority of translocations seen in AML, neither partner of the Ph 
translocation encode a gene involved in the regulation of transcription. The Normal ABL 
protein (c-Abl) is a tyrosine kinase located predominantly in the nucleus were its primary 
role is thought to involve the transduction of DNA damage signals and induction of apoptosis 
(reviewed by Wang 2000 and Blume-Jensen and Hunter 2001 10,117) . Activation of c-Abl is 
dependent on ATM and its critical target is probably p73 that, on phosphorylation induces 
cell cycle arrest and apoptosis in part through induction of p53 target genes. The Bcr protein 
is currently of uncertain function but probably has a role in cellular signalling. Bcr-Abl is 
localized exclusively in the cytoplasm where it forms autophosphorylated oligomeric 
complexes that activate pathways normally controlled by growth factor receptor tyrosine 
kinases (see 1.1.1)(reviewed by Deininger et al 20001 18) . The self-activating properties of 
Bcr-Abl depend critically on the presence of 5' oligomerisation domains donated by Bcr. 
Although the expanded cell population in CML consists of the granulocytic lineages there is 
overwhelming evidence to suggest that the BCR-ABL fusion originates in a pluripotent stem 
cell. For this reason CML is often considered to be a stem cell disorder. Consistent with this 
view is the observation that the blast crisis phase (CML-bc) may be of either myeloid or 
lymphoid type. In 60-80% of cases transformation to blast crisis is accompanied by 
acquisition of additional cytogenetic abnormalities. The most common changes are the 
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appearance of an additional Ph chromosome, trisomy 8 and i(17q)(qlO) all of which are 
found in both myeloid and lymphoid CML-bcl 19. 
ABL has also been found fused with ETV6 in rare cases of CML or T-ALL 74 . ETV6-Abl, 
like 
Bcr-Abl, is localised to the cytoplasm where the oligomerised chimeric protein is 
constitutively activated through autophosphorylation. Other receptor and non-receptor 
tyrosine kinases including PDGFRP, JAK2, TRKC (NTRK3), ARG (ABL2), FGFR3 and 
Syk are similarly activated through fusion to ETV6 in various haematological malignancies 
72,120-123. In all cases exons 1-5 of ETV6, including the oligomerisation domain are fused to 
the 3' part of the partner gene. The Bcr-Abl and ETV6-tyrosine kinase fasion- oncogenes can 
be functionally related to those encoded by a group of translocations associated with cases of 
myeloproliferative disorder/myelodysplastic syndrome (MPD/MDS) that involve the platelet 
derived growth factor receptor 8 gene (PDGFR, 6) (reviewed by Steer and Cross 2002 124). 
Constitutive activation of PDGFRP in MPD/MDSs results not only from translocation with 
ETV6 but also with a growing list of other partner genes including H4, HIP], CEV14, and 
Rab5. 
Like ABL, BCR also has a second, much rarer translocation partner, the fibroblast growth 
factor receptor I gene (FGFRI) 125 . The BCR-FGFR1 
fusion gene occurs in cases of MPD 
resembling CML but with a distinctive clinical course typically involving transformation to 
lymphoma. FGFRI is another example of a receptor tyrosine kinase that becomes self- 
activating as a result of translocation. Unsurprisingly FGFR1 may be activated through 
translocation to other partner genes including ZNF198, CEP110 and FOP that donate 
oligomerisation domains. FISH analysis suggests that other rare translocations including 
t(8; 17)(pl I; q25), t(8; 1 1)(pl I; pl5) and t(8; 12)(pl I; ql5) also disrupt FGFRI 126 . 
1.4. Z2 Translocations and other abnormalities affecting MLL. 
Translocations of 11 q23 occur in AML, MDS, biphenotypic leukaemias and ALL (Reviewed 
in 56,127,128) . 
Approximately 40 different translocations of II q23 have been reported of which 
about 30 have been cloned and found to involve breaks within an 8.3 kb region between 
exons 5 and 11 of the Mixed Lineage Leukaemia (MLL) gene. The better known, cloned 
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partner genes are presented in Table 1.3 with their cytogenetic localisation and a brief 
description of function or functional domains. In addition to gene fusion, two other rare 
classes of Aff-, L mutation have been described; 1) partial amino terminal duplications and 2) 
129-131 deletions of exon 8 
Like the CBF complex proteins and RARA, MLL functions as a master regulator of 
transcription. Mice mutated for AIML show developmental defects and haematopoietic 
abnormalities that are accompanied by aberrant patterns of HOX gene expression 132,133 . At 
its 
amino terminal end MLL has three AT hooks that are thought to mediate DNA binding and 
are always retained in the expressed product of the fusion genes. Other domains that appear 
to make an essential contribution to the transforming properties of MLL fusion proteins are 
two CxxC motifs that are likely to regulate transcription through DNA methylation and two 
134,135 regions that target MLL to subnuclear domains or speckles 
The mechanisms by which diverse AILL partner genes affect transcription of MLL targets, or 
contribute to leukaemogenesis in other ways, is currently a matter of debate (for extensive 
review see Ayton and Cleary 2001 136) . The observation that duplications or deletions within 
IEL can be oncogenic has prompted speculation that the essential leukaemic effect of the 
translocations is loss of normal MLL function. However, in in vitro assays, domains within 
some of the partner proteins as well as the amino-terminal part of MLL, have been shown to 
be essential for transformation 137 . Furthermore, the partner genes are always in 
frame and can 
influence both the type and severity of disease. About half of the partner genes are nuclear 
effectors of transcription of which several, including p300 and CBP (see 1.4.1) are also 
involved in other oncogenic translocations. The incidence of different AffL translocations is 
also highly variable, those most abundant in myeloid disorders are t(9; 11)(p22; q23), 
t(11; 19)(q23; pl3.1) and t(11; 19)(q23; pl3.3) while the t(4; 11)(q2l; q23) is seen in 60% of 
infant ALL patients. 
42 
Chromosomal Gene Reference Domain/Function 
locus 
lp32 
I q2l 
3p2l 
4q2l 
5q12 
5q3l 
6q2l 
6q27 
9p22 
10pl 1.2 
11 q23 
l6p13 
l7p13 
17q2l 
17q25 
19pl3.1 
22ql 1.2 
Xql3 
AF]PIEps]5 138 (x-helical coiled coil 
AFIq 139 ATTA motif 
AF3p21 140 SH3 domain 
AF4 141 Ser/Pro-rich, nuclear localisation sequence 
AF5 aj 42 oc-helical coiled coil, GLGF motif 
AF5q31 143 Ser-rich, similar to AF4 
AF6q21 144 Forkhead DNA binding/transcription factor 
AF6 145 cc-helical coiled coil, GLGF motif 
AF9 146 Ser/Pro-rich, similar to ENL 
ABIJ 147 SH3 domain, Homeodomain homologous domain 
LARG 148 Guanine nucleotide exchange factor 
CBP 149 Transcriptional coactivator, HAT 
GAS7 150 Growth arrest specific gene 
AFI 7 151 Leucine zipper, Zn finger 
AFI 7q25 152 Septin family 
ELLIMEN4 53 Pol Il transcription elongation factor, p53 
p3001 
54 
interaction 
AFXI 155 Transcriptional coactivator, HAT 
Forkhead DNA binding, transcription factor 
Table 1.3. Cloned MLL fusion partners; cytogenetic location, gene and gene function or 
functional domain. 
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1.4. Z3 Deletions. 
Deletions of the p arm of chromosome 17 occur in all haematological malignancies and are 
particularly associated with transformation of myeloproliferative disorders to acute 
leukaemia. The deletions result in loss of one copy of the p53 gene and are frequently, but 
not always, accompanied by inactivating mutations of the second allele 156-159 . As discussed in 
1.1.4, p53 functions include the regulation of apoptosis, cell cycle transition and repair of 
potentially oncogenic DNA damage. Deletion of the p arm of 17 may be accompanied by 
duplication of the q arm through formation of an isochromosome 17 i(17)(q 10). Currently, it 
is not known whether the duplication of genes on 17q also contribute to leukaemia. The 
significance of epigenetic silencing and heterozygous loss of p53 are discussed in 1.5. 
1.4.3 Cytogenetic abnormalities associated with lymphoid malignancies. 
Like those found in AML, translocations occurring in lymphoid disease may result in the 
interruption of transcription factors and production of fusion oncogenes. More typically, 
though intact proto-oncogenes are brought under strong promoter sequences of antigen 
receptors as a result of aberrant recombination occurring during the course of IGH, IGL and 
TCR rearrangement. Hypodiploidy and Hyperdiploidy as well as deletion of specific 
chromosomal regions are also characteristic of lymphoid malignancies. The more important 
cytogenetic abnormalities with disease subtype associations and underlying molecular 
rearrangements, where known, are presented in Tables 1.4,1.5 and 1.6. (for reviews 
see 127,128,160). In the interest of limiting the size of this section and because they have no 
direct bearing on the subject of this thesis, abnormalities that are restricted to the 
Lymphomas have not been discussed. 
1.4.3.1 Translocations affecting ETV6. 
As outlined in 1.4.1 and 1.4.2 rare translocations between ETV6 and either homeobox genes, 
IL3 or one of a variety of receptor or non-receptor tyrosine kinases occur in myeloid 
malignancies. ETV6 also participates in the most common rearrangement found in childhood 
ALL, the t(I 2; 2 1)(p 1 3; q22) that results in production of the ETV6-AAE] fusion oncogene'61. 
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The translocation is cytogenetically invisible and can only be detected using FISH or 
molecular analysis. 
The wild type ETV6 protein codes for a widely expressed, sequence specific transcription 
factor required for normal haematopoiesis. The C terminus DNA binding domain is 
conserved in the ETS family of proteins. At the N terminus a helix- loop-helix (HLH or 
pointed) domain mediates protein-protein interactions and homo-dimerisation. Between the 
ETS and HLH domains is a second protein-protein interacting domain that can repress 
transcription through recruitment of the co-repressor N-CoR. A second co-repressor 
(mSin3A) that appears to augment N-CoR mediated repression, can be recruited by the HLH 
domain 162 . Both N-CoR and mSin3A recruit HDACs and the two probably interact to 
form a 
stable repression complex. The HLH domain can also interact with other proteins including 
UBCIO that conjugates SUMO-I to ETV6. SUMO-I modified ETV6 localises to nuclear 
speckles (TEL bodies) in a cell cycle specific fashion 163 . As 
described in 1.4.1.1, AML1 is a 
DNA binding protein that forms part of the CBF complex that can either activate or repress 
the transcription of genes involved in haematopoietic development through recruitment of 
co-activators and or co-repressors. As a consequence of the t(12; 21) the HLH and N-CoR 
binding repressive domains of ETV6 are fused to almost all of AMLI including the runt 
homology DNA binding domain. It is likely that addition of the ETV6 domains converts 
AMLI from a regulated to an unregulated (repressive) transcription factor, and that this is the 
major mechanism by which ETV6-AML1 contributes to development of ALL 
164 
. However, 
on modification by SUMOI, ETV6-AML1 was observed in the TEL bodies rather than 
distinctly different nuclear domains occupied by wild type AMLL Abnormal nuclear 
compartmentalisation of AMLI, and its associated proteins, might also influence the course 
of ETV6-AML positive leukaemia 163 . 
Tyrosine kinases become self-activating as a result of fusion to ETV6 because dimerisation 
of the chimeric proteins through ETV6 HLH domains takes place (see 1.4.2.1). This 
mechanism clearly differs from ETV6 mediated repression of AML I transcription targets. By 
contrast, dimerisation between ETV6-AMLI and wild type ETV6 probably has an anti- 
leukaemic effect because the translocation is almost invariably accompanied by deletion of 
45 
the second ETV6 allele 165 . Deletions of 12p also occur, albeit very rarely, in cases of 
childhood ALL in the absence of t(12; 21) so ETV6 may have a tumour suppressor function 
independent of the translocation 166 . However, biallelic loss of ETV6 has not been reported, 
raising the possibility that inactivation of one or more other genes on 12p contributes to 
leukaemia (see 1.4.3.4). 
Other much rarer translocations involving ETV6 and arising in ALL result in the ETV6-JAK2 
fusion discussed in 1.4.2.1 and ETV6-PAX5 167 . PAX5, encodes for a transcription factor 
expressed in early B-cells and is also deregulated as a result of translocation to the IGH 
locus. 
Abnormality Molecular Disease sub-type 
t(12; 21)(pl3; q22) 
t(9; 12)(p24; p 13) 
t(9; 12)(q I I; p 13) 
t(1; 19)(q23; pl3) 
t(17; 19)(q2l; pl3) 
t(I 1; 18)(q2 1; q2 1) 
t(2; 5)(p23; q25) 
rearrangement 
Reference 
ETV6-, 4AIlLI 168 
ETV6-J, 4K2 122 
E7'V6-P, 4X5 167 
E2,4-PBXI 169 
E2A-HLF170 
API2-ML7471 
ALK-NPA, fl 72 
Childhood B-ALL 
ALL 
ALL 
B-ALL 
B ALL 
MALT 
ALCL 
Table 1.4. Recurrent translocations of lymphoid malignancy resulting in the formation of 
fusion oncogenes. Cloned genes and disease associations. ALCL (anaplastic large-cell 
lymphoma), MALT (marginal zone lymphoma of mucosa-associated lymphoid tissue type). 
1.4.3.2 Translocations affecting E2A. 
The t(1; 19) resulting in the E2A-PBXI fusion oncogene is associated with about 20% of 
cases of paediatric pre- and pro-B cell ALL. E2A encodes a bHLH transcription factor that is 
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required for immunoglobulin and T-cell receptor rearrangement and later stages of lymphoid 
development. PBX] is a class 11 homeobox gene encoding a protein that participates in the 
regulation of cell differentiation through its interaction with HOX proteins. As a result of the 
t(1; 19) the transactivation domain of E2A is joined to the DNA binding domain of PBXI 
producing a fusion protein that is thought to have multiple leukaemogenic effects (reviewed 
by Aspland and Bendall 2001 173) . First, presence of the E2F transactivation domain allows 
PBXI to activate its target genes in the absence of HOX coactivators. Secondly E2A is 
thought to behave as a tsg because it activates the CDK inhibitor p2 I and mice inactivated for 
E2A develop thymomas 174,175 . Thirdly the N-terminal domain of PBXI, not present in the 
E2A-PBXl fusion protein, contains a nuclear/cytoplasmic localisation signal. Wild type 
PBX I is shuttled from nucleus to cytoplasm in a controlled way while E2A-PBX I is located 
permanently in the nucleus' 76 . The constitutive nuclear localisation of E2A-PBXI may 
fimction to alter expression patterns of HOX/PBX I target genes. 
A second translocation involving E2A [t(l. 7; 19)(q22; p 13)] is seen in rare cases of adolescent 
pro-B-cell leukaemia. In this case the partner gene is HLF a gene involved in an 
evolutionarily conserved cell survival pathway (reviewed in Seidel and Look 2001 177 
1.4.3.3 Oncogenes deregulated by translocation to antigen receptors. 
A diverse selection of genes may be deregulated as a result of translocations that replace 
constitutive regulatory sequences with those governing the antigen receptors (Table 
1.5)(reviewed in 127,160) . The observation that variable 
length non-template sequences become 
inserted at the break point junctions of these translocations suggests that ligases associated 
with normal V(D)J recombination are involved in their production. Illegitimate 
immunoglobulin gene rearrangements are found in B-cell malignancies and TCR 
rearrangements in T-cell leukemia/lymphoma. In most cases the deregulated gene is 
translocated to only one antigen receptor gene and is associated with a specific lineage. A 
notable exception is the gene MYC that may be translocated to IGH, IGL, IGK or TCR, 4 and 
is deregulated in several different sub-types of ALL/NHL. Upregulation of MYC leads to an 
imbalance in the ratio of MYC-MAX to MAD-MAX protein complexes that regulate 
transcription of genes controlling normal lymphoid differentiation, proliferation and 
47 
Abnormality Molecular Disease sub-type 
rearrangementReference 
t(2; 8)(pl2; q24) iGK-AHcl78 B-ALL 
t(8; 14)(q24; q32) AHC-IGH479 B-ALL, DLBCL, BL 
t(8; 22)(q24; ql 1) iGL-mycl78 B-ALL 
t(14; 18)(q32; q2l) IGH-BCL2 
180 B-ALL, DLBCL, FL 
t(I 1; 14)(q 13; q3 2) BCLI_IGH481 B-ALL, MCL, CLL, MM 
t(14; 19)(q32; ql3) IGH-BCL3 
182 B-ALL, CLL 
t(5; 14)(q3 I; q32) IL3-IGW 
83 B-ALL 
t(9; 14)(pl3; q32) PAX5-IGH4 
84 LPL 
t(4; 14)(pl6; q32) FGFR_IGH485 MM 
t(6; 14)(pl6; q32) mumi-iGH186 MM 
t(l; 14)(p22; q32) BCLIO_IGH487 MALT 
t(3; 14)(q27; q32) BCL6_IGH488 FL, DLBCL 
t(10; 14)(q24; q32) NFKB2_, GH189 DLBCL 
t(l; 14)(q2 I; q32) AIUCI-IGW90 DLBCL 
t(1; 22)(q2l; qll) FCGR2B-IGLI91 DLBCL 
t(8; 14)(q24; q 11) wc-Tcj? A192 T-ALL 
t(1; 14)(p32; qll) TALI-TCRD' 
93 T-ALL 
t(7; 9)(q35; q34) TCRB-TAL21 
94 T-ALL 
t(7; 11)(q35; pl3) TCRB-LM02 
195 T-ALL 
t(7; 19)(q35; pl3) TCRB-LYLI 
196 T-ALL 
t(10; 14)(q24; qll) HOXII; TCRD 
197 T-ALL 
t(11; 14)(pl3; qll) LM02; TCRD198 T-ALL 
inv(l 4)(q II q3 2) TCL 1; TCW 19 9 T-ALL 
Table 1.5. Lymphoid malignancy associated translocations of antigen receptor genes. Cloned 
genes and disease associations. FL (follicular lymphoma), MCL (mantle cell lymphoma), 
LPL (lymphoplasmacytic lymphoma), DLBCL (diffuse large B-cell lymphoma). 
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apoptosis (reviewed by Boxer and Dang 200 1200). Other genes associated with deregulation 
by IGH in ALL include transcription regulators such as BCL3 and pAX5184,201 , 
BCL-2 that 
plays an anti-apoptotic role through control of cytochrome-c release (described in 1.1.3) and 
cell cycle regulators such as BCL-I 18 1 and the cytokine IL31 83 .A number of other genes 
translocated to the immunoglobulin. loci contribute to NHL but have not yet been associated 
with leukaemia. 
Deregulated genes that contribute to the development of T-cell malignancy include various 
transcription factors or co-factors. These include: a homeobox gene, HOX 1 1342 . The related 
modifiers of transcription TALI (SCL), TAL2, BHLHBI and LYL that are thought to disrupt 
normal T-cell development by forming heterodimers with, and inactivating, the E2A 
transcription factor (see 1.4.3.2)343,344 . Also the rhombotin genes LM01 and LM02 that are 
thought to participate in the formation of aberrant transcription complexes, possibly in 
cooperation with TALI, which disrupt normal T-cell differentiation 345 . 
1.4.3.3 Deletions and amplifications. 
Both deletion and amplification of specific chromosomal regions occur in lymphoid 
malignancies. Amplification frequently results in up-regulation of the oncogenes that are 
seen in translocation with antigen receptor loci. Consistently deleted regions are thought to 
harbour tsgs and in some cases there is strong evidence that loss of function of one or more 
specific genes influence the course of malignancy. 
Deletions of 13q occur frequently in CLL, MM and NHL and also at a lower level in ALL 
and AML. Because of its role in cell cycle control and unambiguous tsg status in 
retinoblastoma, the Rb gene has been the subject of investigation in these diseases. Results of 
LOH, deletion mapping by FISH or expression analysis studies suggest that inactivation of 
02-205 
Rb contributes to AML and NHL but not CLL or ALL2 . In CLL several groups have 
pinpointed a more distal region of 13ql4 that has been analysed and shown to contain a gene 
of unknown function and multiple splice forms (BCMS). Sequence analysis of the RNA 
variants suggested that the BCMS transcripts belonged to a group of non-coding RNAs. As 
yet a mechanism by which loss of BCMS might contribute to leukaemia has not been 
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,, WI 
CCU 
0 
proposed 
206,207 
. Deletion mapping studies suggest that several 
different critical regions are 
lost in mm208. 
Deletions of 9p are common in ALL and a cluster of related genes p]6'Nx4A, p14ARFand 
p15 
flVK4B 
are considered tsgs both because of their functional roles as inhibitors of 
Cyclin/CDK complex formation and activation of p53 (see 1.1.2 and 1.1.3). pI61NX4A and 
p14ARFare transcribed from the same locus but in different reading frames and probably 
modulate each others expression in ways that are as yet poorly understood 
209 
. The three 
genes are closely linked on band 9p2l and in ALL deletion of the region occurs in up to 45% 
of cases. Heterozygous loss of both loci has been reported but more frequently the deletions 
are biallelic with the p16""ý14ARFlocus most frequently involved 210,211 . Both p16 and p15 
may be inactivated through point mutation or promoter methylation (see 1.5) although 
homozygous deletions appear to be the favoured mechanism in leukaemia where they confer 
a poor prognosiS212. 
Deletions of 12p are also a common finding in cases of ALL, the region harbours the ETV6 
gene and loss of 12p invariably accompanies the ETV6-AA4L] translocation (see 1.4.3.1). 
Loss of 12p also occurs in the absence of t(I 2; 2 1), but in these cases biallelic inactivation of 
ETV6 has not been reported and furthermore one refined deletion map of the region excluded 
E7-V6213 .A 
CDK inhibitor (p27K1P) is also located in the frequently deleted region of 12p 
and has been considered a strong candidate tsg. p271-ý was the most frequently deleted gene 
in the region as demonstrated by FISH analysis. One of 16 patient showing hemizygous 
deletion of p27upl was found to harbour a microdeletion encompassing exon 2 though no 
14 inactivating mutations of the second allele were found2 . In another study a 
600kb common 
deleted region (CDR), bound proximally by ETV6, excluded p27 KIP] . An 
investigation of 
methylation changes to CpG islands within the CDR identified de novo methylation at the 
LRP6 locus in 2 of 22 patients analysed. However, inactivating mutations of LRP6 were not 
found 215 
. 
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Abnormality Molecular Disease sub-type 
rearrangement 
Hyperdiploidy 
Hypodiploidy 
del 13q ? BCMS, ? RBI 
del 9p p15 
INK4B. 
P14,4RFIP16LNW4,4 
del 12p ? LRP6, ? TEL, ? p27'upl 
del I Iq A TM 
del 6q 
del lp 
del Iq 
del 3p 
del 3q 
Childhood ALL 
ALL 
CLL, MM, NKL 
ALL 
ALL 
MCL, CLL 
ALL, DLBCL, CLL, FL, NKL 
DLBCL 
DLBCL 
DLBCL 
DLBCL 
del 7q 
del I Oq 
amp2p REL 
amp 8q MYC 
amp 18q B CL 2, CDK4, 
amp 12q AIIDM2, GL I 
SLL, FL 
FL, DLBCL 
NHL 
NHL 
NHL 
NHL 
Table 1.6. Chromosomal imbalance associated with lymphoid malignancies; chromosome 
arm, cloned genes and disease association. SLL (small lymphocytic lymphoma) 
Deletions and other abnormalities of II q22-q23 are frequent and confer a poor prognosis in 
B-cell CLL. Candidate tsgs in the region include 1EL, BCLI and ATM. Of these, ATM was 
found to be the most frequently deleted and Western blot showed 34% of cases of CLL had 
markedly reduced levels of ATM protein 216 . In a second study 5 of 27 cases of CLL with IIq 
deletions were shown also to carry acquired mutations of ATM, as did three cases without 
deletion 217 - ATM 
is a critical component of DSBR (see 1.1.5) and ataxia telangiectasia 
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patients develop lymphoproliferative disorders consistent with the evidence that ATM 
functions as a tsg in CLL. 
Deletions of chromosome 6 are discussed in detail in section 1.6 and 1.7. 
1.4.1 Overview of cytogenetic abnormalities in haematological malignancies. 
The acute myeloid leukaemias are dominated cytogenetically by translocations that involve 
genes encoding master regulators of haemopoietic development (AAff. 1, CBF, 8, RARA and 
AEL) that normally can be positively or negatively acting, depending on the presence of co- 
regulators. As a result of fusions with multiple partners, the regulated transcription factors 
become unregulated suppressors of transcription that are also powerful oncogenes. 
Additional leukaemic effects may be mediated by the reciprocal translocation product and or 
result from abnormal targeting to nuclear or cytoplasmic domains. A network of homeobox 
genes that are largely regulated by the master transcription factors play an important part in 
maintaining blood cell homeostasis. Rare translocations in AML as well as ALL involve 
deregulation of different homeobox genes. 
Translocations seen in MDS, CML and other MPI)s are characterised by the involvement of 
receptor and non-receptor tyrosine kinases that become self-activating as a result of fusion to 
partner gene oligomerisation domains. Of these BCR-ABL is by far the most common and is 
diagnostic for CML. The constitutively activated kinases are thought to exert an oncogenic 
effect by disturbing the normal balance of cellular signals regulating growth and survival. 
Genes encoding master regulators of transcription (Aff-. L, AAE1, ETV6 and E2A) also 
participate in the formation of fusion oncogenes that make an important contribution to infant 
and childhood ALL. Translocations of AlffL and E2A are also seen in cases of adult ALL but 
BCR-ABL is numerically of much greater importance and carries a particularly poor 
prognosis in this group of patients. In ALL the lymphomas and multiple myeloma various 
oncogenes of diverse function are up-regulated as a result of translocations that place them 
under the control of strong antigen receptor promoters. 
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Some proto-oncogenes (eg AMLI), that as a result of translocation become dominant 
negative regulators of transcription, are also considered to be tsgs because they may be 
homozygously or heterozygously inactivated as a result of point mutations. The frequent 
occurrence of cytogenetically visible deletions of several chromosomal regions suggests that 
other tsgs also contribute to malignancies of myeloid, lymphoid or stem cell origin. Biallelic 
inactivation of the multilineage tsg p53 has been found to accompany deletions of 17p in 
leukaemias of various lineages, other recognised tsgs implicated in haematological 
malignancy include ATM (I 1q), Rb (I 3q), pI 5'NK4'3, pl6 INK4A/pl4 ARF (9p) and p27K1P1 (12p). 
Loss of other genes in these regions may also contribute to leukaemia as may currently 
unrecognised tsgs on chromosomes 5,7,20 and 6. 
1.5 Classical Tumour Suppressor Genes, haploinsufficiency and 
Epigenetic effects. 
1.5.1 The Classical Tumour suppressor gene model. 
In the classical tsg model a single allele of the gene is sufficient to suppress tumour 
development, i. e. loss of the gene is recessive 218 . This definition stems from early work 
which established that germ line inactivation of the RB gene resulted in cancer prone 
families. Individuals carrying the RB mutations invariably developed retinoblastomas that 
were shown to be inactivated for both copies of the gene. Mice hemizygous for the Rb gene 
also developed tumours that, even at the microscopic stage, harboured inactivating mutations 
of the second allele. Sporadic retinoblastomas were also found to show biallelic loss of RB 
fimction and a similar scenario was established for other genes, for example, the 
adenomatouspolyposis coli (APQ gene in colon carcinomas 219 . 
1.5.2 Haploinsufficiency and Malignancy. 
As should be clear from the account given of the investigations of candidate tsgs from within 
leukaernia associated CDRs (1.4.1.4,1.4-2.3 and 1.4.3.3), the frequency with which 
inactivating mutations of the second allele are detected, is highly variable. Failure to detect 
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inactivation of the second allele might occur for several different reasons. 1) Expression of 
the tsg is only protective against malignancy above a certain threshold or the efficiency of 
protection is proportional to the level of expression. In this case loss of heterozygosity would 
be sufficient to promote tumourogenesis but homozygous inactivation might have an 
additional effect. 2) Inactivation of the second allele could have occurred through mutations 
in upstream regulatory sequences or epigenetic silencing (see 1.5.3). 3) Loss of function of a 
different gene in the same chromosomal region has been selected for and the deletions 
incidentally encompass the candidate tsg. Recently mouse models have been used to 
differentiate between the three possible mechanisms. 
In a comparison between homozygous p53 knock out, hemizygous p53 knock out and wild 
type mice, turnours arose most frequently in the homozygous (-/-), at an intermediate level in 
the heterozygous (+/-) and at a much lower level in the wild type animals. In p53 +/- mice 
about half of early arising tumours showed homozygous loss of p53 while later arising 
turnours had predominantly retained the wild type allele. The p53 -/- tumours as well as 
arising earlier showed greater chromosomal instability and were more aggressive. No 
evidence for point mutation of the wild type alleles in +/- tumours was found when the 
coding region was fully sequenced and p53 could be detected on Western blot. Furthermore 
tests of p53 function were consistent with the presence of a functional allele in the 
220 turnours 
The tsg PTEN is deleted in a range of tumours but the rate of occurrence of inactivating 
mutations of the second allele is often low. For example 30-40% of invasive breast cancers 
show loss of lOq23 but inactivating mutations of PTEN are found in less than 5%. The 
offspring of Pten +/- mice bred with transgenic adenocarcinoma of mouse prostate (TRAMP) 
mice were found to develop prostate cancers significantly earlier than Pten wild type 
TRAMP mice. Inactivating mutations of the second allele were not found in the tumours and 
furthermore Pten -/- TRAMP mice developed tumours at a rate only slightly higher than their 
heterozygous counterpartS221. 
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p27"-'ý' has a function consistent with a tsg role and is frequently deleted in human tumours 
(see 1.4.3.3). However, its tsg status was in doubt because inactivating mutations of the 
second allele have not been reported and familial mutations are unknown. p27rý'P' +/- mice 
were shown to develop tumours earlier than wild type controls. None of the tumours showed 
loss or point mutations of the second allele and the protein was expressed and appropriately 
targeted to the nucleus 222 . This data strongly supports the suggestion that loss of 
heterozygo sity of p2 7K'P1 drives selection of the 12p deletions that are seen in many tumours 
including lymphoid leukaemias. 
Inherited mutations may also contribute to malignancy without loss of the second allele. 
Families with the rare autosomal dominant disorder known as familial platelet disorder with 
predisposition to AML (FPD/AML) were recently shown to carry point mutations of AMLI 
)87 (CBFA2 
. 
As discussed in 1.4, AAff, 1 is a component of a transcription complex that is 
critical to myeloid development and through chromosomal translocation is involved in the 
formation of several fusion oncogenes. Analysis of leukaemic cells from patients with 
FPD/AML failed to reveal mutations in the second allele of AAE1 suggesting that this gene 
can also contribute to leukaemia through haplo insufficiency alone. Interestingly point 
mutations in the runt domain of AMLI have been found in approaching 5% of sporadic 
myeloid malignancy (mostly MO AML) but in these cases inactivation was bialleliC86. 
Overall a scenario is emerging in which the classical tsg model, where homozygous 
inactivation is absolutely required to overcome a block in the path towards tumourogenesis, 
represents an extreme that probably applies to only a few genes and maybe limited types of 
cancer. At the opposite end of the spectrum there may be genes for which heterozygous 
inactivation results in complete loss of their anti-tumourigenic effects. In this, as yet 
hypothetical case, deletion or mutation of the second allele would never occur. The majority 
of tsgs probably behave in a way that is intermediate between the two situations, with a 
single functional copy of the gene providing some but not complete protection against 
malignancy. The frequency with which mutations accompany deletion of a tsg would in part 
depend on how closely its function conforms to one or other of the extreme models. The rate 
of homozygous inactivation is also expected to depend on the strength of the selective 
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advantage gained by its loss and the stage of disease at which the advantage is conferred. If 
loss of a tsg is a late stage event and the selective advantage gained is weak, the frequency of 
inactivation of the second allele is likely to be low. Conversely more powerful tsgs that arise 
early in the course of disease will have greater opportunity for biallelic loss. 
1.5.3 Epigenetic silencing and malignancy 
In parallel with the acquired changes that in some way modify the germ line genetic code, 
malignant cells are characterised by major disruptions to the subtle pattern of DNA and 
chromatin associated protein modifications that regulate normal cellular expression patterns 
(reviewed by 223) 
. As discussed in section 1.4 alterations to the acetylation status of histones 
in gene regulatory regions, are brought about when transcription factors are deregulated as 
the result of translocation. A second important type of modification involves DNA 
methylation that may in part also result from the activity of fusion oncogenes 224 . 
Globally, 
transformed cells undergo hypomethylation while at the same time CpG islands associated 
with regulatory regions become densely methylated leading to gene silencing. Methylation 
changes have been implicated in a diverse range of effects that contribute to the malignant 
phenotype including; chromosome instability, activation of endogenous parasitic sequences, 
aneuploidy, loss of imprinting, activation of oncogenes and silencing of tsgs. Depending on 
the tissue and locus involved promoter methylation may replace deletion or point mutation as 
a mechanism for tsg silencing. A good example of a genomic region that can be alternatively 
affected by large deletions, single base pair mutations and CpG island methylation is that 
containing the p]6'7vx4'lp I 44RFand p15 MK4b genes. As discussed in 1.4.3.3 these genes are 
frequently inactivated by deletion and or point mutation in lymphoid malignancies. In T-cell 
leukaemia/lymphoma the p 15 locus was methylated at a rate of 20% while p 14 and p 16 were 
methylated at rates of 6 and 3% respectively 225 . In 
hepatocellular carcinomas 
hypermethylation of p14ARFwas reported to be at a level of 29-46% and of pl6flvK4' at 25- 
32%. LOH of the locus was also common among these patients and found to bear a 
reciprocal relationship to methylation 226 . 
Imprinted genes are methylated differentially with one parental homologue unmethylated and 
actively transcribed and the second allele methylated and inactive. In principle 
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deletion/mutation of only the active allele at an imprinted locus could lead to complete loss 
of function of a tsg. Loss of imprinting (LOI) appears to be a mechanism by which 
oncogenes such as IGFIl are upregulated in some malignancies including those of the 
haematopoietic systeM227. 
In summary cytogenetically visible deletions may unmask inactivating mutations in classical 
tsgs that are either present in the germ line or somatically acquired. Animal models 
demonstrate that loss of a single allele of some tsgs is sufficient to promote tumour 
formation. Tsgs lost as the result of leukaemia associated deletions show great variability in 
the rate of mutation/deletion of the second allele and it is likely that in some cases a 
functional protein is produced but at a sub-optimal level. In other cases the second allele may 
be silenced through an alternative mechanism such as promoter methylation. 
1.6 Cytogenetic abnormalities of 6q in haernatological 
malignancies. 
Reported cytogenetic abnormalities of both myeloid and lymphoid malignancies include 
sporadic and rare recurrent translocations involving the long arm of chromosome 6. Four 
oncogene partners have so far been cloned from 6q translocations, others are still 
uncharacterised at the molecular level. Among lymphoid malignancies rearrangements that 
result in apparent loss of 6q material are numerically of much greater importance than are the 
balanced translocations. Deletions, unbalanced translocations and trisomy of chromosome 6 
also occur in cases of myeloid malignancy but at a lower frequency. As yet, no tsg has been 
identified on 6q. 
1.6.1 Balanced translocations of 6q. 
Two translocations involving Aff. L, t(6; I 1)(q27; q23) and t(6; I 1)(q2 I; q23) result in the AffL- 
AF6 and AffL-AF6q2l chimeric oncogenes, respectively. AffL-AF6 accounts for about 5-6% 
of all Aff. L translocations and although chiefly associated with AML M4 and M5 has also 
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been found in cases of ALL 228. Only a few cases of AILL-AF6q2l have so far been described 
though there is an apparent association with therapy-related AML 144,229 . As discussed in 1.4.2 
MLL is a highly promiscuous oncogene partner that as a result of rearrangement always 
maintains its DNA binding domain. As a consequence of the rearrangements the 
transcriptional regulation of MLL targets, that include genes involved in haematopoietic 
development, is disrupted. However, additional leukaemogenic effects may be mediated 
through the partner genes that can influence disease type and prognosis. 
AF6 encodes a RAS binding protein that as a result of fusion to AIILL is moved from its wild- 
type cytoplasmic location to the nucleus 230 . Since RAS itself is an important oncogene 
encoding a protein that transduces growth and survival signals, loss of normal AF6 fimction 
resulting from abnormal cellular localisation, may well influence the phenotype of 
t(6; I 1)(q27; q23) positive leukaemias. In addition AF6 was recently shown to bind LM02, a 
LIM only protein known to act as a bridging molecule between different components of the 
haematopoietic gene regulatory protein complexeS231 . Thus as a result of translocation AF6 
may recruit regulatory complexes to the promoters of MLL target genes. 
AF6q21 encodes a member of a family of proteins that have in common a forkhead DNA 
binding domain. Among the forkhead family members AF6q21 showed highest homology to 
two other oncogene partners AFX and FHKR. 4FX is also a an ALL oncogene partner and 
FHKR is found fused to two related transcription factors PAX3 and PAX7 in alveolar 
rhabdomyo sarcomas 155,232,233 . 
On the basis of their functional domain content, the forkhead 
genes are considered to be transcription regulators. In haematopoietc tissues the forkhead 
family members are expressed in a lineage-restricted manner although their specific 
functions are currently unknown. Formation of the oncogenic fusion genes result from breaks 
occurring in the first intron of the forkhead gene in each case, suggesting that one or more 
common domains make a critical contribution to transformation. 
Tbree of the related constitutively activated tyrosine kinase fusion oncogenes (introduced in 
1.4.2.1) involve the fibroblast growth factor receptor (FGFRI) gene positioned on the short 
arm of chromosome 8. As a consequence of t(6; 8)(q27; p 11) the FGFRI oncogene partner 
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(FOP) becomes fused to FGFRI in rare cases of MPD. FOP encodes a widely expressed 
and evolutionarily conserved protein with multiple splice forms. The function of FOP is 
unknown but the presence of novel leucine-rich repeats suggests that it can participate in 
protein-protein interactions. The FGFRI gene encodes one of four tyrosine kinase receptors 
that transduce growth, survival and differentiation signals on binding members of the 
fibroblast growth factor family. As a result of t(6; 8) the intracellular tyrosine kinase domain 
of FGFRI becomes joined to the N-terminus leucine rich region of FOP that is assumed to 
mediate oligomerisation of the chimeric gene 234 . Based on the known activity of related 
oncogenic fusion proteins (such as Bcr-Abl or ZNF198-FGFRI) it is likely that 
oligomerisation of FOP-FGFRl results in a constitutively phosphorylated tyrosine kinase that 
activates FGFRI downstream targets and stimulates haematopoietic stem cell proliferation. 
In the case of the t(6; 8) originally cloned, fusion between exon 6 of FOP and exon 9 of 
FGFRI occurred and both FOP-FGFRI and FGFRI-FOP transcripts were expressed. A 
leukaemogenic role for the reciprocal FGFRI-FOP fusion protein has not been postulated. 
Two further cases of t(6; 8), including patient 34 analysed by FISH in this study, have since 
126 been cloned and shown to involve fusion of exon 9 of FGFRI but exons 5 and 7 of FOP . 
Analysis of a larger group of patients would be required to determine whether the position of 
break points in FOP influence the course of leukaemia in any way. 
One further gene on 6q has been implicated in leukaemia as a result of analysis of a t(6; 12) in 
a cell line established from a case of childhood B-cell precursor ALL. Cloning of the gene 
revealed that fusion between ETV6 and a novel gene (six twelve leukaemia or STL) had taken 
place 235 . ETV6 is a proto-oncogene that can contribute to the generation of 
haematological 
malignancies of different lineages through translocation to multiple partner genes (see 1.4). 
Leukaemogenic mechanisms resulting from ETV6 translocations include ectopic expression 
through position effect and the formation of chimeric genes that are either deregulated 
transcription factors or self-activating tyrosine kinases. The significance of the involvement 
of STL in this rare, if not unique, translocation was difficult to gauge from sequence and 
expression data. The ETV6-STL transcript was relatively abundant but gave rise to only a 
very short open reading frame that excluded the critical HLH and ETS domains of ETV6, and 
coded for only 14 amino acids from SM The STL-ETV6 transcript could not be isolated from 
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the cell line c-DNA and would have been transcribed under control of the STL promoter. 
Northern analysis suggested that STL was transcribed only at a low level in haematopoietic 
cells. An important consequence of the translocation may have been loss of ETV6 function 
because a deletion of 12p that resulted in loss of the second allele was detected in the cell 
line. Of interest, in relation to this study, was the fact that the t(6; 12) was only recognised 
after FISH analysis when the break point on 6 was assigned to q23. 
Translocations between 6 and 12 with a 6q23 break point have not been reported in cases of 
leukaemia though a rare but apparently recurrent t(6; 12)(q2l; pl3) was associated with 
childhood ALL and an early pre-B immunophenotype 346 . In these cases no molecular 
analysis was performed so it is possible that the break point had been mis-assigned and that 
these cases also involved STL. Two cases of infant acute basophilic leukaemia were reported 
to have a t(X; 6)(pl I; q23) as the sole karyotypic abnormality 236 .A third case of t(X; 6) with 
identical break points was associated with acute megakaryoblastic leukaemia 237. Though 
evidently rare the t(X; 6) seems also to be a recurrent rearrangement though the break points 
have not been cloned in any of these cases. A second t(X; 6) with a break point at 6ql5-16 
was reported in three cases of congenital or infant leukaemia 238 . 
In addition to the rare recurrent but uncloned translocations sporadic translocations involving 
6q have been reported. In one of the sporadic rearrangements a t(2; 6), found in a case of 
biphenotypic leukaemia, was also assigned a 6q23 break point239. Individual reports of other 
translocations that so far remain unique include a t(6; I 0)(q27; ql 1) in a case of idiopathic 
myelofibrosis and a t(6; 8)(q25; q22) in T-cell blast crisis of Ph+ CML 240,241 . Further examples 
of sporadic balanced rearrangements of 6q that had been included in large cytogenetic studies 
can be found on searching the Mitelman database of published chromosome aberrations in 
cancer at (http: //cgap. nci. nih. gov/ Chromosomes/Mitelman). These included translocations, 
paracentric and pericentric inversions and insertions and were in no case the sole cytogenetic 
abnormality. Twelve of the additional sporadic 6q abnormalities were associated with 
myeloid and 7 with lymphoid leukaemias. Of myeloid associated abnormalities 5 involved 
6q27, other bands were not preferentially involved. 
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1.6.2 Unbalanced rearrangements of 6q. 
Cytogenetically detectable deletions of 6q [del(6q)] are common in both B and T ALL of 
childhood and adults, CLL, MM and NHL, they may also be found in myeloid malignancies 
but at a much lower frequency. In several large cytogenetic studies, 4-13% of cases of ALL 
and 17-23% of NHLs have been assigned deletions of 6q 242-249 . In childhood ALL 
loss of 6q 
was found to be associated with abnormalities of either 12p or 9P250. In other cases del 6q co- 
existed with deletions of 12p suggestive for involvement of the other homologue in t(I 2; 2 1). 
Loss of a tsg on 6q may therefore be selected preferentially against a genetic background that 
includes the ETV6-AAE] fusion or loss of CDK inhibitors. 
Morphology of ALL karyotypes is poor and the banding pattern of 6q not highly distinctive, 
factors that may account for the wide variety of break points assigned to 6q deletionS25 I- 
Despite these difficulties it has been claimed that all 6q deletions seen in ALL involve the 
band q21 suggesting that a tsg may be located in this region 250 . Early reports that 6q deletions 
252,253 
are associated with a poor outcome in ALL have not been substantiated by later studies 
1.7 FISH and molecular studies of 6q deletions in Leukaemia. 
With the aim of identifying a tsg several groups have attempted to establish a common 
deletion region (CDR) (also often referred to as region of minimal deletion [RMD]) on 6q, 
using either FISH or the molecular technique of microsatellite analysis. Studies of 
haematological malignancies, focusing on chromosome 6, have been restricted to the 
lymphoid malignancies. Some groups analysed both leukaemias and NHL while others have 
chosen to concentrate on a disease sub-type. Published FISH studies have made use of YAC 
clones containing sequences of genetic markers or genes mapped to 6q. An early FISH study 
defined 2 CDRs. The proximal region, common to both ALL and NHL were bounded 
centromerically by the gene M6P] (6ql4) and distally by the marker D6S246 (6q2l). A 
second CDR in the q23-q telomere region was restricted to lymphomas and based on the 
observation of non-contiguous deletions in two patientS254. In a follow up study from the 
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same group further non-contiguous deletions in cases of lymphoma confirming the distal 
CDR. Proximally two ALL and two lymphoma patients defined a narrow CDR between two 
markers at band 6q2l, D6S447 (proximal marker) and D6S246 (distal marker)255 . Further 
YACs positioned between these two markers were isolated and used to investigate 21 
patients with ALL and cytogenetic deletions of 6q in a study conducted in this department256 . 
We found five patients that retained the marker D6S447 but were deleted for more proximal 
markers. Two patients while retaining D6S447 were deleted for the more distal YAC 
36CB II (containing CD24). Furthermore, one of the patients retained YAC 860fI0 that was 
mapped distal to D6S447. An uncloned gap, that on the basis of interphase FISH we 
estimated to be approximately I Mb in size, existed between YACs 860FIO and 36CBI I. We 
concluded that either 1) expression of a large gene, positioned within the uncloned gap, was 
affected by both proximal and distal deletions or 2) two discrete and independent regions of 
deletion in the 6ql6-q2l region existed. One case included in the study (patient 21) showed 
evidence for clonal evolution from a small to a large deletion. The smaller deletion was 
situated proximal to D6S447 and the larger, detected in a smaller proportion of metaphase 
cells, extended distally to include D6S302 (band 6q22). The pattern of deletion seen in this 
case was consistent with loss of the more proximal of our two regions being an earlier stage 
event in ALL than loss of the more distal region. Deleted and retained probes for critical 
patients used to define CDRs from the 3 FISH studies are presented diagrammatically in Fig 
1.2. 
One further FISH study and a further four reporting on LOH of 6q markers in ALL samples, 
have been published 257-261 . The position of the 
CDRs, derived from these studies, in relation 
to each other as well as the data obtained in the present study, are presented more extensively 
in chapter 3 (Fig 3.7). In one case two CDRs were obtained making a total of six. All six of 
the published CDRs overlapped with the more proximal of the two independent regions we 
identified, two also overlapped with the more distal of our regions. It should be emphasised 
that in three of the five studies not all patients fell within the published CDR and that there 
were some differences in the disease sub-types, included in the studies. The relationship 
between the published CDRs is discussed further with respect to data obtained in the current 
study in chapters 3 and 4. 
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Fig 1.2 Informative patients from three studies in which metaphase cells from 
cases of lymphoid malignancy with deletions of 6q were analysed by FISH with 
YACs. Black boxes indicate that the probe was deleted, white boxes indicate that 
the probe was retained. Common deleted regions (CDRs) defined in each study 
are indicated by broken lines. In the first two studies loss of the region telomeric to 
D6S238 was associated with cases of NHL while a more proximal region was 
common to both NHL and ALL. In the most recent of the studies cases of ALL 
only were analysed using newly identified YACs from within the earlier defined 
proximal CDR. Two independent ALL associated CDRs were identified as a 
result of this study, one proximal to D6S447 and the second distal to YAC 860t-10. 
Clonal evolution from a small (A) to a large (B) 6q deletion appeared to have 
Taken place in one patient analysed in the final study. 
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1.9 Aims of the project. 
The present project was set up in part to address a number of questions posed by our 
published 6q deletion study. Firstly, a more detailed analysis of patients with deletions 
restricted to either the proximal or distal region was needed in order to evaluate the 
possibility that transcription of a single gene could be affected by both sets of deletions. 
Secondly, if the two regions could be established to be truly independent it would be 
important to determine the relative frequency of deletion within the proximal and distal 
regions and to attempt to define narrow CDRs within them. Evaluation of the importance of 
the CDRs and any candidate tsgs would be based not only on the pattern of deletion among 
patients in our own study but also through comparison with published data. 
To accomplish the above aims effectively, material was collected from additional patients 
referred to our department and also from laboratories contributing to the leukaemia research 
fund UK cancer cytogenetics karyotype database in acute leukaemia (Database) (kindly 
requested by Dr C. J. Harrison and Dr M. Martineau). Cytogenetic samples from ALL 
patients and also a small number of AML patients, with cytogenetically detectable deletions 
of 6q, were obtained. Additional cases of both ALL and AML reported to bear balanced 
translocations or inversions of 6q were also included in the pool of samples to be analysed. 
The YAC probes previously used for FISH analysis of 6q abnormalities were large in size 
and hence of limited use for the resolution of chromosomal breakpoints. YACs are also prone 
to recombination and technically difficult to use. Since contigs of PAC and BAC probes now 
cover a large part of the genome it was decided to establish a panel of these smaller, more 
robust probes for the analysis of leukaemia associated abnormalities of 6q. 
In summary the aims of the project were: 
1) To establish a panel of PAC and BAC FISH probes distributed between 6qI I and the 6q 
telomere. 
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2) To map the position of breakpoints in cases of acute leukaemia with cytogenetically 
detectable deletions or balanced rearrangements of 6q, using the panel of FISH probes. 
3) To identify one or more CDRs that would then be mapped in greater detail with further 
PACs and BACs. 
4) To identify and assess, by comparison with published data and ultimately using molecular 
techniques, candidate tsgs from within the CDR/CDRs. 
5) To identify common 6q break points among the cases with balanced rearrangements. 
6) To map in detail by FISH any common 6q breakpoints identified. 
7) To assess the involvement of known proto-oncogenes on partner chromosomes of the 6q 
translocations. 
8) To determine the sequence, at the breakpoints of 6q translocations, found to be either 
recurrent or to disrupt genes known to be involved in malignancy. 
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Chapter 2 (Materials and Methods) 
Details of the preparation of materials, where not described in the text of this chapter, can be 
found in appendix 1. All oligonucleotide sequences are presented in Appendix 2. 
2.1 Patients' material. 
Fixed cell suspensions from bone marrow samples of patients with ALL and AML as 
prepared for cytogenetic analysis with accompanying karyotypes were obtained from the 
Department of Haematology, Royal Free and University College School of Medicine. Further 
ALL samples were obtained from laboratories of the United Kingdom Cancer Cytogenetics 
Group (UKCCG) on request through the Database. Slides were made (as described in 2.2 
below) and stored at -20'C for future analysis by FISH. 
2.2 Cell lines. 
Cell lines RPMI 8402, Molt 4 and Peer were obtained from the German National Tissue 
Culture collection (DSMZ). Cells were grown in RPMI-1640medium (Sigma cat # R8758) 
with 10% batch tested foetal calf serum, penicillin I mg/ml and streptomycin I mg/ml in 50ml 
plastic tissue culture flasks. After overnight incubation with 40gg/ml colcemid (Gibco cat 
#15210-040) 10 ml of cells were transferred to 15ml centrifuge tubes and pelleted by 
spinning at 1,600 rpm for 10 minutes. The supernatant was discarded and the cells re- 
suspended in 10ml 0.075 M KCI before incubating at 370C for 10 minutes. The cells were 
again centrifuged at 1,600 rpm for 10 minutes and the supernatant removed leaving 
approximately Iml to resuspend the cells in. After resuspending the cells, 10 ml of ice cold 
freshly prepared 3: 1 methanol/acetic acid fixative was added dropwise while gently agitating 
the tube. The cells were pelleted and resuspended in fixative twice more, the second time 
adding only enough fixative to create a milky solution. 
Cytogenetic preparations were made by running a drop of cell suspension, followed by a 
drop of fixative, down a dampened slide. Slides for FISH analysis were sealed in plastic and 
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stored at -200C. Slides for G-banded analysis were baked on a hot plate at 600C overnight, 
dipped briefly in 1-2% trypsin in PBS then washed in PBS. Slides were then washed in pH 
6.8 'Gurr' buffer (Gibco BRL cat # 10582-013) then stained in 20% Leishmans solution in 
pH 6.8 buffer. After drying and coverslipping the G-banded slides were analysed to confirm 
the presence of del(6)(q). Further slides were made and stored at -20'C for future analysis by 
FISH. 
2.3 Database Searches. 
Clones containing specific markers were identified by searching the chromosome 6 ACEDB 
database, available through a link at the web site http: //www. sanger. ac. uk /HGP/Chr6/. PACs 
positioned onto contigs, in the ACEDB database, are assigned 6-fpc values for left hand 
(centromeric) and right hand (telomeric) ends that identified their positions relative to other 
probes on chromosome 6. The 6-fpc values could therefore be used as a measure of the 
relative position of all chromosome 6 PACs and BACs in the database although the size of 
remaining gaps between contigs were necessarily estimated. Sets of probes used for more 
detailed secondary FISH analysis were obtained by selecting PACs or BACs with fpc 
numbers intermediate in value between pairs of probes in the primary panel. 6-fpc values 
quoted for PACs and BACs obtained through HGMP throughout this thesis were accurate at 
the time of analysis but may be altered in future versions of the chromosome 6 physical map. 
FISH analysis of patient and cell line material identified several regions of 6q likely to harbor 
genes that make some contribution to leukaemia. The regions were contained within contigs 
derived from mixtures of fully and partially sequenced clones. Fully sequenced clones were 
viewed in the 6 ACEDB Database where exons of known or predicted genes, positioned on 
the clones, are presented in graphical form. Relatively large regions of the genome were also 
scanned rapidly for the presence of known genes using ENSEMBLE, a graphical database 
run jointly by the European Bioinformatics Institute and the Sanger center at 
http: //www. ensembl. org. Detailed positioning of exons genetic markers and ESTs was 
carried out using the BLAST search facility of the National Centre for Biotechnology 
Information (NCBI) at http: //www. ncbi. nlm. nih. gov. 
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2.4. Preparation of DNA Probes for FISH analysis. 
2.4.1 Large-scale preparation of DNA from PAC and BAC clones (maxiprep) 
PAC (from libraries RPCI 1, and 4) and BAC (from library RPCI 11) clones positioned on 
chromosome 6 by the human Genome Mapping Project (HGMP) were obtained on request 
through the UK HGMP resource Centre, Hinxton, Cambridge (bftp: //www. h=. mrc. ac. uk). 
The clone PI-3742 (containing CCNC) was kindly supplied by Dr J. M. Lahti, Department of 
tumour cell biology, St. Jude Children Research Hospital, USA. Clones were streaked onto 
LB agar plates containing appropriate antibiotic (PI-3742, RPCI, and 4 kanamycin 25gg/ml, 
RPC11 ampicillin 100 gg/ml), and placed in a 370C incubator for 16-48 hours. Single 
colonies were picked and grown overnight in 50 ml 2xTY containing the appropriate 
antibiotic. 
600 gl of the overnight culture was used to prepare a 15% glycerol stock for storage at -700C. 
The remainder of the culture was transferred to a 50ml Falcon tube and spun in a MSE 
mistral 2000 centrifuge at 3,000 rpm for 15 minutes. The supernatant was discarded and the 
cell pellet resuspended by vortexing in 5ml of cold GTE. Following a 10 minute incubation 
at room temperature the cells were lysed by addition of 10ml of freshly prepared 0.2M 
NaOH/1% SDS. After mixing and incubating for 5 minutes at room temperature, bacterial 
DNA, proteins and lipids were precipitated by adding 5ml of 3M Na Acetate (pH 4.8). The 
contents of the Falcon tube was shaken vigorously and incubated on ice for 15 minutes to I 
hour before centrifuging at 3,000 rpm for 15 minutes. The supernatant was strained through 
gauze into a fresh Falcon tube. PAC or BAC DNA was then precipitated, by adding an equal 
volume of isopropanol and incubating on ice for 5-10 minutes. The DNA was pelleted, by 
centrifuging as before, then resuspended in 2ml of TE. High molecular weight RNA was 
precipitated by adding 2 ml of 5M LiCl to the suspension and incubated on ice for 5 minutes. 
The tube was then centrifuged at 3,000 rpm for 5- 10 minutes and the supernatant transferred 
to a fresh Falcon tube. DNA was again precipitated by adding 2 volumes of ethanol (kept at - 
200C), and incubating on ice for 5 minutes. After again centrifuging at 3,000 rpm for 5-10 
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minutes and discarding the supernatant, the pellet was dissolved in I ml of TE. To degrade 
remaining RNA, the tube was placed in a 370C water bath for 15 minutes after addition of 
4gl of I Omg/ml DNase free RNase. DNA was recovered by transferring the solution to a 2ml 
microcentrifage tube, adding 500gl 2.5M NaCI/20% polyethylene glycol and incubating on 
ice for 5 minutes. After centrifuging at 13,000 rpm for 5 minutes the supernatant was 
discarded and the pellet dissolved in 500gl TE. The DNA solution was cleaned twice with 
PCIA and once with chloroform/isoamyl alcohol (24: 1; v: v) then precipitated by adding 0.1 x 
3M Na Acetate and 2x ethanol and storing over night at -700C. The DNA was pelleted by 
centrifuging at 13,000 rpm for 10 minutes, washed once with 70% ethanol and, after 
removing the supernatant, allowed to dry at room temperature. The dried pellet was dissolved 
in 100-200gl TE. Concentrations of DNA were determined and purity checked by measuring 
absorbance at 260 and 280 nm. DNA solutions were stored at -700C. 
2.4.2 Preparation of Yeast Artificial Chromosome (YAC) DNA. 
YAC clones where obtained on request from the UK HGMP resource center, Hinxton Hall 
Cambridge, streaked onto AHC agar plates and incubated overnight at 300C. Individual 
colonies were then picked and used to inoculate 10ml AHC medium in 25 ml plastic 
universal tubes. The cultures were grown in a shaking incubator at 370C overnight and cells 
pelleted by centrifuging for 10 minutes at 3,000 rpm in a MSE Microcentaur bench top 
centrifuge. After discarding the supernatant the pelleted cells were washed with 500gl 
distilled H20 and transferred to 1.5 ml microcentrifuge tubes. The cells were again pelleted 
by centrifuging at 13,000 rpm for 30 seconds and after discarding the supernatant 
resuspended in 200gl GDIS solution. Tubes were then vortexed continuously for 5 minutes 
after adding 0.35g of acid washed glass beads (Sigma cat # G-1152) and 200gI phenol 
(Sigma cat # T/P633/05). 200gl distilled H20 was then added to the suspensions before 
centrifuging at 13,000 rpm for 4 minutes. The aqueous layer was carefully transferred to a 
second eppendorf tube and treated with 5gl 10mg/ml DNase free RNase A (Sigma) for 20 
minutes at 370C. The DNA was then cleaned by extracting twice with PCIA and once with 
chloroform/isoamyl alcohol (24: I; v: v). Cleaned DNA was precipitated with 0.1 x IOM NaAc 
and 2x Ethanol at -700C overnight. Tubes were then centrifugation at 13,000 rpm for 10 
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mmutes, the supernatant discarded and DNA pellets washed with 70% ethanol. After 
washing, the pellets were dried at room temperature and re-suspended in 20-100gl TE 
depending on the pellet size. An estimate of the concentration of DNA was made by running 
5ýd aliquots on a 50 ml 0.8% agarose gel with 100-500ýtg uncut phage X. 
2.4.3 Preparation of fluorescence labeled DNA probes 
For two colour FISH experiments probes were labelled by incorporation of Spectrum Green 
or Spectrum Red conjugated d-UTP (Vysis cat # 30-803200 and 30-803400) using a nick 
translocation kit (Vysis cat # 32-801024). Individual labelling reactions containing the 
following were set up in 1.5ml microcentrifage tubes on ice; xgl (Igg) probe DNA, (17.5 - 
x) gl nuclease free H20,2.5gl 0.2mM SpectrumGreen or SpectrumRed dUTP, 5gl O. IMM 
dTTP, I OgI dNTP mix (0.1 mM each of dATP, dCTP and dGTP), 5gl Nick translation buffer, 
I OgI Nick translation enzyme (a mixture of DNA polymerase I and DNase 1). Reactions were 
mixed by vortexing and incubated for 14 hours in a water bath at 150C in the dark. Labelled 
probes were precipitated overnight at -700C with 50[tg Cot I DNA, 50gg salmon sperm 
DNAý 50gg tRNA, 0.1 x volume 3M NaAc and 2.5 x volume EtOH. After spinning for 10 
minutes at 13,000 rpm in a microcentrifuge the supernatant was discarded. Probes were then 
washed with 500gl 70% EtOH, centrifuged for 5 minutes and after removing supernatant by 
pipette allowed to dry at room temperature. Dried probes were resuspended at a 
concentration of 20ng/gl in hybridisation buffer (Applygene Oncor, cat # S1390-1) and 
stored at -200C in the dark. All probes where hybridised to normal metaphases obtained from 
PHA stimulated peripheral blood to check for the presence of red or green signals on the long 
arm of chromosome 6. 
For three-colour FISH analysis a third fluorescently labelled dNTP, Alexa, 532-5-dUTP 
(Molecular probes) was incorporated by nick translation as for Spectrum Green or Red. 
2.5 FISH procedure and analysis. 
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2.5.1 Pre-treatment of cytogenetic preparations. 
After removing from -20'C slides for FISH analysis were immersed in a freshly prepared 3: 1 
methanol: acetic acid fixative on ice for I hour, dried then treated with 100gl 0.01% pepsin 
(manufacturer cat #) at room temperature under a coverslip. Slides were placed in a coplin jar 
containing 2xSSC at 60'C for I hour then dehydrated through an ethanol series (70%, 90% 
and 100%), excess ethanol was allowed to dry at room temperature. Slides to be reused after 
a previous FISH experiment (re-FISH) where soaked in PBS for I hour after first removing 
nail varnish. Coverslips were then carefully removed before placing slides in fresh ice-cold 
fixative for I hour and then dehydrating as above. 
2.5.2 Hybridisation using single locus probes. 
2gl of each probe to be used were mixed and made up to a total volume of 5-6gl with 
hybridisation buffer. The probe mixture was then placed onto the slide and covered with a 22 
xII mm. plastic coverslip and after removing air bubbles sealed with rubber cement. Target 
DNA and probes were then denatured simultaneously by placing the slides on a 70'C hot 
plate for 2 minutes. Hybridisation of probes to their complementary sequences was achieved 
by placing slides in a sealed moist chamber for 24-72 hours at 37'C in the dark. Following 
hybridisation, coverslips were removed and the slides washed once in OAxSSC for 3 minutes 
at 70'C and 3 times for 2 minutes at room temperature in 4xSSC + 0.05% Tween 20 (BDH 
cat # 663684B). Slides were then coverslipped with lOgI vectorshield antifade solution 
(Vector Laboratories, Burlington, CA. cat # H-1000) containing 0.2ng/gl DAPI. Before 
analysis the edges of the coverslips were sealed with nail varnish. Care was taken to 
minimise exposure of the fluorescent probes to light throughout the procedure. 
2.5.3 Hybridisation of whole chromosome paint (WCP) probes. 
WCPs derived from flow sorted chromosomes and pre-labelled with Spectrum Green or 
Spectrum Red were obtained from Cambio Ltd, Cambridge UK. I gl of each WPC to be used 
was added to a microcentrifuge tube, made up to a total volume of 6gl with the 
manufacturers hybridisation buffer and mixed by vortexing. Hybridisation to slide bound 
chromosomes was performed as described in 2.7.2. Following hybridisation slides were 
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washed in 0.5xSSC at 720C for 5 minutes then 3 times for 2 minutes at room temperature in 
4xSSC + 0.05% Tween 20. Slides were mounted as for single locus probes. 
2.5.4 Analysis of FISH preparations. 
Visualisation of FISH signals was performed on an Axioplan fluorescence microscope (Karl 
Zeiss, Germany) equipped with appropriate filters (Chroma Technology) and MacProbe 
software (Applied Imaging International, UK). For analysis of leukaemic samples single 
locus probes were hybridised in pairs labelled with Spectrum Red and Spectrum Green. 
Probes labelled in Spectrum Red were either from the 6q centromeric region (RPC I-71H 19) 
or the 6q telomeric region (RCPI-167AI4 or RCPI-57M24). A primary panel of 25 
Spectrum Green labelled probes positioned on Sanger centre PAC/BAC chromosome 6 
contigs between the centromeric and telomeric markers were used for the initial analysis. 
Analysis was restricted to metaphase cells and signals defmed by the appearance of pairs of 
closely aligned red or green dots, one on each of the two sister chromatids of a chromosome. 
A metaphase cell was scored only if 2 clearly positive red and or green signals were visible 
(or 3 or 4 signals in the case of clones trisomic/tetrasomic for chromosome 6). A cell was 
scored as deleted for a probe if either a red or green signal only was seen on a chromosome 
and the missing signal not present on any other chromosome (Fig 2.1). For each cell scored 
the retained probe acted as an internal positive control for hybridisation efficiency and the 
marked chromosome was examined to ensure that a signal had not been obscured by overlap 
with a second chromosome. Clonal deletion was defined by the loss of signal in a minimum 
of 5 metaphase cells and in not fewer than 20% of the total cells observed. 
If red and green signals were seen on two different chromosomes the cell was scored as 
having a translocation of 6q with a break point between the two probes (Fig 2.2). A case was 
defined as having a clonal translocation of 6q if red and green signals were seen on different 
chromosomes in a minimum of 3 cells and in not fewer than 20% of the cells observed. 
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Fig 2.1 Example of FISH probes hybridised to metaphase cells from an ALL 
patient(Number 2) with del(6q) a) Pairs of red and green signals are present on 
both the del (6q) and the normal chromosome 6 (probe retained). b) Red and 
green signals mark the normal chromosome 6 but red signals only are seen on 
the del(6q) (probe deleted). 
Fig 2.2 Example of FISH probes hybridised to metaphase cells from an ALL patient 
(Number 29) with a balanced translocation of 6 [in this case t(6; 19)]. a) A red 6q 
centromeric probe marks the normal and derivative 6 chromosomes, the green probe 
is hybridised to the normal 6 and to the derivative 19 idicating that it is positioned 
telomeric to the break point in this case. b) A red telomeric 6q probernarks the 
normal 6 and derivative 19 chromosomes. In this case the green probe is seen on the 
normal and derivative 6 chromosomes indicating that it is positioned centromeric to 
the breakpoint. 
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By performing sequential FISH experiments with probes from the primary panel the 
boundaries of deletion or the translocation break point was determined in each case. A fresh 
slide was used for each new set of probes unless all the fixed cells had been used in which 
case a slide from a previous experiment was prepared for re-FISH as described in 2.5.1. The 
HGMP chromosome 6 Database was then searched for additional probes, which could be 
used to more accurately defte deletion boundaries or translocation break points of interest. 
In some cases the process was repeated several times with the ultimate objective of 
positioning a break point to within a single clone. 
2.6 Gel electrophoresis. 
DNA samples to be analysed by gel electrophoresis were mixed with 0.2x volume of loading 
buffer. For analysis of PCR products and restriction enzyme digests 50ml 0.8-1.2% agarose 
minigels were made in 0.5x TBE containing I gg/ml ethidium bromide. Minigels were run in 
0.5x TBE as running buffer at 50-IOOV in Hybaid tanks. For preparation of genomic DNA 
for Southern blot analysis a 400ml agarose gel was made with Ix AGB and run at 40V 
overnight using Flowgene apparatus and Ix AGB as a running buffer. Size markers used 
were bacteriophage ;ý cut with Hind 111, OX 174 cut with Hae III (Northumbria Biologicals 
cat # 030204 and 031201) (Gibco BRL) or a 100 Kb ladder (Hyperladder 11, Bioline). In 
figures (chapter 3) the three markers are denoted by ;ý Hind 111, OX and MWM. 
2.7 Preparation of Genornic DNA. 
DNA was extracted from cell lines using the Purescript DNA isolation kit (Gentra systems). 
Patient DNA samples had been extracted previously and stored at -200C by other members of 
the department. 
Cell numbers were measured on a Bayer Advia 120 automated haematology system and 
approximately 107 cells aliquoted into a 15ml centrifuge tube for extraction. Small volumes 
of lysis buffer were added to the cells until completely lysed. I ml of protein precipitation 
solution was then added to every 3 ml of cell lysate and the mixture vortexed for 20 seconds. 
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The tubes were then centrifuged at 2,000rpm in a MSE Microcentaur bench top centrifuge 
for 10 minutes. Supernatant was transferred to fresh centrifuge tubes and a volume of 
isopropanol, equal to the amount of lysis solution used, was added. Tubes were then inverted 
approximately 50 times, until a visible DNA precipitate could be seen, then centrifuged at 
2,000 rpm for 10 minutes. Supernatant was carefully removed and the pellets transferred to 
1.5 ml microcentrifage tubes and washed with I ml of 70% ethanol. After centrifuging at 
13,000 rpm for 2 minutes the supernatant was removed and the pellets dried at room 
temperature. The pellets were then re-hydrated by adding 50gl TE and standing at room 
temperature overnight. After estimating the concentration by measuring the OD260of a 1: 100 
dilution, samples were stored at -200C. 
2.8 Preparation of RNA. 
RNA was extracted from cell lines using the purescript RNA isolation kit (Gentra systems). 
Patient RNA samples had been extracted previously and stored at -700C by other members of 
the department. 
Approximately 107 cells were lysed as described in 2.8, then I ml of protein-DNA 
precipitation solution added to each 3 ml of lysate. Tubes were inverted gently 10 times and 
incubated on ice for 10 minutes before centrifuging at 2,000 rpm for 10 minutes. Supernatant 
was transferred to fresh centrifuge tubes, an equal volume (to the lysis solution) of 
isopropanol was added and the tubes inverted approximately 50 times. The precipitated RNA 
was then centrifuged at 2,000 rpm for 10 minutes, the supernatant discarded and the pellets 
transferred to 1.5 ml microcentrifage tubes. RNA pellets were washed by addition of I ml of 
70% ethanol then centrifuged at 13,000 rpm for 2 minutes and after discarding the 
supernatant dried at room temperature. 20-100 ýtl (depending on pellet size) of PCR grade 
H20was added to the microcentrifiage tubes and the RNA left to rehydrate on ice for 30 
minutes. Samples were then vortexed for 5 seconds before storing at -700C. 
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2.9 Preparation of first strand cDNA. 
I gl of 40U/gl RNasin (Promega cat # N21 I A) was added to 2gg of RNA in a sterile 
microfuge tube and the volume adjusted to 20gl with sterile PCR grade H20. The reaction 
was then placed in a 650C water bath for 5 minutes then cooled on ice for 5 minutes. The 
following was then added to the tube in the form of a pre-made master mix; lOgI 5x first 
strand cDNA buffer (Gibco BRL), 2.5gl lOmM dNTP mix, IgI RNasin, IgI 0.5 gg/gl 
pd(N)6 (Pharmacia), 2gl of Reverse Transcriptase (Gibco BRL cat #), 0.5gl 100mM DTT, 
10.5gl sterile PCR grade H20- 
After mixing the tube was placed in a 370C water bath for I hour then at 650C for 10 minutes 
and on ice for 5 minutes. The cDNA was diluted with 50gl sterile PCR grade H20 and stored 
at -200C. 
2.10 Evaluation of cDNA using primers from the G6PD andflActin 
genes. 
Standard sets of primers for the Glucose- 6-phosphate dehydrogenase (G6PD) and orfiActin 
genes were used in PCR reactions to assess quality of c-DNA. A master mix was made 
containing the following for each reaction; 2gl lOx buffer (Promega), 2gl 2mM dNTP mix, 
2gl O. Igg/ml forward primer, 2gl O. Igg/ml reverse primer, 0.2gl Taq DNA polymerase 
(Promega cat #MI 86A), 6.8gl PCR grade H20- 
15gl of the master mix and 5gl of test c-DNA were mixed in a 0.5ml microcentrifuge tube 
and overlaid with a drop of mineral oil (Sigma cat # M-3516). PCR was performed using a 
hot start at 940C for 10 minutes then 35 cycles at 940C for I minute, 580C for I minute and 
72 0C for 2 minutes followed by a final extension step at 720C for 10 minutes. 
5gl of the PCR product was run on a 50ml 1% agarose gel and examined over a UV 
transilluminator. The G6PD primers produced a 168 base pair product and the 8 Actin 
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primers a 480. base pair product. Quality of test cDNA was determined by evaluating the 
strength of the band of predicted size produced with the two sets of primers. The sequence of 
primers for amplification of G6PD andflActin are presented in appendix 2. 
2.11 Analysis of Gene expression by RT-PCR. 
The quality of cDNA was first assessed using primers for the G6PD orflActin genes. A PCR 
reaction was then performed using forward and reverse primers from different exons of the 
gene to be analysed. The PCR reaction conditions were identical to those described in 2.13 
but with the annealing temperature adjusted to 50C below the melting temperature of the 
primers used. PCR products were analysed by running on a 1% agarose gel, and checking for 
bands of the expected size over a UV transilluminator. 
2.12 Mutation analysis of GIuR-6. 
Sequence analysis was used to investigate the possibility that large deletions encompassing 
the GluR-6 gene are accompanied by inactivating mutations of the second allele in ALL 
patients. 
2.12.1 PCR amplification of GluR-6 exons from normal and patient DNA. 
Exons of GluR-6 were positioned on sequenced fragments AP002531, AP002530, 
AP002529, and forward and reverse primers from the flanking genomic regions designed. 
Primer pairs were designed to amplify the entire exons and splice recognition sites and to 
have a T,, of either 70 or 650C (see appendix 2). Initially, to test the efficiency of the primer 
pairs, 20gl PCR reactions were set up as described in 2.11 using I OOng of normal (remission) 
bone marrow genomic DNA. For primer pairs with a T,,, of 700C the following program was 
used; 940C for 10 minutes then 35 cycles at 940C for I minute, 650C for I minute and 720C 
for 7 minutes, followed by a final extension of 720C for 7 minutes. For primer pairs with a 
Tn, of 650C the annealing temperature was reduced to 600C. PCR products were assessed by 
agarose gel electrophoresis for products of the expected sizes. For amplification of patient 
DNA, for direct sequencing, 40gl reactions were set up using 200ng of DNA. The PCR 
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products were assessed by agarose gel electrophoresis and those that resulted in a single 
intense band of the expected size were purified for sequence analysis. PCR reactions that 
resulted in either no band or a weak band or more than a single band were repeated. If no 
satisfactory product resulted from duplication of the original reaction, PCR was performed 
using 400ng of DNA template. When necessary the additional strategy of reducing the 
annealing temperature by 20C was used to improve efficiency of PCR reactions. 
2.12.2 Purification of PCR products for sequencing. 
After examining reaction products by gel electrophoresis the remaining 35gl were purified 
using an Amersham GFX DNA purification kit (cat # 27-9602-01). The procedure makes use 
of a chaotrophic agent that denatures proteins and promotes binding of double stranded 
DNA, over 100 base pairs in size, to a glass fibre matrix. Once bound, the DNA is washed to 
remove contaminating proteins, salts, and primers. Samples were added to 500gl of DNA 
binding buffer in GFX columns placed in numbered microcentrifage tubes and centrifuged at 
13,000 rpm for 30 seconds. The flow through was discarded and 500gl of wash solution 
added to each column before centrifuging as before. Columns were transferred to fresh 
numbered microcentrifage tubes and 50gl of PCR grade water added to the top of each. After 
incubating for I minute at room temperature the bound DNA was recovered by centrifuging 
for I minute. The eluted PCR products were then diluted with I 00gl of PCR grade H20 and 
stored at -200C. 
2.12.3 Direct sequencing of PCR products. 
An automated procedure was used to directly sequence the cleaned PCR products. The DNA 
templates were first labelled by incorporation of four fluorescent dyes (one for each dNTP) 
using a PCR primer extension technique. Labelled DNA was electrophoresed through a 
denaturing acrylamide gel the base of which was continuously scanned with a laser beam. As 
sequence passed through the base of the gel each dNTP was excited by the laser, emitting 
light of a specific wavelength. The emitted light was collected by a spectrograph and focused 
onto a cooled charged couple device from where the data was collected and stored by 
dedicated software. Since each dNTP was labelled with a different fluorochrome, variations 
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in the wavelength of emitted light could be translated into a genetic code for the 
electrophoresed DNA molecule. 
Z IZ 3.1 Labeling ofPCR products for sequence analysis. 
Primers used for the original PCR reaction were prepared at a concentration of 0.8pmoles/gl 
then separate forward and reverse sequencing reactions containing the following were set up 
in 250gl PCR tubes; 2gl cleaned PCR product, 2gl primer, IgI Big Dye (Perkin Elmer), 7gl 
2.5x automated sequencing buffer, 8gl PCR grade H20. After mixing gently by pipetting the 
reactions were placed in a Applied Biosystems Gene Amp PCR System 9700 and labelled 
with the following program; 25 cycles at 960C for 10 seconds, 500C for 5 seconds and 600C 
for 4 minutes. 
Labelled sequences were transferred to 0.5ml microcentrifiage tubes and precipitated by 
incubating on ice for I hour with 2gl 3M Na acetate and 50gl ethanol. The tubes were then 
centrifuged at 13,000 rpm for 30 minutes, the supernatant discarded and the pellet washed 
with 70% ethanol. After centrifuging for 10 minutes, the 70% ethanol was removed by 
pipette and the pelleted DNA dried at room temperature. Labelled DNA was resuspended by 
vortexing vigorously with 5gl deionised formamide (Amresco, cat # 0606) and IgI loading 
dye (Blue Dextran, Perkin Elmer cat # 402055). The resuspended DNA was denatured at 
980C for 2 minutes then kept on ice until loading. 
Z IZ 3.2 Electrophoresis using the ABI 3 77 automated sequencer. 
All sequencing was performed using a Perkin Elmer ABI Prism 377 sequencing machine 
with apparatus and protocols supplied by the manufacturer. The plates were washed with 
sequencing grade H20 then assembled using 2mm spacers. A gel mix was prepared by 
dissolving l8g of urea in 25ml sequencing grade H20,5ml of lOx filtered TBE and 5ml of 
acrylamide/bisacrylamide (40% 19/1) (Kramel Biotech cat # EC-850) solution. The solution 
was made in the presence of 0.5g of mixed bed ion exchange resin (PE Applied Biosystems 
cat # 400655) that was then removed by vacuum filtering. The filtered solution was made up 
to a total volume of 50ml with sequencing grade H20. Immediately prior to pouring 35ýtl of 
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Temed (Amresco cat # 0761) and 25gl 10% ammonium persulphate were added to the gel. 
The gel was poured using the supplied gel pouring apparatus and allowed to set for 2 hours. 
When set the gel was assembled on the ABI 377 sequencing machine and pre-run with TBE 
buffer for 20 minutes. 2gl of each denatured DNA sample to be sequenced were then loaded 
into individual wells and electrophoresis performed for 7 hours. 
2.12.4 Analysis of sequenced GluR-6 exons. 
Sequences were opened in DNASTAR and edited to remove any nucleotides not lying 
between or within the forward or reverse primer sequences. The forward and reverse 
sequences for each exon from each patient were then compared with the complete wild type 
sequence (including primers and intronic sequence) and the exon sequence alone. If forward 
or reverse sequence corresponded to the wild type sequence over the entire length of the 
exon, including the splice recognition sites, the exon was considered not mutated in that 
patient. If both forward and reverse sequence differed from the wild type sequence at one or 
more base pair positions, within the exon or at the splice recognition sites, the sequencing 
reaction was repeated. If after repeating the sequencing, differences between wild type and 
patient sequence remained at one or more of the same base pair positions, the original PCR 
reaction was repeated. Repeated PCR reactions were sequenced and compared with both the 
wild type and earlier patient sequences using the Megalign programme of DNASTAR. If a 
difference between wild type and patient sequence was found consistently at any one 
nucleotide position in both forward and reverse directions the exon was considered to 
harbour either a mutation or polymorphism at that site. 
2.13 Southern-blot analysis of lGF2R (patient 22). 
2.13.1 Preparation of Hannahan's competent cells. 
A single colony of the TGI strain of Escherichia coli was used to inoculate 5ml of SOB 
medium containing 50gl of 20% glucose and 50gl Of 
IM M902. After growing overnight at 
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370C in a shaking incubator, 500gl of the culture was added to 50ml of SOB medium with 
500gl of 20% glucose and 500gl of IMM902 in a sterile 250 ml flask. The expanded 
culture was then returned to the incubator and grown to an OD600nm of 0.5-0.55. The flask 
was then placed on ice for 15 minutes before transferring the cells to a 50 ml Falcon tube. 
Cells were collected by centrifugation at 1,600 rpm for 10 minutes, the supernatant discarded 
and the pellet resuspended in 16.5ml of ice cold TFB. After incubating on ice for 10 minutes 
the cells were centrifuged as before and resuspended in 4ml of TFB. The cell suspension was 
then incubated on ice with 140gl DnD for 10 minutes before addition of a second 140gl 
aliquot of DnD. After a further 15 minutes incubation the cells were ready for use and 
remained competent for 4 hours. 
2.13.2 preparation of IGF2-R cloned cDNA. 
The complete cDNA sequence of the Insulin Like growth Factor-2 receptor (IGF2-R) cloned 
into the Sal I sites of pGEM-2 (known as pGEM-8) was a kindly provided by Dr S. Sly 
[Department of Biochemistry and Molecular Biology, St Louis University, USA]. The 
lyophilised DNA was resuspended in TE at 50 ng/gl and I and 5gl aliquots added to 200gl 
competent TG1 cells on ice for 45 minutes (see 2.13.1). Following incubation on ice the cells 
were heat shocked by placing in a 420C water bath for 2 minutes then incubated with 400gl 
2xTY at 370C for 30 minutes before plating onto LB or TY agar containing ampicillin at 
100gg/ml. Individual colonies were then used to inoculate 50ml LB medium containing 
ampicillin and DNA prepared by standard maxi-prep (see 2.4.1). 
2.13.3 Construction of probes for Southern Blot analysis. 
PGEM-8 DNA was then used as a template for the construction of 5 probes, covering the 48 
exons of the IGF2-R, by PCR. The forward and reverse primer sequences used to amplify 
each probe, their base pair positions on the lGF2R and the exons covered by each set of 
primers are shown in Appendix 2.50gl PCR reactions containing: 0.5gl Promega Taq 
polymerase (cat # M186AI), 5gl Promega Taq buffer, 5gl 2mM dNTPs, 5gl each primer 
(100ng/gl) and I OOng of pGEM-8 DNA were set up for each pair of primers. After covering 
with a drop of mineral oil the PCR reactions were denatured at 94'C for 10 minutes then 
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cycled 25 times at 94'C for I minute, 650C for I minute and 72'C for 4 minutes followed by 
a fmal extension at 72'C for 10 minutes using a Techne Cyclogene thermal cycler (PH3). 
Satisfactory PCR products were obtained from primer sets 2-5 but not from set 1. PCR 
reactions were therefore carried out using the same conditions but using a forward primer 
from the SP6 promoter region of pGEM-2 (see Table 2.1 for sequence) with reverse primers 
from sets I and 2. A suitable PCR product resulted from the combination of SP6 forward and 
the reverse primer from set 1, the probe derived from this PCR product will be referred to as 
lGF2R SB probe 1. The probes derived from the products obtained from primer sets 2-5 will 
be termed lGF2R SB probes 2-5. The lGF2R SB probes were purified by running the PCR 
products on a 1% agarose gel, and excising the bands of expected size with a scalpel blade 
over UV light. The excised agarose fragments were placed on top of small pads of glass wool 
in 0.5ml microcentrifuge tubes. The bottoms of the tubes were punctured with a pin and then 
placed inside 1.5ml microcentrifuge tubes and centrifuged at 13,000 rpm for I minute. The 
extruded DNA solutions were cleaned once with PCIA and once with chlorophorm/isoamyl- 
alcohol (24: I; v: v), then passed through a Sephadex G50 column. To estimate the DNA 
concentration 5gl was run on a 50ml 1% agarose gel and band intensities compared with 
those of X Hindlll marker bands of known concentration. 
2.13.4 Restriction Enzyme Digest of Genomic DNA. 
Stored DNA from bone marrow samples from patient 22 taken at 2 different dates (between 
13.02.98 and 21.09.98) and from three lymphoma, patients (identification numbers B22A6, 
B22A7 and B22A8) were used for Southern Blot analysis. Master mixes for EcoRl and 
BamH I digestion of DNA containing the following per reaction were prepared; 5gl 
restriction enzyme digestion buffer, 0.5gl spermidine, 0.5gl DTT, 4 gl enzyme (EcoRI or 
BamH I) (New England Biolabs / 20U/gl activity), 30gl H20. Each digest consisted of lOgI 
of one of each of the 5 DNA samples (Igg/gl) and 40 [d of master mix. The 10 digests were 
incubated in a water bath at 370C for 16 hours then loaded onto a 0.8% agarose gel made 
with Ix AGB buffer and run at 40V overnight. 
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2.13.5 Southern Blot Procedure 
After electrophoresis the gel was examined over UV light, an image taken and the position of 
size marker bands indicated with ink using a 19-gauge needle. The gel was then placed in 
depurination solution and gently agitated for 20 minutes. Depurination of sites within DNA 
allows cleavage during denaturation resulting in fragmentation of longer pieces of DNA and 
allowing efficient transfer of high molecular weight DNA to the membrane. The gel was then 
rinsed once in distilled H20 and soaked in denaturing solution for 30 minutes. After rinsing 
once more in distilled H20the gel was transferred to neutralising solution for 30 minutes. 
While preparing the gel, IL of 20xSSC was added to a transfer tank containing a platform 
overlaid with 2 sheets of Whatman 3MM paper. The ends of the Whatman paper were 
submerged, acting as wicks to draw up the 20xSSC. The prepared gel was then carefully 
placed on the saturated Whatman paper and overlaid with Saran wrap. The Saran wrap was 
cut away from around the edge of the gel and a piece of pre-wetted Hybond-N and 4 pieces 
of pre-wetted Whatman 3MM were then laid over the gel. 5-10 cm of paper towels were 
stacked over the Whatman paper and weighted with a suitable heavy object. The Southern 
blot apparatus was then left overnight to allow transfer of DNA to the Hybond membrane by 
capillary action. 
The weight and papers were removed from the blot and the gel and Hybond membrane 
inverted onto a glass plate. The position of molecular weight marker bands and loading wells 
were marked on the membrane before discarding the gel. The membrane was then washed 
twice for 15 minutes in 3xSSC, baked in an oven at 800C for 2 hours and cross-linked with 
UV light (using a Stratalinker). Immediately prior to hybridisation the membrane was soaked 
in 3x SSC for 30 minutes at room temperature, then pre-hybridised in 20ml Church buffer at 
650C for 1-2 hours. Prehybridisation and hybridisation were performed using a Hybaid 
hybridisation apparatus. 
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2.13.6 Probe labelling and hybridisation. 
50 ng of lGF2R SB probe I was made up to a total volume of 50[d with PCR grade H20 
placed in a boiling water bath for 5 minutes then transferred to ice for 5 minutes. The 
denatured probe was added to a pre-prepared random prime labelling mix (Rediprime, 
Amersham life sciences) with 2[d of [(X-32 P]dCTP (lOgCi/gl) and incubated at 370C for I 
hour. Labelled probe was then made up to a total volume of I 00gl with PCR grade H20 and 
unincorporated nucleotides separated from the probe by centrifuging through a Sephadex 
G50 column. The Sephadex column was prepared in aI ml-syringe barrel plugged with glass 
wool and equilibrated with distilled H20. After cleaning, the labelled probe was denatured by 
boiling for 5 minutes and immediately added to the pre-hybridising membrane. Hybridisation 
was carried out overnight at 650C. To remove non- specifically bound probe, the membrane 
was washed 3 times in 0.5x SSC/0.2% SDS in a shaking water bath for 20 minutes at 650C. 
A storage phosphor screen (Packard) was exposed to the washed membrane for 72 hours and 
imaged on a Packard Cyclone storage phosphor system. 
After imaging, lGF2R SB probe I was stripped from the membrane by washing for 2 minutes 
in denaturing solution at room temperature on a rocking platform and for 2 minutes in 
neutralising solution at room temperature. lGF2R genomic probes 2-5 were labelled and 
hybridised to the membrane sequentially, with probe from the previous experiment being 
stripped before each fresh hybridisation. 
2.14 RACE-PCR analysis of IGF2R (patient 22). 
2.14.1 Principle of the SMART RACE PCR system. 
Rapid amplification of cDNA ends (RACE) PCR techniques have been developed for the 
purpose of identifying unknown exons spliced to either the 5' or 3' end of an already 
characterized expressed sequence 262 . The full-length transcripts of many genes 
have been 
cloned in this way but the technique has also been used to identify partner genes of 
oncogenic translocations where one partner is known. The SMART RACE system (Clontech 
cat # K181 1-1) involves two steps. 1) The preparation of cDNA templates appropriate for the 
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amplification of 5' (5' RACE ready cDNA) and 3'(3' RACE ready cDNA) ends of genes. 2) 
The amplification of 5' or 3' sequences from the cDNA templates using gene specific 
primers. 
cDNA is prepared using a mutant form of MMLV reverse transcriptase which adds an 
overhanging CCC sequence after it reaches the end of an RNA template (Clontech 
PowerScript Reverse Transcriptase cat # 84601). The 5' RACE ready reaction contains 2 
primers one of which is designed to hybridise to 3' poly A tails (5'- CDS) and a second (the 
SMART 11 oligonucleotide) consisting of a universal primer tagged to a GGG sequence 
which hybridises to the CCC overhang added by the mutant MMLV Reverse Transcriptase. 
Reverse transcription proceeds from the 3' poly A tail to the 5' end of the gene where the 
SMART II oligonucleotide anneals to the added CCC sequence. At this point Reverse 
Transcriptase switches templates adding the complement of the universal primer to the I st 
strand cDNA sequences. The 5' end of genes can be amplified from the cDNA using the 
universal primer sequence as a forward primer in combination with gene specific reverse 
primers. 
The 3' RACE ready reaction contains a 3' cDNA synthesis primer (3'-CDS) consisting of an 
oligo-dT, which hybridises to 3' poly A tails, coupled to the universal primer. Reverse 
transcription advances from the poly A tail towards the 5' end of the gene resulting in 
production of cDNA templates with a sense version of the universal primer attached to the 3' 
end. Using a combination of gene specific forward primers and the universal primer (as 
reverse primer) the 3' ends of genes can be amplified by PCR from the 3' RACE ready 
cDNA. 
A nested PCR reaction can also be achieved by performing a first round PCR with a 
universal primer mix and a touchdown program. The universal primer mix contains two 
different primers, a long universal primer consisting of the universal primer sequence with an 
additional 22 base pair sequence on its 5' end and a short universal primer consisting of the 
22 base pair sequence alone. The first few cycles of PCR are carried out using a relatively 
high annealing temperature at which the long universal primer can pair with the template 
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cDNA adding the 22 base pair short primer sequence to the original cDNA template. Further 
cycles are carried out at a reduced temperature allowing the short primer to amplify the 
extended template. First round PCR products made using this protocol can then be used as a 
substrate for nested PCR using the universal primer sequence (nested universal primer) in 
combination with nested gene specific primers. 
2.14.2 Strategy for cloning a putative unknown fusion partner of the IGF2-R. 
A translocation of chromosome 6 observed in patient 22, was shown by FISH to disrupt the 
IGF2-R (see 3.6.4), with a break point estimated to fall between exons 4 and 5 of the gene. 
To investigate the possibility that the translocation resulted in production of a fusion gene, 5' 
and 3' RACE PCR were performed using the SMART RACE system. Forward primers from 
exons 1-3 were designed for the 3' RACE reactions and reverse primers from exons 7-10 for 
the purpose of cloning the 5' end of any IGF2-R fusion gene. Products resulting from nested 
RACE PCR reactions were cloned into plasmid vectors and sequenced. BLAST search was 
then carried out on any non-IGF2-R sequence. An overview of the approach is shown in figs 
2.3 and 2.4. 
2.14.3 Evaluation of patient RNA. 
Stored RNA made from a bone marrow sample was taken from patient 22 on 21.09.98 (when 
the chromosome 6 translocation was present in approximately 50% of cells) and used for 
RACE-PCR analysis. The patient RNA sample was first checked for quality and quantity by 
running on a 50 ml 1% agarose gel with a commercially prepared placental RNA sample 
(Clontech). The following precautions were taken to prevent RNA degradation: water 
containing 0.1% (DEPQ was used for the preparation of the gel. The gel former and tank 
were washed with detergent, dried with ethanol then soaked in 3% hydrogen peroxide for 10 
minutes before a final wash with the DEPC water. 0.5 x TBE was made with the DEPC water 
and used both to make a 1% agarose gel and to run the gel after loading. 3gl each of the 
placental RNA (I gg/gl), the patient RNA and a 1: 10 dilution of the patient RNA were run on 
the gel. 
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Fusion gene RNA -aaaaa 
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Reverse Transcription 
1" strand cDNA synthesis 
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Nested PCR 
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Fig 2.3 Strategy for cloning the Yend of the putative unknown partner gene of the IGF2-R. 
3'CDS (3' RACE cDNA Synthesis Primer), LUP (Long universal primer), SUP (Short 
universal primer), NUP (Nested universal primer). 
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Fig 2.4 Strategy for cloning the 5' end of the putative fusion partner of the IGF2-R. 5'CDS 
(5'-P, ACE cDNA Synthesis primer), LUP (Long universal primer), SUP (Short universal 
primer), NUP (Nested universal primer) 
2.14.4 Preparation of RACE ready cDNA. 
5' and 3' RACE ready cDNA was prepared from the patient RNA and supplied positive 
control placental RNA using a SMART RACE kit (Clontech cat #K 1811 - 1) following the 
manufacturers protocol (oligonucleotide sequences for these reactions are presented in 
appendix 2). Jýtl (Iýtg) positive control RNA or 3gl patient RNA were used for each reaction. 
For the preparation of 5' RACE ready cDNA Iýtl 5'CDS primer and IgI SMART 11 oligo 
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were added to the RNA in 0.5 ml microcentrifage tubes. For preparation of 3' RACE ready 
cDNA IgI 3'CDS primer was added to the RNA. All reactions were made up to a total 
volume of 5gl with sterile H20, mixed and incubated in a 700C water bath for 2 minutes. 
Tubes were then cooled on ice for 2 minutes and centrifuged briefly before adding the 
following; 2ýd 5x first strand buffer (250mM Tris-HCL pH 8.3,375MM KCL, 30MM 
MgCL2)9 IgI 20mM DTT, IgI lOmM dNTP mix, IgI Clontech PowerScript Reverse 
transcriptase (cat # 84601). After briefly mixing and spinning, the tubes were incubated at 
420C for 1.5 hours in an air incubator. The resultant I" strand reaction products were then 
diluted with I 00gl Tricine-EDTA buffer (pH 8.5), placed in a 720C water bath for 7 minutes 
and stored at -200C. 
2.14.5 1" round RACE PCR reactions. 
The following master mix was prepared (volumes given for a single reaction). 34.5gl PCR 
grade H20,5gl lOx Advantage 2 PCR buffer, IgI lOmM dNTP mix, IgI 50x Advantage 2 
polymerase mix. For each reaction 41.5gl of master mix was added to 2.5gl 3' or 5' RACE 
ready cDNA, 5gl of lOx universal primer mix (UPM consisting of 0.4gM long universal 
primer, 2gM short universal primer), and I gl I OgM forward or reverse gene specific primer 
(GSP). Negative controls in which either the UPM or the gene specific primer was replaced 
with an equal volume of PCR grade water were included. For positive control reactions GSPs 
for the transferin receptor (TFR), supplied with the SMART RACE 11 kit, were used. The 
PCR reactions were performed on an Applied Biosystems Gene Amp PCR System 9700 
using the following program for the first round PCR. 
5 cycles 94'C 5 sec, 72'C 3 min 
5 cycles 94'C 5 sec, 70'C 10 sec, 72'C 3 min 
25 cycles 94'C 5 sec, 68'C 10 sec, 72'C 3 min 
All primers used for I" round and nested PCR reactions (see section 2.14.6) are presented in 
appendix 2. PCR products were assessed by running 5gl on a 1.2% agarose gel, remaining 
product was stored at -200C. 
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2.14.6 Nested RACE PCR reactions. 
For nested PCR reactions 5gl 1" round PCR products were diluted in 245[d tricine-EDTA 
buffer. 5gl of the diluted product was then added to 41.5gl of the master mix described in 
2.9.5, with IgI nested universal primer, IgI nested GSP and 1.5gl PCR grade H20. The 
following program was used for nested PCR reactions; 
25 cycles 94'C 5 sec, 68'C 10 sec, 72'C 3 min 
I cycle 72'C 7 min. 
Nested PCR products were assessed by running 5gl on 50ml 1.2% agarose gels. 
2.15 Cloning of SMART RACE PCR products. 
SMART RACE PCR products were cloned using a TOPO TA cloning kit (Invitrogen cat # 
45-0641). The TOPO cloning system depends on the non-template dependent terminal 
transferase activity of Taq polymerase that results in addition of a single deoxyadenosine to 
the 3' end of PCR products. The supplied linearised vector (pCR 2.1-TOPO) has single 
overhanging 3' deoxythymidine residues which allow efficient ligation of PCR inserts. The 
activated form of the vector has topoisomerase I molecules covalently bound to the 3' 
phosphate of the thymidine residues. The covalent bond to topoisomerase I is broken and the 
released energy used to complete a DNA phosphodiester backbone in the presence of DNA 
5' hydroxyl groups. Introduction of PCR products to the vector provides both a template for 
the single base pair overhangs and 5' hydroxyl groups that cause release of topoisomerase 
and provides energy for the ligation of insert to vector. 
2.15.1 Cloning procedure. 
Cloning reactions containing the following were set up in 150gl PCR tubes; 1-3gl fresh PCR 
product, IgI salt solution (1.2 mM NaCl, 0.06MMgCI2), PCR grade H20 to a total volume 
of 6gl, activated TOPO vector lgl. The reactions were mixed gently incubated at room 
temperature for 5-30 minutes then placed on ice. 
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2gl of cloning reaction was then added to 200ýtl competent cells (either thawed frozen cells 
supplied with the kit or freshly prepared TGI cells) mixed gently and placed on ice for 5-30 
minutes. The cells were then heat shocked by placing in a water bath at 420C for 30 seconds 
and immediately transferred to ice. 40%tl 2xTY was added to each tube before incubation for 
I hour at 370C in a shaking incubator. 200gl and 400gl aliquots from each culture, with 40gl 
40mg/ml X-Gal, were then spread on pre-warmed LB plates containing 5%tg/ml kanamycin. 
Plates were incubated overnight at 370C. 
2.15.2 Selection of clones for sequencing. 
After overnight incubation white but not dark blue, colonies were selected for further 
analysis. To confirm the presence and determine the size of cloned DNA sequences a rapid 
PCR based assay was performed on individual colonies. Using a sterile tooth pick cells from 
each colony were first smeared onto the bottom of a numbered PCR tube then streaked onto a 
single square of a gridded agar plate. A number corresponding to one of the PCR tubes 
identified each square of the grid so positive colonies could later be identified and sequenced. 
The agar plates were incubated at 370C overnight then stored at 40C. To amplify insert 
sequences lOgI PCR reactions were set up in each of the numbered tubes. A master mix 
containing the following (per reaction) was prepared; IgI lOx buffer (PerkinElmer), IgI 
2mM dNTP mix, IgI nested universal primer, IgI GSP (as used to produce the cloned 
product), 0.1 gl Taq polymerase (PerkinElmer), 5.9gl PCR grade H20. After addition of I Ogl 
master mix tubes were place in a an Applied Biosystems Gene Amp PCR System 9700 and 
cycled 25 times at 940C for 30 seconds, 680C for 30 seconds and 720C for 3 minutes. PCR 
products were sized by running on a 1% agarose gel. Clones containing inserts similar in size 
to the bands obtained by RACE PCR were then picked from the gridded agar plates and used 
to establish small-scale cultures for DNA preparation and sequencing. 
2.15.3 Small-scale DNA preparation of RACE PCR clones (miniprep). 
2 ml 2xTY cultures were inoculated with the selected clones and grown overnight at 370C. 
DNA was then purified using a Sigma GenElute plasmid miniprep kit (cat # PLN 350). 
Following a modified alkaline-SDS lysis procedure plasmid DNA was adsorbed onto a silica 
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membrane in the presence of high salts. Contaminants were removed by spin-wash and the 
DNA eluted with H20. 
1.5 ml of culture was transferred to a microcentrifage tube and centrifuged at 13,000 rpm for 
I minute and. After discarding the supernatant the pellet was resuspended in 200gl of 
resuspension solution (containing RNase A) by vigorous vortexing. 20ORI of lysis solution 
was then added and the cell suspension mixed by inverting 6-8 times to produce a clear 
viscous solution. Cell debris, proteins, lipids, SDS and chromosomal DNA were precipitated, 
by adding 350gl of neutralization solution and gently inverting the tube 3-4 times. The 
precipitate was pelleted by centrifugation at 13,000 rpm for 10 minutes and the supernatant 
loaded onto a binding column. The column, resting in a microcentrifage tube, was then 
centrifuged at 13,000 rpm for 30 seconds and the flow through discarded. The bound plasmid 
DNA was then washed by adding 750gl of wash solution to the column and centrifuging at 
13,000 rpm for 30 seconds. After discarding the flow through excess ethanol was removed 
from the column by centrifuging for 2 minutes. The columns were transferred to fresh 
microcentrifage tubes and DNA eluted by adding 50gl PCR grade H20 and centrifuging for 
I minute at 13,000 rpm. Recovered DNA solutions were stored at -200C. 
2.15.4 Restriction enzyme digest of cloned DNA. 
The insertion sites of the pCR 2.1 -TOPO vector are flanked by EcoRl restriction enzyme 
sites. To confirm the presence of insert sequences in clones, before sequencing, a restriction 
enzyme digest was carried out. Digests were carried out at 370C for 1.5 hours and consisted 
of 5gl of clone DNA, 3gl of restriction digestion buffer, 0.3gl DTT, 0.3gl spermidine, I. Ogl 
EcoRl and 20.4gl PCR grade H20- I Ogl of each digest was then run on a 50 ml 1% agarose 
gel and clones containing inserts selected for sequencing. 
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2.16 Sequence analysis of cloned DNA. 
Sequencing was carried out essentially as described in 2.13.4 using 2gl of purified cloned 
DNA and I gI of for-ward or reverse primer, supplied with the kit and hybridizing to vector 
sequences flanking the insert site. 
Before analyzing sequences for evidence of the presence of an IGF2R fusion partner gene, 
vector sequences were removed by editing the sequence using the DNASTAR software. The 
trimmed sequence was then compared with the wild type IGF2R sequence. To determine the 
origin of non-IGF2R sequence, BLAST search was conducted using the NCBI database 
(http: //www. ncbi. nlm. nih. gov/BLAST/). 
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Chapter 3 (Results) 
3.1 Karyotypes (G-banded analysis). 
The full reported karyotypes of patients and cell lines for which successful FISH analysis 
was carried out are presented in Table 3.1. The analysed cases include 21 ALL patients 
reported to carry a cytogenetically detectable deletion of 6q, two translocations of 6q (cases 
26 and 29) and one case with monosomy 6 and markers of unknown origin (case 23). 
Of the 7 patients with AML, 2 had deletions, one had an unbalanced translocation and 5 had 
balanced rearrangements of 6q. One of the AML patients (case 32) was reported to carry a 
deletion as well as a translocation and an inversion of chromosome 6. 
Of the 3 cell lines (cases 5,13 and 16) all were derived from T-ALL patients and had 
deletions of 6q that were confinned by G-banded analysis. 
Patient or 
Cell line 
Karyotype (G-banded analysis) 
I 46, XX, (Icl(6)(q? l 3q2 1), add(9)(p24), del(I 3)(q? 14), der(I 9)t(l; 19)(q23; p 13) 
2 46, XX. dch 6)(q I 5q23), i(9)(qlO), der(19)t(l; 19)(q23; p 13) 
3 46, XY, klel(6)(q2l) 
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4 46, XY, del(6)(q2 I q25), del(9)(p 13) 
5 79-91<4n>, XXX, -X, der(I)t(1; 9)(p35-36ql 1), +3, +3, dup(4)(ql3q23)x2, 
del(6)(ql4q22)x2, -10, t(I 1; 14)(pl5; ql I)x2, -13, add(13)(q34), -14, +15, 
add(I 5)(p I 3), -18, -20, +2mar[cp] 
6 46, XY, dcl(6)(ql? q2l) 
7 46ýXYqdc Iý 6)(q I 3q23) 
8 46, XY, del(6)(q2l ý, t(8; 14)(q24; ql 1) 
9 46, XY, de](6)(q? I 6q? 24) 
10 47, XY, der(2)add(2)(p)del(2)(q),, lel(6)(q2 lq23), add(9)(p 13), 
add(I 1)(q23), +21 
11 46, XY,, J,, 1(6)(q? ), del(12)(p? ) 
12 46, XY, del(6)(q2? q2? ) 
13 89-99<4n>, XXYY, +4, (Iý: 1(6)(ql6)x2, +7, der(7)t(7; 7)(pl5; qI I)x2, 
+8, +20, +20[cp] 
14 46, XY, kIk: Iý 6)(q? I 5q2? 3) 
15 46, XY, k 1,, 1ý 6)(q I 3q2 1) 
16 42-47, XX, der(4)? dup ins(4; 4)(p? 11; q? 2 I q25), del(5)(q22q3 1), 
del(6)(ql 'kl -"), del(9)(pl lp22), del(9)(q22)[cp] 
17 46, XX, klc1(6)(q2 I q2 1) 
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18 45, XY, t(2; 3)(pl 5; q26), (Icl(6)(ql 3-15q2 1), add(9)(p 11-1 3), del(9)(q32q34), 
der(12)t(12; 17)(PI I; ql I), - 17[26]/45, idem, del(3)(p? 23p25)[41 
19 58, XY, +X, t(2; I 1)(p 1? 6; ql 3), +4, +5, +69t k: I (6)(q22, ), +10, +13, +14, +16, 
+17, +18, +20, +21, 
20 45, XX, dup(5)(q22q3 1), ý kl(6)(q2 I q23), -7, der(9)t(7; 9)(ql 1.2; p24), 
del(I 4)(ql 3q24), -16ý- I 8, der(22)t(?; 22), +mar 1, +mar2[13] 
/45, idem, del(I 0)(q22q25)[3]/44, idem, -2, del(I 0)(q22q25) [4] 
21 44, XY, -3, del(4)(q ? ), del(6)(q2l), -7, der(IO)t(?; 10)(?; pI 1.2), +i(10)(p 10)5 
- 11, - 12, der(I 2)t(3; 12)(p 1 3; p I 1), +? i(I 2)(p I 0), del(l 5)(q ? ), - 17, 
der(I 7)t(?; 17)(?; p 11.2), -18 
22 47, XY, add(2)(q2? ),? inv(3)(p2? 4q2l), ''(1ý, 1(6)(q2? 1), add(7)(qI 1), 
-8, t(8; 15)(p? l I; ql? ), add(12)(pl? ), add(13)(q3? 4), der(16)t(7; 16)(qI I; pl3), 
add(I 7)(p 13), der(20), add(20)(q 1? ), -21, +3 mar 
23 46, XX, t(l; 19)(q23; p I 3), -(), add(8)(q24), +mar 
24 46, XX, t(9; 22)(q34; ql 1)[6]/46, idem, kk, ii 6)t(1; 6)(q? 23; q? 21)[I 11 
/49, idem+8, +19, +der(22)t(9; 22)(q34; qI 1)[2]/50, idem, +8, +19, +22, 
+der(22)t(9; 22)(q34; ql 1) 
25 45, XY, klch 6)(q2D, i(9)(qlO), der(12)t(12; 17)(pl I; p 11), -17 
26 5 I, XY, +X, t(2; 18)(p I 3; q23),? t(3; I 0)(q2 I; q26), t(3; 16)(p25; p 1 3)ý 
t(6; 9)(q2? 5; q22), inv(l 2)(pl 2q2l), +14, del(I 7)(q2 1; q2l), +20, +2 I +mar, 
27 46, XY, del(6)(q? I 3q? 2 1), add(7)(q3? ), del(9)(p 1? 3), t(I 1; 14)(p I 3; q 11) 
28 46, XY, dc I (6)(q'-'), del(I 0)(q? ), add(20)(p? ) 
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29 46, XX, der(I 8; 2 1)(qlO; qlo)[4]/87<4n>, XX, -X, -X, - 1, -3, add(4)(q? 3 I)x2, 
der(5)t(5; 2 1; 15)(q22; q22; q I ? 5)t(12; 15)(p I 3; q22)x2, -6, -6, 
t(6; 19)(q? 2 I; p 13) \ -', t(7; 22)(q22; ql 3), +der(7)t(7; 22)(q22; ql 3)ý del(7)(q22q36)x2, t(8; I 1)(p? 10; ql? 4), del(I 1)(ql? 4q23)x2, -16, 
+der(I 9)t(6; 19)(q? 2 I; pl 3), der(21)t(6; 2 1)(p? 2 1; q22)x2[5] 
30 46, XX, t(6; I 1)(q I 3; q23) 
31 46, X,? t(X; 22)(q2? 4; ql 1),? t(4; 13)(q2? 5; ql? ),? t(6; 7) 
(q2? I; p I 5), del(I 5)(q IIq? 2 1) 
32 489XY9+6, (1ý-, 1(6)(q? 21q2? 5), iiiý (' 6)(pl ', q "), der(7)t(7; 17)(p10; q10), 
t(7; 8)(p1? 3; q1? 1), der(15)t(15; 17)(q2? 5; q10), +22[3]/48, idem, 
-del(6)(q? 2 1 q2? 5), t(8; 9)(q22; q32), +mar[5] 
/47, idem, t(2; 6)(q3? 1. (1 -"-',, ),? inv(5)(ql ? q22),? der(6)t(6; 6)(q2? 2 l; p 10)9 
-del(6)(q2? 2 1 q2? 5) [4] 
33 46ýXXqadtfi 6)(q23) 
34 46, XY, i(6; 8)(q27; p 11.2) 
Table 3.1 Karyotypes of patients/cell lines included in the study. 6q abnormalities are 
highlighted in red. 
3.2 Primary FISH analysis. 
PACs or BACs, used for initial FISH analysis, were selected through the ACEDB database 
on the basis of their genetic marker content. The markers used for clone selection were either 
taken from publications in which they had been used for LOH analysis of cases of ALL, or 
were positioned on the YACs used to map deletions in our own department256 . Additional 
clones containing genes either known or thought to be involved in malignancy were also 
selected for initial analysis. To achieve a more comprehensive coverage of 6q further PACs, 
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assigned to a cytogenetic band by FISH, were included in this primary panel of probes 
(personal communication from A. Mungal Sanger Centre, Hixton Cambridge UK). The 
probes used with cytogenetic band assignments, corresponding genetic markers and genes 
and chromosome 6-fpc values are presented in Table 3.2. Of the 34 cases analysed, 24 were 
found to bear deletions and 12 translocations of 6q (patients 22 and 23 were associated both 
with translocation and deletion). 
PAC P13743 (marked with * in Table 3.2) was not part of the panel of clones used by the 
Sanger center in map construction and therefore not assigned a 6-fpc map position by 
ACEDB. However, P13743 was known to contain the CCNC gene 287 that on earlier releases 
of the chromosome 6 physical map was positioned between RPI-235B9 and RPI-202B13. 
Three colour FI SH on interphase cells placed P 13 743 between RP I -202B 13 and YAC 748c8 
that contains the marker D6S283 (Fig 3 . 1)256 . The marker D6S283 
had been positioned 
telomeric to RP I -202B 13 so interphase FISH placed CCNC between RP 1-202B 13 and RP I- 
132E6. At the time of initial analysis the assumption was made that the HGMP database 
order: centromere- RP 1-23 5 B9, P13743 (CCNC), RPI-202BI3-telomere was correct and the 
three probes were placed accordingly in Tables 3.2,3.3 and 3.4 and in Fig 3.2 and 3.3. A 
later release of the chromosome 6 map was in agreement with the order derived from 
interphase FISH analysis, placing CCNC distal to RPI-202B13 (see 3.4.2). 
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Fig 3.1 PAC P13743 (containing the gene CCNQ is positioned to between PAC 
RPI 1-202B 13 andYAC 748c8 (containing marker D6S-283) using 3 colour FISH 
on interphase cells. RP11-202B13 was labelled with Spectrum Green, P13743 with 
Alexia 532 and 748c8 with Spectrum Red. 
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Probe Chromosome 6 Cytogenetic Marker Gene 
fpc values band 
RPI-71HI9 59950-60050 qll PRIM2A 
RP 1 -260B21 79950-80050 q14 D6SI625 
RPI-102HI9 90250-90400 q15 D6SIO04 
RPI-67NI5 91650-91750 q15 D6S 1185 
RPI-235B9 93550-93650 q15 D6S462 BACH2 
P13743* q16 CCNC 
RP 1-202B 13 100600-100700 q16 D6S501 
RPI-132E6 108150-108300 D6S447 
RP 11-5919 110200-110300 q2l 
RP I -429G5 111150-111200 q2l D6SI594 
RPI-I I IB22 111100-111150 q2l D6SI 113 
RPI-66HI4 114450-114600 q21-22 D6S302 FYN 
RP I -240M 13 116600-116750 q22 D6S499 
RPI-162C6 117950-118050 q22 
RP 1-59B 14 121250-121400 q22 D6S433 ERV9 
RPI-293L8 128350-128500 q22 D6SI311 HEY2 
RPI-179EI3 129200-129350 q22 D6SIO76 
RP I -76H23 135800-135900 
RPI-17INI 1 141100-141300 q23 
RPI-172KIO 142850-143000 q24 
RPI-178DI8 144050-144200 D6SI648 
RPI-237G20 149550-149650 q25 
RPI-278NI2 156950-157100 q25 D6S425 
RPI-137K2 159450-159650 q25 D6SI878 
RP I -65A9 170802-170937 D6S5481 
RPI-167AI4 178304-178414 q27 FOP 
RPI-57M24 q27 6q telomere 
Table 3.2 Probes used in the primary FISH analysis of patients and cell lines, showing associated HGMP 
chromosome 6 map positions, chromosomal band assignments, genetic markers and genes. 
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3.2.1 Patients and cell lines with deletions. 
Numbers of metaphase cells deleted for or retaining each probe, in each case, are recorded in 
Table 3.3.24 patients/cell lines had deletions that included a region corresponding to one or 
more of the probes used in the primary analysis. For each case, probes that met the criteria 
for deletion (see 2.7.4) are marked in red. Data derived from an earlier FISH study using 
YAC probes (marked in green) has been included for two patients (numbers 2 and 22 in this 
study, 21 and 15 in the previous study)256. In each case the figures refer to loss or retention 
not of the indicated probe but of a YAC hybridizing to the same region of 6q. In the earlier 
YAC study two distinct clonal deletions (21a and 21b) were found to coexist in one patient 
(number 2 in this study). The smaller of the two clones (21a) was present in approximately 
95% of cells while 21b, which extended distally from 21a, was only seen in about 15% of 
cells. The additional PAC data presented in Tables 3.3 and 3.8 confirms the existence of a 
minor clone in patient 2, although the relatively stringent scoring criteria (20% of analysed 
cells deleted) mean that not all probes within the second clone are marked as deleted. Thus 
RP 1-293 L8 has been scored as retained (marked in black) while RP I- 179E 13 was considered 
deleted (marked in red). The apparent existence of a non-contiguous deletion in patient 2 is 
therefore explained by the presence of a low level clone, with numbers of deleted cells close 
to the cut off level for this study. In all other cases, numbers of cells deleted were scored 
above the 20% level for all probes within the deleted region. In other words, no evidence for 
the existence of non-contiguous deletions was seen in this study. 
All except 4 of the cases were deleted either for RPI-202BI3 or the adjacent probe RPI- 
132E6; the region between these two probes was therefore a potential common region of 
overlap or most frequently deleted region among the cases analysed. The primary deletion 
data is presented in the form of a summary map with the potential common region of overlap 
highlighted (Fig 3.2). More detailed FISH analysis of the putative common region of overlap 
was carried out using probes from between RP I -202B 13 and RP I- I 32E6 (see 3.4.1). 
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Patient or cell line 
Probe (Number of cells deleted/number of cells retained) 
12345678 
RPI-71HI9 00/10 00115 00/37 
RP 1 -260B21 10/02 00/10 05100 10/04 
RP1-102HI9 10/02 
RP I -67N 15 14/06 10/02 
RPI-235B9 10/00 10/01 10105 05100 
P 13743 00/10 08/04 10/04 
RPI-202BI3 00/10 14/06 10/01 10/02 10/00 07/01 08/38 
RPI-132E6 03/15 00/10 00/10 10/00 13/02 10/24 
RP 11-5919 01/11 00/10 00/10 00/10 00/10 
RP I -429G5 7/23 00/10 13/02 09/28 
RPM I IB22 
RP I -66H 14 01/10 00/10 10/00 
RP I -240M 13 
RP I-I 62C6 
RPI-59BI4 00/10 
RPI-293L8 04/46 
RP1-179EI3 07/43 
RPI-76H23 00/10 
RPl-171NI 1 00/20 00/30 
RPI-172KIO 01/19 
RPI-178DI8 
RPI-237G20 
RP I -278N 12 
RPI-137K2 
RP I -65A9 
RPI-167AI4 00/12 00/20 00/20 00/20 00/20 00/20 00/20 00150 
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Probe 
Patient or cell line 
(Number of cells deleted/number of cells retained) 
9 10 11 12 13 14 15 16 
RPl-71HI9 
RP 1 -260B21 
RPI-102HI9 
RP I -67N 15 
RPI-235B9 
P 13743 
RPI-202BI3 
RPI-132E6 
RP 11-5919 
RPI-429G5 
RPI-I I IB22 
RP I -66H 14 
RP I -240M 13 
RPI-162C6 
RP I -59B 14 
RPI-293L8 
RPI-179EI3 
RP 1 -76H23 
RPI-17INI I 
RPI-172KIO 
RPI-178DI8 
RPI-237G20 
RPI-278NI2 
RPI-137K2 
RP I -65A9 
RPI-167AI4 
00/13 00/17 00/20 
00/10 
10/01 00/10 00/10 
10/00 10/00 10/02 01/20 
10/03 10/01 10/09 
10/04 10/00 
10/01 10/00 
10/07 10/00 
05/09 10/00 
10/00 10/00 
11/02 10105 10/08 10/00 08/08 
11/03 10/00 
10/00 
00/10 07/15 10/00 
05/13 10/00 
10/01 09/12 10/00 
10/00 10/07 00/10 00/10 10/00 
11/11 00/10 
13/05 00/10 
00/10 00/10 10/07 00/10 00/10 
00/10 
10/17 
00/20 00/20 00/20 10/09 00/20 00/20 00/20 00/20 
10/00 
00/20 00/10 
10/06 10/00 10/00 
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Probe 
Patient or cell line 
(Number of cells deleted/number of cells retained) 
17 18 19 20 21 22 * 23* 24 
RPI-71HI9 
RP 1 -260B21 
RP I- 102H 19 
RP I -67N 15 
RPI-235B9 
P 13743 
RP I -202B 13 
RPI-132E6 
RP 11-5919 
RPI-429G5 
RPI-I 1 lB22 
RP I -66H 14 
RP I -240M 13 
RPI-162C6 
RP 1 -59B 14 
RPI-293L8 
RPI-179EI3 
RP I -76H23 
RPI-171NI 1 
RPI-172KIO 
RPI-178DI8 
RPI-237G20 
RP I -278N 12 
RPI-137K2 
RP I -65A9 
RPI-167AI4 
00/20 00/10 
01/10 00/10 
00/10 
10/03 
10/02 10/00 00/10 
10/01 
00/10 00/10 00/20 00/10 00/20 
00/10 00/10 
00/14 
10/00 00/10 00/10 00105 
10/00 10/02 10/00 00/10 00/14 
10/00 10/00 07/05 01/12 
10/01 
10/00 00/10 00/14 
10/01 10/02 00/10 
10/00 10/01 10/00 
10/00 
10/00 
10/01 10/00 
11/02 
01/11 
00/10 
10/04 
10/03 
00/09 
00/06 
00/10 00/10 
08/06 00/12 
06/07 
00/10 
00/10 10/00 
00/20 00/20 20/00 00/20 
07/08 
11/06 
11/07 10/10 
06/05 
10/00 21/16 00/20 21/07 
Table 3.3. Numbers of cells deleted for and retaining probes used in the primary FISH 
analysis of patients and cell lines with abnormalities of the q arm of chromosome 6. 
* Deletion was associated with translocation in this patient. Probes scored as deleted are 
marked in red, data taken from an earlier study with YAC probes are marked in green. 
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3.2.2 Patients with 6q translocations. 
Twelve patients (5 AML and 7 ALL) where shown by FISH to have translocations of 6q. Of 
these, one ALL patient (case 22) also had a deletion of the other homologue of chromosome 
6 and a second case (23), carried an interstitial deletion associated with a translocation (for 
details see 3.2.3). Only two of the ALL associated translocations (cases 26 and 29) were 
accurately characterized by G-banded analysis the remaining 5 were reported to be deletions 
or monosomy 6. By contrast 4 of the 5 cases of AML were classified as 
translocations/inversions and one was described as add(6q) (additional material of unknown 
origin was seen on 6q). Initially the translocations were mapped with the same panel of FISH 
probes used for primary analysis of deletions (Table 3.2). The positions of probes used in 
each case, relative to the break points, are presented in Table 3.4 (cases of ALL) and Table 
3.5 (cases of AML). A summary map of translocation break points among both myeloid and 
lymphoid malignancies, highlighting regions selected for more detailed analysis, is shown in 
Fig 3.3. 
Of the two regions selected for further analysis with 6q probes, one contained the break point 
of a translocation that appeared to have been duplicated (see patient 22 in 3.2.3 and 3.6.3) 
The second contained a cluster of translocation break points (see 3.6.2). The possibility that 
known oncogenes participated in several of the translocations was also investigated, using 
FISH with probes from the translocation partner chromosomes (see 3.6.1). 
The FISH data was used to redefine the break points of either translocations or deletions in 
29 (85%) of the 34 cases analysed. A comparison of chromosome 6 abnormalities as defined 
by FISH analysis with the original karyotype is made for each case in Table 3.6. The high 
degree of discrepancy between 6q abnormalities as defined by G-banded analysis and 
following FISH emphasizes the limitations of conventional cytogenetics. In particular, 
among cases of ALL, deletions of 6q were invariably assigned breakpoints that were 
inaccurate and only two of 6 balanced translocations were recognized as such on G-banding. 
The results obtained in this study highlight the importance of using FISH, not only to define 
CDRs, but also prior to assigning clinical characteristics to recurrent cytogenetic changes. 
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Probe Cases of ALL with translocations of 6q 
22 23 25 26 27 28 29 
RPI-71HI9 c c c 
RP 1 -260B21 c 
RPI-102HI9 c 
RP I -67N 15 c c 
RPI-235B9 c c 
P13743* 
RP I -202B 13 c c c 
RPI-132E6 c c c 
RP 11-5919 c c c c c 
RPI-429G5 c 
RPI-11IB22 c c 
RP 1 -66H 14 D c c c 
RP I -240M 13 
RPI-162C6 D c c 
RP I -59B 14 D c c c c 
RPI-293L8 T c c 
RPI-179EI3 c c 
RP 1 -76H23 T T c T c 
RPI-17INI I c T T T T 
RPI-172KIO c T T T 
RPI-178DI8 
RPI-237G20 c T 
RPI-278NI2 c 
RPI-137K2 c 
RP I -65A9 c T 
RPI-167AI4 T T T T T T T 
RP I -57M24 T T T 
Table 3.4. Results of FISH analysis of ALL patients with translocations of 6q. Abbreviations 
are as follows: C: probe positioned on the centromeric side of the translocation break point. 
T: probe positioned on the telomeric side of the break point; D: probe deleted. 
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Probe Cases of AML with balanced rearrangements of 6q 
30 31 32a 32b 33 34 
RPI-71HI9 c c c 
RP 1 -260B21 c 
RPI-102HI9 
RPI-67NI5 c 
RPI-235B9 T 
P13743* 
RPI-202BI3 T 
RPl-132E6 
RP 11-5919 
RP I -429G5 c c c c 
RPI-I I IB22 
RP 1 -66H 14 T c c 
RP I -240M 13 
RP I-I 62C6 
RPI-59BI4 c 
RPI-293L8 c c 
RPI-179EI3 T c 
RP 1 -76H23 T c c 
RPI-17INII T T T c 
RPI-172KIO T T 
RPI-178DI8 
RP1-237G20 c 
RPI-278NI2 
RPI-137K2 T 
RP I -65A9 
RPI-167AI4 T T T T T 
RP I -57M24 T 
Table 3.5. Results of FISH analysis of cases of AML with translocations or inversions of 6q. 
Abbreviations are as in Table 3.4; in addition: S: probe split by translocation. 32a; 
translocation of 6q, 32b; pericentric inversion of 6q. 
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Case 6q abnormality (G-banding) 6q abnormality (FISH) 
I del(6)(q? 13q2l) del(6)(q I I- I 4q 15-16) 
2 del(6)(ql5q23) del(6)(q I I- I 4q 16) (ml) 
del(6)(q I I- I 4q22-23) (stl) 
3 del(6)(q2 1) del(6)(q I I- I 4q 16) 
4 del(6)(q2lq25) del(6)(ql4-15ql6) 
5 del(6)(ql4q22) del(6)(q I I- I 4q2 I) 
6 del(6)(qlq2l) del(6)(q 11- 15 q 16-2 1) 
7 del(6)(ql3q23) del(6)(q I 1-14q2l-23) 
8 del(6)(q2 1) del(6)(q I I- I 5q2l-23) 
9 del(6)(q2 I q23) del(6)(q I 1~15q22-23) 
10 del(6)(q2 I q23) del(6)(q I 5q22) 
II del(6)(q? ) del(6)(q I 5q22-27) 
12 del(6)(q2? q2? ) del(6)(q 15) 
13 del(6)(ql6) del(6)(q I I- I 5q2 1) 
14 del(6)(q? 15q2? 3) del(6)(q I I- I 4q22) 
15 del(6)(ql3q2l) del(6)(q I I- I 4q22) 
16 del(6)(ql3q22) del(6)(ql 1-14q22-23) 
17 del(6)(q2 1) del(6)(ql4-15q24-25) 
18 del(6)(ql3-15q2l) del(6)(q I 5q22-27) 
19 del(6)(q22) del(6)(q 15-16) 
20 del(6)(q2 I q23) del(6)(q I 6q22-23) 
21 del(6)(q2 1) del(6)(q 16) 
22 ? del(6)(q2? 1) del(6)(q I 6q27), t(6;? )(q27;? )+der? 
23 -6 t(6;? )(q22;? ) 
24 der(6), t(l; 6)(q? 23; q? 2 1) der(6), t(1; 6)(q?; q24-q25) 
25 del(6)(q2 1) t(6;? )(q22;? ) 
26 t(6; 9)(q2? 5; q22) t(6; 9)(q23; q? ) 
27 del(6)(q? 13; q? 21) t(6;? )(q22;? ) 
28 del(6)(q? ) t(6;? )(q22-q23;? ) 
29 t(6; 19)(q? 2 I; p 13) t(6; 19)(q22-q27; p? ) 
30 t(6; I 1)(q I 3; q23) t(6; I 1)(q I 5; q23) 
31 t(6; 7)(q2? 1; pl5) t(6; 7)(q2l; pl5) 
+6, del(6)(q? 2 I; q2? 5), +6, del(6)(q? q? ) 
32 inv(6)(p 13 q22), t(2; 6)(q3? 1; q2? 5) inv(6)(p? q22), t(2; 6)(q?; q22-q23) 
33 add(6)(q23) t(3; 6)(q26; q25) 
34 t(6; 8ý(g27; pl 1.2) t(6; 8)(q27; p 11.2) 
Table 3.6. Comparison of 6q abnormalities as defined by G-banded analysis and after FISH. 
Cases with a redefined karyotype as a result of FISH analysis with 6q locus specific probes 
are highlighted in red. 
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3.2.3 Complex rearrangements of chromosome 6. 
Patterns of FISH signals consistent with complex rearrangements, that merit more detailed 
description, were seen in three of the cases included in the primary analysis. 
Patient 22. This case was included in a previous published study from this laboratory in 
which deletions of 6q were mapped using FISH with YAC probes (patient 15 256) . YACs 
860flO and 36CBII (equivalent to PAC RPI-32E6 and BAC RP11-5919) defined the 
proximal boundary of deletion. In this study it was confirmed that the deletion encompassed 
the region containing clone 3 6CB 11. FISH with probes between RP 11-5919 (6q2 1) and RP 1- 
65A9 (6q27) resulted in a single green signal hybridising to a chromosome marked by the red 
6q centromeric probe (RP 1 -7 1H 19). As is typically seen with large deletions of 6q, these 
probes failed to hybridise to a second chromosome marked by the centromeric PAC. 
Unexpectedly, however, hybridisation of a probe mapped telomeric to RPI-65A9 (RPl- 
167A14), produced two green signals, neither of which were positioned on a chromosome 
marked by RPI-71HI9. This pattern of FISH signals was open to more than one 
interpretation. In the least complex of these intrepretations, deletion of one homologue of 6q 
extend distally to include the telomere, and was therefore likely to be an unbalanced 
translocation. The second homologue of 6 underwent translocation with a break point 
between PACs RPI-65A9 and RPI-167AI4. Following the translocation, the product 
containing the telomeric region of 6q was duplicated. The two chromosomes marked by RP I- 
167A14 differed in size suggesting that further rearrangement of one or both, in addition to 
translocation and duplication, had occurred. More complex models involving translocation of 
both homologues of 6q can also explain the pattern of signals seen. 
Because the case evidently involved rearrangement of both copies of 6q, with the likely 
scenario being deletion of one homologue accompanied by translocation of the second, it 
seemed possible that the translocation break point would flag the site of a tumour suppressor 
gene. Paradoxically the apparent duplication of a translocation product was more 
characteristic of the type of gain of function changes associated with oncogenic fusion genes. 
It was decided to map the break point of the 6q translocation more precisely using PACs 
ill 
localised to the region between RPI-65A9 and RPI-167AI4. The results of analysis with 
further probes as well as FISH images illustrating the described signal pattern associated with 
this case are presented in 3.6.4. 
Patient 23. In this case PAC RPI-293L8 (6q22) and more telomeric probes hybridized to a 
chromosome of unknown origin and probes between the centromere and PAC RP I-III B22 
(6q2 1) were retained on the derivative chromosome 6, consistent with the presence of 
translocation. However, intervening probes RPI-66HI4, RPI-162C6 and RPI-59BI4 were 
present on one homologue of chromosome 6 only, demonstrating that an interstitial deletion 
accompanied translocation in this case. 
Patient 32. On G-banded analysis distinct clones with both an extra copy and structural 
rearrangements of chromosome 6 were recognised. In one clone, pericentric inversion of 6 
was associated with deletion of a second homologue of 6q. A sub-clone with identical 
involvement of chromosome 6 but apparent duplication of the deletion was also reported. 
The deleted chromosome was not present but one homologue of 6 was involved in a 
translocation with chromosome 2 [t(2; 6)(q3? I; q2? 3)] in a second sub-clone. Evidence for the 
presence of an unbalanced t(6; 6) was also found in the second sub-clone. 
FISH with the 6q probes produced a pattern of signals consistent with the presence of both an 
inversion and a balanced translocation in approximately 50% of cells. The translocation and 
inversion were always co-existent and accompanied by a third, apparently normal, copy of 
chromosome 6. Evidence for interstitial deletion or unbalanced translocation of 6q was never 
seen in cells carrying the balanced rearrangements. However, a sub-clone with two normal 
copies and a large deletion of chromosome 6 was seen. Numbers of cells with del(6q) did not 
meet the scoring criteria adopted in this study so this case has not been included in the 
deletion analysis. 
Examples of metaphase cells from patient 32 hybridised with PACs from the primary panel, 
are presented in Fig 3.4. The 6q inversion break points was found to fall between RP I- 
76H23 and RP I- 17 1NII and the t(2; 6) translocation break point between PACS RP 1 -293 L8 
112 
Fig 3.4 Example of FISH analysis of complex cytogenetic rearrangements 
including both translocation and inversion of chromosome 6 in patient 32. 
a) Red signal; RPl-167A14 (marking the the 6q telomeric region). Green 
signal; RPI-179EI3 (hybridising to band q22 on chromosome 6). RPI-179EI3 
is positioned proximal and RPI-167A14 distal to the break points of both the 
t(2; 6) and inv(6). b) Red signal; RPI-167A14 (marking the 6q telomeric 
region). Green signal RPI-17INI I (hybridising to band q23 on chromosome 
6). Both RP I- 167A 14 and RPI - 17 1NII are positioned distal to translocation 
and inversion break points. 
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and RPI-179EI3. The two balanced rearrangements therefore both interrupted the band 
6q22-23 region within 7-11 Mb of each other. Translocation break points from 5 cases of 
ALL also fell within this region and additional PACs from between RPI-293L8 and RPI- 
17 IN II were used to map the 7 rearrangements in greater detail (see 3.6.2). 
3.3 Clinical details of Patients included in the study. 
Clinical details (where available) for the patients and cell lines analysed by FISH are 
presented in table 3.7. Of the 21 patients with deletions (including unbalanced translocations) 
of 6q, complete clinical data was obtained for all except three, of these two were cases of 
AML (21 and 24). Full clinical details were also unavailable for the three cell lines analysed 
(cases 5,13 and 16). The deleted patients represent a relatively homogeneous group in that all 
were children or young adults (age range 3-19 years) and of the 24 all except two were cases 
of ALL. Of these II were cases of T-Cell ALL, 6 had common ALL and two Pre-B ALL. 
The last three cases were described as ALL, unusual ALL and Null ALL/AML. White blood 
cell counts (WBCs) at diagnosis varied between 5.9 and 300x109/L and there was an 
imbalance in the male/female ratio (17/7). Length of first remission varied between I and 
111 months. Excluding two patients that remained in remission at the time the data was 
acquired the mean length of first remission was 35.4 months for the patients with 6q 
deletions. 
Cases of ALL with balanced translocations of 6q (25-29 excluding patient 22 who carried 
both a deletion and a translocation) included two cases of common ALL and two of T-ALL 
with the remaining case being described as ALL. As for the deleted cases, there was a 
preponderance of male patients (4 male I female). WBCs were low for the cases of common 
ALL (3.5 and 2.3) but high for the T-Cell ALL patients (97.8 and 52.9). The mean remission 
time for four of the five patients was slightly higher than for the deleted cases (41.8 months) 
though the number of cases with translocations excluded the possibility of performing 
meaningful statistical analysis. Cases of AML with translocations of 6q had heterogeneous 
breakpoints (see Fig 3.3) and no obvious common clinical features. 
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Case Age at sex VVBC Disease sub type Length of lst 
Number Diagnosis remission 
1 12 F 272.0 Common ALL (L 1) 22 
2 13 F 8.8 Pre-B ALL 10 
3 13 M 51.0 T-Cell ALL (LI) 13 
4 10 M 166.4 T-Cell ALL 24 
5* 16 F T-Cell ALL 
6 8 M 282.0 T-Cell ALL (LI) 12 
7 15 M 200.0 T-Cell ALL 1 
8 15 M 300.0 T-Cell ALL 36+ 
9 13 M 44.5 T-Cell ALL (LI) 31 
10 4 M 13.9 Common ALL (L 1) 34 
11 3 M 5.9 Unusual ALL (L 1) 95 
12 4 M 16.1 Common ALL 27+ 
13* 19 M T-Cell ALL 
14 16 M 104 T-Cell ALL 9 
15 8 M 15.7 T-Cell ALL (LI) 26 
16* 5 F T-Cell ALL 
17 4 F 9.9 Pre- B ALL (L 1) ill 
18 11 M 8.5 Common ALL (L 1) 102 
19 10 M 35.0 Common ALL (L 1) 25 
20 F ALL 
21 M AML 
22 10 M 7.3 Null ALL/AML 39.5 
23 8 F 17.6 Common ALL (L 1) 12 
24 M AML 
25 M ALL 
26 16 M 3.5 Common ALL 21.5 
27 10 M 97.8 T-Cell ALL 33 
28 2 M 52.9 T-Cell ALL 77 
29 10 F 2.3 Common ALL 36 
30 13 F 9.0 AML (M4) 1.5 
31 1 F 15.4 AML (M2) 2 
32 M AML 
33 F AML (M5) 
34 15 M 12.0 AML (M4) 11 
Table 3.7 Clinical data for patients with abnormalities of 6q analysed by FISH. Age (years), 
WBC (x I 09Q, length of first remission (months). * indicates cell line. 
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3.4 Further analysis of deleted Cases. 
FISH analysis with the primary probes demonstrated that in all, except for four cases, 
deletions extended into the region between PACs RP 1-202B 13 and RP I- 132E6. Three cases 
(2,3 and 4) were deleted for RPI-202B13 but not RPI-132E6 and two cases (20 and 21) 
retained RP 1-202B 13 and showed loss of RP I- 132E6. It was therefore of interest to map, in 
greater detail, the extent of deletion in these patients. Firstly to establish if there was a 
common overlapping region of deletion between the five cases and secondly to investigate 
the possibility that any of these deletions shared a common break point. 
3.4.1 Secondary FISH analysis of deleted cases. 
A further 6 PAC probes localised between RPI-202B13 and RPI-132E6 were used in FISH 
experiments to more accurately map the position of deletion break points in the five cases. 
The probes used, their corresponding genetic markers and HGMP map positions are 
presented in Table 3.8. Numbers of cells retaining or deleted for the probes used in each 
patient are detailed in Table 3.9. 
On further analysis each of the five deletions overlapped to give a common deletion region 
(CDR) of 4.5 Mb, between PACs RP I -48F9 and RPI-299C21 (Fig 3.5). At least 4 different 
break points were shared between the five cases suggesting that there was no common 
sequence underlying the mechanism leading to deletion in these cases. Potentially a common 
break point forms the distal boundary of deletion in patients 3 and 4. However, the region 
between RP I -299C21 and RP I- 132E6 is large (not less than I Mb) and at the time of analysis 
was partly uncloned. Because of limitations in the availability of both suitable clones and 
patient material, further analysis to determine whether the two cases shared a common break 
point was not performed. 
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Probe Chromosome 6 map Cytogenetic Marker 
position band 
RP 1-202B 13 100600-100700 6q16 D6S501 
RP 1-48F9 101700-101900 6q16 D6SI510 
RPI-12IG13 103550-103650 6q16 D6SI409 
RP 1-204F 17 104700-104800 6q16 D6SI543 
RPI-256Ell 105250-105350 6q16 D6S1642 
RP 1-201 G21 105900-106050 6q16 D6S283 
RPI-299C21 106350-106450 6q16 D6SI692 
RP I- 132E6 108150-108300 6q16 D6S447 
Table 3.8. Probes used for FISH analysis of the common deleted region, with 
corresponding HGMP chromosome 6 map positions, band assignments and 
genetic markers. 
Probe 
Patient or cell line 
(Number of cells deleted/number of cells retained) 
23 
14/06 10/01 RP 1-202B 13 
RPI-48F9 
RPI-12IG13 
RPI-204F 17 
RPI-256E II 
RPI-20IG21 
RP 1-299C21 
RP I- 132E6 
10/02 
10/02 
10/03 
03/10 
03/15 
10/03 
11/01 
00/10 
4 
10/02 
10/03 
00/10 
20 21 
00/10 00/10 
10/00 00/10 
09/01 10/00 
10/00 
09/02 10/01 
Table 3.9. Secondary FISH analysis of patients 2,3 and 4 (deletions ending 
distally between RPI-202BI3 and RPI-132E6) and patients 20 and 21 
(proximal ends of deletions falling between RP I -202B 13 and RP I- 132E6). 
Numbers of metaphase cells showing deletion/retention of probes positioned 
between 202B13 and 132E6. Probes scored as deleted are marked in red, 
retained probes in black. Data marked in green refers to analysis with YAC 
830d9 performed in an earlier FISH stud Y256 
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Patient 
2 3 20 21 
centromere 
Marker PAC 
D6S501 202-B13 0 0 
6q16 D6S1510 4849 0 0 
D6S 1409 121-G13 0 
D6S 1543 204417 CDR 
D6S283 201-G21 (4.8 Mb) 
D6S 1642 256-Ell 
D6SI692 299-C21 
6q2l 
telomere D6S447 132-E6 
Fig 3.5. Detailed FISH map of the region between PACs 202-B13 and 132- 
E6 in patients with leukemia related deletions of 6q. Open circle (probe 
retained), Filled circle (probe deleted). A common region of deletion was defined 
between PACs 48-F9 (marker D6S 15 10) and 229-C21 (marker D6S 1692). 
3.4.2 Gene content of the new CDR. 
Analysis of the region between RPI-299C21 and RPI-48F9 using the ENSEMBL and 
ACEDB human genome browsers revealed the presence of 16 genes. At the time the search 
was conducted (March 2002) fully sequenced clones accounted for 98-99% of the region. 
Additional exons either associated with one of the recognized genes or with as yet 
unrecognized genes in the region were also predicted by the presence of open reading frames 
(Gene scan predicted) and or of NCBI curated cDNA sequences. Of the 16 genes, 6 had been 
previously characterized, 8 corresponded to full length or near full length cDNA or protein 
sequences and 2 were predicted on the basis of similarity to ESTs or known protein 
sequences. The positional relationship between the recognized genes, predicted genes and 
sequence segments is summarized in fig 3.6. Further information about the size, number of 
exons and function or predicted function of the genes is presented in tables 3A. 1 and 3A. 2 
(Appendix 3). 
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Centromere 
4.5Mb 
telomere 
AL022395 
AL078603 
AL590022 
AL591803 
AL034371 
AL513550 
AL137784 
AL035087 
AL390959 
AL590725 
AL590732 
AL080285 
AL583822 
AL121948 
Z86062 
AL513207 
AL121965 
A 
ýHMN 
AL161720 
AL109934 
AL450427 
AL16040 
AL365276 
AP002528 
AP002529 
AP002530 
AP002531 
AL592296 
AL357139 
AL357506 
AL513011 
AL591844 
AL136975 
Z98755 
AL009029 
AL121937 
Z99290 RP1-299C2 
I Unfinished sequence segment. 
0 Gap in contig 
Fig 3.6 Gene content of the 6q16 CDR derived from FISH analysis of cases of 
acute leukaemia with cytogenetic deletion of chromosome 6. Showing the 
Positional relationship between sequenced segments, genes, predicted genes and 
transcripts 
I 
I 
I 
I 
I 
I 
I 
I 
I 
I 
I 
I 
I 
I 
1 
I 
I 
I 
I 
I 
2 
3 
I 
I 
POU3F2 RPl-48F9 
I RXL4 
(, ), )BXE6 
Novel 
I Q9B552 
NA 10 1714 "I I Qgpoc"(-) Novel 
I Q9BRU: I 
0 CCNC 
n PRDM13 
I Q9BX, AS 
Isim 
I 
L043738 
Q9H5A2 
GluR-6 
x Gene scan predicted gene 
M NCBI transcript 
Annotated and finished gene 
deposited in EMBL nucleotide 
sequence database. 
Gene predicted by Ensembl and 
corresponding to near or full length 
c-DNA and or protein sequence 
already available in the public 
sequence database. 
Novel gene predicted by Ensembl 
on the basis of identity to EST's 
and or similarity to protein 
sequences. 
I Finished sequence segment. 
=I 
E 
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The CDR can be divided into four sub-regions of similar size. The most telomeric region 
between sequence segments Z99290 and AP002530 contains no recognised genes and few 
genescan predicted exons or NCBI transcripts. The second region between AP002530 and 
AL365276 contains a single relatively large gene, GluR-6, which also has some long intronic 
sequences causing it to extend over 670 Kb of the genome. The third region, AL365276 to 
AL080285, contains 3 genes with large to medium sized transcripts and an intermediate level 
of compaction. The largest gene in this region, a small ribonuclear protein (L043738), when 
compared with GluR-6 has more than twice the number of exons coding for a transcript of 
double the size but is localized to a genomic region of similar size. The remaining 12 genes 
are medium or small in size and clustered into a region of approximately I Mb in the 
centromeric part of the CDR. In total the 12 genes encode 70 exons with a combined length 
of 304.4 Kb. Three of the genes in this region have only a single exon, in one case (POU3F2) 
encoding a 1329 b. p. transcript. 
Three criteria were used to prioritise the further investigation of genes from within the CDR- 
First functional characteristics were considered (discussed in more detail in chapter 4). 
Characterised genes or those containing known functional domains, included a ubiquitin 
processing enzyme, an oxidoreductase and an RNA helicase that were newly identified so 
functionally not well characterized, though related genes have not been implicated in 
malignancy. Also newly discovered was a methyltransferase. While disturbance to normal 
DNA methyletransferase activity can contribute to malignancy through loss of imprinting or 
epigenetic silencing of tsgs (see 1.5), in this case methylation targets are as yet unknown and 
not suggested to be DNA. 
Two functionally related transcription factors, BRN-2 (POU3F2) and SIM-], both play a role 
in neuronal development. SIM- I is essential for early stages of development but is also 
263 
required to maintain expression of BRN-2 that in turn directs terminal differentiation 
BRN-2 is also required for melanocyte development and SIM- I for differentiation of 
neuronal cells that regulate aspects of behavior such as appetite. A patient with a 
constitutional translocation involving SIM] developed obesity but not malignant disease 264 . 
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A second gene involved in appetite regulation, MCH2 is a G-protein coupled receptor 
265 
activated by melanin concentrating hormone 
The last two characterized genes, CCNC and GluR-6, are both functionally interesting 
candidate tsgs. GluR-6 because it encodes a transmembrane receptor sub-unit that is involved 
in the transduction of pro-apoptotic signals and CCNC because it forms part of a mediator 
complex that modulates RNA polymerase 11 activity and has been implicated in the negative 
regulation of cell growth (for further discussion and references see 5.1). 
In addition to considering the functional properties of encoded proteins, knowledge of the 
tissue specific expression of genes from within the CDR could potentially be used to 
prioritise candidate TSGs. Expression patterns of many of the genes within the CDR were 
unclear but SIMI and GluR- 6 have been associated exclusively with a role in central nervous 
system. BRN-2 (POU3F2) expression has been reported only in brain and melanocytes. 
MCH2 (Q9BXA8) was expressed at highest levels in various regions of the brain. However, 
among 19 other tissues investigated, lower numbers of transcripts were detected in 
lymphocytes, the intestine, adipose and prostate tissue 265 . CCNC was transcribed at highest 
levels in pancreas, heart, liver, skeletal muscle and kidney but a functional role for the 
66 
protein in haematopoietic cells has also been reported2 . 
As a third means of focusing the search for a TSG on 6q the data was compared with 
previously published CDRs derived either from FISH or LOH analysis of leukemia and 
lymphorna patients (see 3.4.3). 
3.4.3 Comparison with previously published CDRs. 
Genetic markers, defining the proximal and distal boundaries of 6 previously published 6q 
CDRs, were positioned on Sanger Centres's PAC and BAC contigs by searching the ACEDB 
and NCBI databases. The positions of the 6 published CDRs and the new FISH CDR were 
then mapped relative to each other (Fig 3-7). The CDR obtained in this study overlapped 
with four of the six previously published. In one study distinct proximal and distal CDRs, 
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6q16 
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Fig 3.7 Relative position of CDRs derived from FISH or LOH analysis of 
lymphoid malignancies in relation to the new FISH CDR. 5 of the 8 CDRs 
overlapped to give a consensus region centred on marker D6S283 (highlighted by the 
blue box). 
both of which overlapped with our own region, were published (Takeuchi et al)259 Thetwo 
CDRs also overlapped with two additional published CDRs to give a consensus region 
centred on marker D6S283 and coinciding with the second of the two sub-regions described 
in 3.4.2. The sub-region was composed of 4 fully sequenced segments (AP00253 1, 
AP002530, AP002529 and AP002528) and contained a single recognized gene, GluR-6. 
Using the BLAST search facility of NCBI the markers used to define the published CDRs 
and individual exons from the publicly available GIuR-6 cDNA sequence (NCBl accession # 
NM021956) were mapped on the four sequence segments. NCBI EST databases were also 
compared for matches with the four sequences. 
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GluR-6 exons, ESTs, markers used to define CDRs and, from one study, the position of 
deletions in individual patients, have been positioned relative to one another in Fig 3.8. Most 
strikingly the CDR published by Merup et a1258 was defined proximally by D6SI709 and 
distally by D6S434 with a single intermediate marker (D6S283) displaying LOH in the 
majority of patients. The three markers were positioned between exons II and 14 of GIuR-6 
on AL0002529. An individual patient from this study displayed LOH only for marker 
D6S283 while remaining heterozygous for all other markers tested including D6SI709 and 
D6S434. A second patient, from the same study, also showed LOH only for markers 
(D6S283, D6SI709, D6SI642 andD6S449) mappingtowithin GluR-6 A third patient, while 
retaining markers used to define the CDR, carried a deletion with a proximal boundary 
defined by D6S 1543, positioned between exons I and 2 of GluR-6. 
Of the two CDRs defined by Takeuchi et al, the marker D6S283 defined both the distal 
boundary of the more centromeric and the proximal boundary of the more telomeric. Both 
CDRs therefore encompassed exons of GluR-6. Consequently, loss of fimction of GluR-6 
could result from all of the deletions observed in this study, obviating the need to postulate 
the existence of two distinct TSGs on 6q. The CDR from a third study also included exons I- 
13 of GluR-6 (Zhang et al)257. 
A detailed blast search of the four sequenced segments revealed 18 ESTs. On the basis of 
sequence homology to common repeat sequences, lack of evidence for splicing and lack of 
cross species conservation, it seemed unlikely that any of the ESTs represented functional 
genes. 
In summary, there was no single clear region of overlap between the new CDRs and those 
published by other groups. However detailed comparison between published leukemia 
associated deletions of 6q and genes located within the new CDR identified GluR-6 as the 
most promising candidate tumour suppressor. 
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Fig 3.8 The positional relationship between sequenced fragments, ESTs, exons 
of GluR-6. and published CDRs (and deletions in individual patients) derived 
from LOH analysis of cases of ALL. 
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3.5 Investigation of the potential role of GluR-6 in malignant 
transformation. 
Analysis of our own and published deletion data clearly suggest that loss of GluR-6 may 
contribute to the pathogenesis of leukaemia and GluR-6 function is consistent with a tumour 
suppressor role. However, glutamate receptor expression had not previously been reported in 
the haematopoietc system. Because deletions of chromosome 6 are common not only in ALL 
but in a variety of other malignancies the expression of GluR-6 was assessed in 
haematopoietic and several additional tissues. 
3.5.1 Analysis of expression of GIuR-6 in haematopoietic and other tissue. 
Initially forward and reverse primers from exons 13 and 15 producing a 469 base pair 
product were used to amplify c-DNA from a remission bone marrow sample, two ALL 
patients and from RAT brain. Brain was selected as a positive control since GluR-6 is 
expressed at high levels in the central nervous system. The quality of all c-DNAs had been 
checked previously, by colleagues using amplification for G6PD sequences, as previously 
described 267 . Gel electrophoresis of the RT-PCR product from the brain sample revealed 
products of the expected size, consistent with the expected high level of expression in this 
tissue. A band of identical size but of weaker intensity was obtained from amplification of 
the leukaemia and remission marrow c-DNA templates (Fig 3.9). This result suggested that 
GluR-6 was transcribed either at a low level or in a sub-population of haematopoietic cells. In 
this initial experiment an annealing temperature of 660C was used and products of both larger 
and smaller size in addition to the expected one were amplified from the marrow samples. 
Increasing the annealing temperature to 680C resulted in elimination of extraneous bands so 
subsequent reactions were carried out under these conditions. 
c-DNA from 5 further remission bone marrow samples, a T-ALL cell line (CEM), aB cell 
ALL cell line (REH) and a presentation sample from a CML patient were then amplified with 
the same GluR-6 primers. Products of the expected size were obtained from all the remission 
samples, though with some variation in band intensity (possibly relating to differences in the 
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Fig 3.9 PCR with paired GluR-6 
specific primers and cDNA from 
brain, normal and leukemic bone 
marrow. (I and 2) rat brain, (3) 
remission bone marrow sample, (4) 
B-ALL patient (5) T-ALL patient 
(6) H20* 
ox 23456789 
Fig 3.10 PCR with paired GluR-6 
specific primers and cDNA from 
cell lines a CML patient and 
normal marrow. (1-5) remission 
bone marrow sample, (6) CML 
presentation sample, (7) REH; 
B-cell ALL cell line, (8) CEM; 
T-ALL cell line, (9) H20 
quality of analysed cDNA). No visible product resulted from amplification of the CML 
patient or cell line c-DNA (Fig 3.10). A further 2 remission bone marrow samples, 2 
lymphoid cell lines (CEM and NC37), a CML cell line (K562), 2 ALL patients, 2 CLL 
patients and 5 AML patients were then tested with the GIuR-6 primers. Clear bands of the 
expected size were seen in both remission samples, the lymphoid cell lines, the cases of ALL 
and one of the AML patients (Fig 3.11). Amplification from the other samples produced 
either very weak or no visible bands. Though not fully consistent, these results suggested that 
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expression of GluR-6 is associated with lymphoid rather than myeloid lineages. It should be 
noted that CEM gave a positive result although it had been negative in the previous 
experiment using the same primers. The inconsistent results obtained with these primers 
suggested either that there were technical problems associated with their use or that GluR-6 
mRNA were present at a level close to the threshold of sensitivity of the technique applied. 
Fig 3.11 RT-PCR analysis of marrow samples from leukaemia patients and 
cell lines using primers specific for GIuR-6. (1) H209 (2-6) cases of AML, (7-8) 
cases of CLL, (9-10) cases of ALL, (11) K562, (12) CEM, (13) NO 7, (14-15) 
remission samples. 
1 
123 (DX 
Fig 3.12 RT-PCR analysis with 
the new GluR-6 (2) primers. (1) H20 
(2) remission bone marrow, (3) rat 
Brain. 
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In an effort to improve the efficiency of detection of GluR-6 transcripts, new primers were 
designed from exons I and 2, the expected product size was 173 base pairs. Amplification of 
brain and remission bone marrow cDNA templates resulted in products of the expected size 
(Fig 3.12), and consistent with the earlier findings GluR-6 transcripts appeared significantly 
more abundant in the brain sample. 
On, ow 0* o0aw ow 
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Fig 3.13 RT-PCR analysis of 
Different tissues with (a) G6PD 
and (b) GIuR-6 (2) primers. 
(1) HA (2) B-cells, (3) liver, (4) 
lung, (5) trachea, (6) kidney, (7) 
heart. 
is-310 
-194 
-118 
3 4- 5 6,1 (DX 
cDNA was then prepared from EBV transformed B-lymphocyte RNA, and commercially 
available liver, lung, trachea, kidney and heart RNA. The quality of cDNAs samples was 
assessed by amplification of G6PD sequences prior to amplification using the new GluR-6 
primers. cDNA prepared from liver and heart appeared of low quality, as judged by 
amplification with G6PD primers, and no visible product resulted from amplification of these 
two samples with GIuR-6 primers (Fig 3.13a). PCR with G6PD primers and the remaining 
four cDNAs resulted in similar levels of amplification, consistent with high quality cDNA 
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templates in each case. By contrast, considerable variation was seen in the quantity of 
product resulting from amplification of these templates with GluR-6 primers (Fig 3.13b). 
Based on this experiment, GluR-6 transcripts were several-fold more abundant in kidney than 
in lung, with B-cells and trachea showing evidence for intermediate levels of expression. 
In summary; a visible RT-PCR product was consistently obtained from normal bone marrow 
samples using GluR-6 primers and one-round PCR amplification. Analysis of patient and cell 
line cDNA suggested that expression might be confined to the lymphoid lineages. Evidence 
for variable levels of GluR-6 expression was also found in several non-haematopoietic 
tissues. 
3.5.2 Mutation analysis of GluR-6 in patients with large deletions of the region. 
The possibility that large deletions of 6q contribute to the pathogenesis of leukaemia, by 
unmasking inactivating point mutations of GluR-6 was next investigated. Genomic DNA 
from ALL patients or cell lines with evidence for deletions that included all or part of GluR-6 
was obtained from two sources. Seven cases were analysed by FISH, either with PACs in the 
present study or with YACs in an earlier study from this department (cases 7-14). Seven 
further cases had been found to display LOH of markers in the region (cases 1-7) (analysis 
conducted by Dr A. Sorour in this department, personal communication). 
PCR reactions using primers designed to amplify each of the 16 known exons of GIuR-6 
were first performed with a remission bone marrow DNA sample. Products of the expected 
size, without significant secondary bands, were obtained for all exons except 6 12 and 15 
(Fig 3.14a). On repeating the PCR reaction a satisfactory product was obtained using primers 
for exon 12 and 15 but not for exon 6. However, this was shown to be due to poor 
amplification ability of these primers. A new set of primers flanking exon 6 amplified a 
suitable product (Fig 3.14b). Evidence for the existence of a 17 th exon (I 5b) was published in 
the course of the analysis of patient DNA sampleS268. Primers flanking the additional exon 
were designed and tested retrospectively (Fig 3.14c). 
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Fig 3.14 Amplification of normal genomic DNA with primers flanking exons of 
GIuR-6. (a) for exons 1- 16 (b) with a second set of primers for exon 6 (c) with 
Primers for exon 15b. 
Fig 3.15 Amplification of 
GIuR-6 exon 6 from 14 
cases of ALL. No product 
was amplified from cases 
13 and 14 in this example. 
400 
300 
Primers pairs for all the seventeen identified exons of GluR-6 were used to amplify DNA 
from the 14 leukaemic cases, with repeat PCR reactions being performed when necessary as 
detailed in 2.13.2. As an illustrative example the PCR products resulting from amplification 
of patient and cell line DNA with exon 6 specific primers is shown if Fig 3.15. In this case 
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no visible product resulted from amplification of cases 13 and 14 (cell lines RPMI 8402 and 
Peer). After repeating the PCR reactions with these cases a satisfactory product was obtained 
from RPMI 8402 but not from Peer. Despite repeated attempts no visible PCR product was 
ever obtained from Peer using the exon 6 specific primers raising the possibility that 
inactivation of the second allele of GluR-6, through sub-microscopic deletion, occurred in 
this instance. A successful PCR reaction was achieved for all other primer sets on all 14 
cases. 
Forward and reverse sequencing reactions were performed using the cleaned PCR products 
as templates. GluR-6 exon sequences amplified from cases of leukemia were then compared 
with corresponding wild type sequences. Sequencing reactions, and where necessary PCR 
amplification from genomic DNA, were repeated when a mismatch between the amplified 
leukaemic sample and the wild type sequence was seen in both forward and reverse 
directions (see 2.13.5 for details of criteria). Sequences obtained from exon II consistently 
included numerous mismatches in both forward and reverse strands. After repeating 
amplification and sequencing reactions the mismatches were still too frequent to confidently 
distinguish between mutations and sequencing errors. The intronic regions flanking exon II 
(see appendix 2) contained poly-thymidine repeats that were assumed to have interfered with 
the sequencing reactions. To avoid sequencing through the repeats, nested forward and 
reverse primers from just within exon II were designed and used to prime sequencing 
reactions from the original PCR products. As a result of this strategy wild type sequence for 
exon II was obtained from all cases. 
The final results of the mutation analysis of GluR-6 are presented in Table 3.10. Wild type 
sequences were obtained in every case for all exons except 6 and 15. A cytosine to guanine 
transversion was found at base pair position 113 in exon 6 from patient I (Fig 3.16a and b). 
After repeated attempts no PCR product resulted from amplification of DNA with exon 6 
primers from case 14 (cell line PEER, as described above). In four patients (2,5,8 and 9) aG 
to A transition was found in exon 15 at position 114. Transition of base pair 114 of exon 15 
from G to A would not result in a change in amino acid sequence since both GAG and GAA, 
encode for a glutamic acid residue. Thus the G to A transition would be silent at the protein 
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Table 3.10 Sequences of exons of GluR-6 amplified from genomic DNA from cases of ALL 
with deletions of 6q. Wild type sequence base pair change (x, y), PCR failed to result in 
a visible amplification product (NS). 
level, ruling out the possibility that it plays a role in leukaemogenesis. By contrast the C to G 
transversion observed in exon 6 of patient I would result in an amino acid change from 
Serine (TCG) to tryptophan (TGG) at position N297C of the protein. 
To determine whether the C to G change observed in exon 6 of patient 1, resulted from 
somatic mutation and clonal expansion, DNA from the remission marrow sample from this 
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Fig 3.16a Normal 
Sequence from exon 
6 of GIuR6. 
CCACAGAAAAGG GIEý GGA8CGAGCA 
130 140 150 
Fig 3.16b GIuR-6 
sequence from exon 
6 in the presentation 
sample of case 1. AC 
to G transversion was 
present at position 113. 
Fig 3.16c GIuR-6 
sequence from exon 
6 in the remission 
sample of case 1. 
Both C and G residues 
were present at 
position 113. 
patient was also amplified with the exon 6 primers and sequenced. Like the leukaemic 
sequence, exon 6 from the remission sample displayed evidence for a base pair change at 
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position 113. The forward sequence gave the same C to G transversion and the reverse 
sequence aC to N change at the same site, consistent with the presence of both wild type and 
mutated sequence. Examination of the sequence trace (Fig 3.16c) from the remission sample 
revealed evidence for the co-existence of both C and G nucleotides at position 113. 
No base pair change at position 113 of exon six was seen in any of the leukaemic samples 
except patient 1, making it unlikely that the C to G transversion was a common 
polymorphism. In an attempt to find evidence for a rare polymorphism at this site a further 
20 normal DNA samples were sequenced using the exon 6 primers. All tested normal 
samples were wild type for exon six, so the possibility remains that patient I carried a germ 
line mutation that conferred a predisposition to develop leukaemia. 
3.6 Further analysis of cases with balanced rearrangements of 6q. 
3.6.1 FISH analysis of 6q translocation partners. 
Partner chromosomes and break points were defined on G-banded analysis for 6 of the 
translocations of 6q. The identified translocations were t(6; 9)(q2? 5; q22) (case 26) and 
t(6; 19)(? q2l; pl3) (case 29) in an ALL, t(6; 11)(ql3; q23) (case 30), t(6; 7)(q2? 1; pl5) (case 
31), t(2; 6)(q3? 1; q2? 3) (case 32) and t(6; 8)(q27; pll. 2) (case 34) among AML patients. In 
addition re-analysis of G-banded chromosomes from patient 32 suggested that the 
abnormality described as add(6q) was a t(3; 6)(q26; q25). Chromosome painting with whole 
chromosome paints confirmed the presence of t(3; 6) in this patient (Fig 3.17a and b). Of the 
6 identified translocation partners, breakpoints in 5 coincided with the location of oncogenes 
known to make a contribution to leukemia, 19p 13 (E2A), II q23 (MLL), 7p 15 (HOXA 9), 
8p 11.2 (FGFRI) and 3q26 (EVII). 
Rare translocations between FGFRI and a gene on 6q27 (FOP) had already been 
characterized (see 1.5). One of the PACs included in the primary FISH analysis (RPI- 
167AI4) contained the FOP gene sequence. Hybridisation of RPI-167AI4 to case 33 
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add (6q) 
3 'ý3 
10 A 
Fig 3.17 a. Patient 3 1: re-analysis of G-banded metaphases suggests 
that a rearrangement defined as add (6q) is a t(3; 6). 
Fig 3.17b. Patient 3 1: FISH with whole chromosome paints confirms the 
presence of a t(3; 6)(q26; q25). 
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produced a fluorescent signal of reduced intensity on the derivative chromosome 6 when 
compared to that seen on the normal homologue. No signal was seen at any other 
chromosomal location suggesting that a translocation of FOP was accompanied by deletion 
of 6q material. Further FISH analysis with a YAC containing FGFRI (899e2) in combination 
with RPI-167AI4 produced a fusion signal on the derivative chromosome 6 but a signal 
from 899e2 only on the derivative 8 chromosome (Fig 3.18). The FISH data therefore 
suggested that the t(6; 8) resulted in fusion between FOP and FGFRL Molecular analysis of 
stored cDNA from this patient confirmed the presence of the chimeric gene (Analysis 
performed at the Department of Haematology, Hammersmith Hospital) and these data have 
been recently summarized in a manuscript 126 . 
FISH analysis with a commercially available dual colour locus specific probe was used to 
confirm the involvement of MLL in the t(6; 11) found in patient 29 (personal communication 
from the Database). Two recurrent translocations involving MLL and genes on 6q have been 
cloned. These are the t(6; I 1)(q27; q23) resulting in production of the AILL-AF6 oncogene and 
the t(6; 11)(q2l; q23) encoding MLL-AF6q2l(see 1.6.1) FISH analysis with the primary 
probes positioned the break point for the MLL translocation included in this study to a region 
of approximately 5Mb between PACs RP 1-67N 15 and RP 1-23 5B9 at band q 15. Insufficient 
stored DNA or RNA was available for molecular analysis of this case. 
The break point of the t(3; 6) was investigated using dual colour FISH with a YAC (14e-el2) 
which contained sequences of the EVII gene and 6q locus specific probes. A signal from 
l4e-e6 was seen consistently on the same chromosome arm as the 6q27 specific probe 
167A14. No l4e-el2 FISH signal was seen on the der(6) chromosome marked by the 6q 
centromeric probe RP 1-7 1H 19. Since the whole of the EVII gene was contained within 14e- 
e 12 it was concluded that the break point on chromosome 3 was positioned distal to the EVII 
locus. 
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Fig 3.18 FISH analysis of a t(6; 8)(q27; p11.2) in patient 34. Green signals; 
YAC 899e2 (containing the FGFRI gene). Red signals; PAC RPI-167AI4 
(containing the FOP gene). 899e2 hybridised to the normal chromosome 8 
and as a result of the translocation produced a split signal visible on both the 
derivative 6 and derivative 8 chromosomes. RPI-167AI4 produced a signal 
on the normal chromosome 6 and a reduced signal on the derivative 6 but no 
signal on the derivative 8 chromosome. The pattern of signals suggested that 
fusion between FGFRI and FOP was in this case accompanied by a deletion 
of chromosome 6. 
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3.6.2 Detailed FISH analysis of patients with translocation break points clustered in the 
6q22-23 regions. 
Analysis with the primary FISH probes revealed 6 translocation/inversion break points in 5 
patients that clustered between PACs RPI-293L8 and RPI-172KIO. Additional probes 
positioned between RPl-293L8 and RPI-172KIO were used in FISH experiments to more 
accurately define the break points in these cases. Patient 29 was also shown to carry a 
translocation breakpoint within the region, using the new probes directly without completing 
comprehensive analysis with the primary panel of probes. The probes used with chromosome 
6 fpc map positions are presented in Table 3.11. The position of the 7 breakpoints with 
respect to each probe analysed is shown in Table 3.12. 
Probe HGMP chromosome 6 
map position 
Sequenced Fragment 
Accession Number 
RP 1-293 L8 128350-128500 AL121959 
RPI-179EI3 129200-129350 AL035603 
RPI-28D7 129850-130000 AL109939 
RP I- 197K23 130500-130600 AL035465 
RPI-86DI 130800-130950 AL034349 
RP 1- 150F 17 131400-131550 AL589927 
RPI-69D17 131850-132000 AD 5 6124 
RPI-13IF15 134200-134400 ALI 17378 
RPl-55C23 135300-135400 AL032821 
RP 1-76H23 135800-135900 AL121959 
RPI-258LI 137350-137550 AL121943 
RP I- 12L6 137850-137950 AL353596 
RPI-42A6 138400-138550 AL035604 
RPI-35M23 139050-139250 AL023284 
RPI-199HI4 139650-139850 AL357082 
RP I- I 17-D4 140350-140500 AL023580 
RP I- 17 1N 11 141100-141300 AL031433 
RPl-172KlO 142850-143000 AL022477 
Table 3.11 PACs used for secondary FISH analysis of translocation breakpoints 
falling between 293L8 and 172K 10. Left and right hand HGMP chromosome 6 map 
positions are given for each clone. 
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Probe Cases Number 
25 26 27 28 29 32a 32b 
RPI-293L8 c c c c 
RPI-179EI3 c T c 
RP 1-28D7 T c 
RP I- 197K23 T c 
RPI-86DI c T c 
RP I- 1 50F 17 T c 
RP 1-69D 17 c c T c 
RPI-13IF15 c T 
RPI-55C23 c 
RP 1-76H23 T c T c T c 
RPI-258LI T T c 
RP I- 12L6 c T T c 
RP 1-42A6 T T c 
RPI-35M23 T T c 
RP I- 199H 14 T T c 
RP I- I 17-D4 T T T 
RPI-17INII T T T T T 
RPI-172KIO T T T T T 
Table 3.12 Secondary FISH analysis of cases of AML/ALL with translocation/inversion 
breakpoints falling between 293L8 and 172KIO. Abbreviations are follows: C: probe 
positioned on the centromeric side of the translocation break point. T: probe positioned on 
the telomeric side of the break point. 
In two cases, numbers 25 and 26, the extent of analysis was limited by the availability of 
suitable cytogenetic material and break points were mapped only to within relatively wide 
regions. Of the remaining five rearrangements, four were positioned to within I Mb intervals 
and one (patient 29) to within approximately 2.5 Mb. The five breakpoints, mapped in detail, 
were shown to occur at different positions on 6q. The interval containing the break point 
from case 25, overlapped with both those for cases 29 and 27. Similarly, the wider region 
defining a breakpoint from patient 26 contained more precisely mapped translocation 
(patient 28) and inversion (patient 32) breakpoints. The translocation in case 32 had the most 
139 
centromeric breakpoint and was separated from the co-existent inversion by not less than II 
mb. 
3.6.3 Gene content of the 6q22-23 break point cluster region. 
The probes used for secondary analysis of the clustered breakpoints were then positioned 
with respect to sequenced fragments using the Sanger Center ACEDB and ENSEMBL 
human genome browsers. Apart from two unsequenced gaps of approximately 50Kb, the 
region between RPI-293L8 and RPI-172KIO contained 157 sequenced fragments forming a 
complete 14.8 Mb contig. The region contained a large number of genescan predicted genes 
and NCBI curated transcripts, 91 of which were classified as genes by ENSEMBL or EMBO. 
A known or predicted function had been assigned to 60 of the recognized genes. Names and 
details of transcript size, number of exons, genomic size, ENSEMBL I. Ds and functions of 
the genes are presented in Tables 3A. 3 and 3A. 4 (appendix 3). The position of the genes 
with respect to the PACs used for FISH analysis and the translocation/inversion breakpoint 
regions for each patient is presented in Fig 3.19. The gene content of the five breakpoint 
regions, mapped in detail, will be briefly described in a centromeric to telomeric order. 
Patient 32 (translocation). The most proximal of the 7 break points falling between RCPl I- 
293L8 and RCPII-179EI3 contained three known/predicted genes and three genes of 
unknown function. Two genes HEY2 and Q9NQES were similar to genes expressed at 
specific stages of development in Drosophila. Q9NQE9 coded for a gene with homology to 
protein kinase C inhibitors. Protein kinase C inhibitors modulate activity of cyclin dependent 
kinases that in turn control cell cycle progression through phosphorylation of the Rb protein. 
Recently protein kinase C inhibitors have been demonstrated to have anti tumourogenic 
e ff CtS269. e 
Patient 29. The 2.5 Mb region encompassing the t(6; 19) translocation break point contained 
5 genes of unknown and 10 genes of known or postulated function. Most centromeric of 
these and falling only partly within the region was LAA14 2, a large (9.5 kb) gene, mutations 
of which are the cause of merosin deficient muscular dystrophy. EPB41L2 encodes a member 
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Fig 3.19 Gene content of the 6q22-23 break point cluster region derived from FISH 
analysis of cases of acute leukaemia with cytogenetic deletion of chromosome 6. 
Sequenced fragment accession numbers are given at I Mb intervals. The position of 
genes of known or predicted function are marked in red with their ENSEMBL IDs. 
Genes of unknown function are marked in black without corresponding IDs. 
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of the protein 4.1 family that link the actin cytoskeleton to cell surface glycoproteins. Two 
other members of the protein 4.1 family, merlin and DAL-] are thought to act as tumour 
suppressors in neurofibromatosis 2 and meningiomas respectivel Y270. AKAP7 encodes an 
anchor protein targeting the c-AMP dependent protein kinase (PKA) to the plasma 
membrane. PKA plays an important role in immuno suppression, inhibiting lymphocyte 
proliferation by down-regulating cyclin D3 and inducing p27(k'P') expression 271 . 
Remaining genes within the break point sub-region were tightly clustered, the first of these 
(ARGI) was a liver type arginase. Close to ARGI in the telomeric direction was CRISP 3 
encoding a vitamin D3 receptor interacting protein. CRISP 3 was shown to be a pre-B cell 
specific target for the transcription factor Oct2 that plays an essential role in terminal B cell 
differentiation 272 
. Immediately distal. to CRISP 3 was the gene for an enzyme involved in the 
hydrolysis of extracellular nucleotides (Q9N7_TS or PDNP3) expressed specifically in 
immature glial cells. ENPPI and a related novel gene encoded enzymes thought to play a 
role in N-glycosylation, both contained smaller genes oriented in the opposite direction, one 
resembling an olfactory receptor and the other of unknown function. Other genes in the 
region were of unknown function but one (095046 or MGEA6111) encoded a protein that is 
over-expressed in a significant proportion of meningiomas and gliomas 273 . 
Patient 27. Five genes of known and two of unknown function were located in this sub- 
region. Three of the five were related vascular non-inflammatory molecule (Vanin) genes 
(VNN 1, VNN 2, and VNN 3). The vanin genes are thought to have hydrolase activity and 
have been implicated in the processes of lymphocyte migration, cell adhesion and in the 
colonization of the thymus by haernatopoietic precursor celIS274,275. The two remaining genes 
of know function, RPS12 and Q9UN80 code for an S40 ribosomal protein and a Line I 
reverse transcriptase, respectively. 
Patient 28. This translocation break point fell between PACs RCPl I- 12L6 and RCPl 1-42A6, 
a region encompassing all or part of six genes only one of which was of unknown function. 
The most proximal gene (HBSIL) positioned partly on 199HI4, coded for a member of the 
elongation factor I alpha family. The yeast homologue of HBS IL (HBS I) is aG protein that 
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interacts with the ribosome and regulates steps in the process of protein synthesis 276 . 
The 
entire sequence of the known proto-oncogene C-MYB was positioned within the region. C- 
WB is expressed at high levels in immature haernatopoietic cells where it plays important 
roles in growth regulation and differentiation 277 . Activated truncated 
forms of C-MYB have 
been isolated from chicken leukaemia viruses and also from a cell line established from a 
patient with T-cell blast crisis of CML and a del (6q)278. Overexpression of normal C-MYB 
has also been described in haematopoietic malignancies. 
A large (5.267 kb) gene of uncertain function, Q9NXTI, was positioned within the sub-region 
and distal to C-MYB. Q9NXTI encoded several known functional domains including one 
homologous to the Rec A bacterial recombination protein, suggestive of a role in DNA 
repair. A smaller gene of unknown function was positioned within Q9NXTI and a further two 
genes coding for glyceraldehyde 3 phosphate dehydrogenases also fell within this 
translocation break point region. 
Patient 32 (inversion). The most distal of the break points mapped in detail contained seven 
genes of known and one of unknown function. The most proximal, MAP3K5, was positioned 
largely outside the region and therefore was unlikely to be interrupted by the translocation. 
However, AIMPM5 encodes a MAP kinase kinase kinase that plays an important role in the 
regulation of apoptosis. Cytotoxic stresses such as exposure to TNF, FAS or reactive oxygen 
species activate MAP3K5, which in turn activates JNK and p38 pathways. AIIAP3K5 -/- cells 
were shown to be resistant to TNF and H202 induced apoptosis 279 . 
Of the genes positioned unambiguously within the break point region, one coded for a 
peroxisomal targeting signal receptor (PEX 7) and one for a novel amino acid transporter 
protein. Also within the region were three class 11 cytokine receptors, the interleukin 20 
receptor alpha (IL20RA), the interleukin 22 binding protein (Q96A41 or IL-22BP) and the 
interferon-gamma receptor alpha chain precursor (IFNGRI). IL20RA transduces growth 
280 promoting signals through STAT3 in keratinocytes and is upregulated in psoriatic skin . IL 
22BP apparently acts as an agonist, blocking binding of IL-22 and subsequent STAT 
activation through the functional receptor. Expression of IL-22BP was reported to be highest 
143 
in breast, lung and colon. The third cytokine receptor IFNGRI is secreted by natural killer 
cells and T-lymphocytes, dominant negative mutations within the gene confer susceptibility 
to mycobacterial infectionS281. Of the two remaining genes in the sub-region one was of 
unknown function and the other coded for a novel protein kinase C binding protein. 
3.6.4 Detailed FISH analysis of a complex duplicated translocation. 
A translocation between 6q and an unknown partner chromosome, with a break point 
between PACs RPI-65A9 and RPI-167AI4 at band q27, was detected by FISH analysis 
using the primary probes (see section 3.2.3 patient 22). A complex pattern of signals, 
consistent with duplication of one of the translocation products accompanied by deletion, 
resulting from unbalanced translocation of the second homologue of 6q, was observed. 
Sequential FISH experiments with probes mapped to between RPI-65A9 and RPI-167AI4 
(Table 3.13) positioned the break point of the translocation to between PACs RP 1-249F5 and 
RP4-655C5 (Fig 3.20). The two PACs positioned on either side of the translocation break 
point both contained part of the Insulin-like growth factor II receptorlMannose-6-phosphate 
receptor gene (IGF2-RIM6PR). According to left and right hand fpc values, a gap existed 
between the two clones (right hand RPI-249F5 = 177215 - left hand RPI-655C5 = 177394). 
However, the NCBI database positioned the two clones contiguous to each other. RPI-249F5 
was fully sequenced but RPI-655C5 is still in several unordered pieces. BLAST search with 
the 48 individual exons of IGF2R positioned exons 1-4 on RPI-249F5, and the following 
exons on RP4-655C5: 5,8-13,16-19,20-21,31-33,36-39, and 40-46. Based on the FISH 
data the most likely position for the translocation break point in patient 22 was therefore 
between exons 4 and 5 of the IM-R. All the IGF2-R exons from 5 to 48 could be 
positioned on a PAC (RPI-288HI2) that occupied the same genomic region as RPI-655C5 
but which had been fully sequenced. 
3.6.5 Southern blot analysis of the IGF2-R (patient 22). 
A Southern blot was made from 3 remission bone marrow DNA samples and from DNA 
from patient 22 leukaemic bone marrow taken on two different occasions, including the date 
on which the cytogenetic sample used for FISH analysis was taken. BamH1 and EcoRl 
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digests of each sample were used to prepare the Southern blot (Fig 3.21). The blot was then 
probed sequentially using IGF2-R SB probes 1-6 (see 2.13 for details of preparation and Fig 
3.22 for image of the probes after gel electrophoresis). 
Probe Chromosome 6 Cytogenetic Marker Gene 
fpc values band 
D 
RPI-65M 
RPI-56L9 
RPl-249F5 
RP4-655C5 
RP 1-247120 
RP I- 102N2 
RP I- 167-A 14 
170802-170937 6q27 
176761-176977 6q27 
177059-177215 6q27 
177394-177638 6q27 
177569-177748 6q27 
178212-178336 6q27 
178304-178414 6q27 
D6S305 
AMSIIIGF2-R 
IGF2-R 
FOP 
Table 3.13 PACS used for secondary FISH analysis of the translocation of 6q seen in patient 
22. Showing right and left hand ACEDB chromosome 6 map positions for each clone and 
corresponding band assignments, genetic markers and genes. 
The position of probes with respect to IGF2-R exons and the sequences of PACs RPI-249F5 
(sequence accession # AL035691) and RPI-288HI2 (sequence accession # AL353625) are 
presented in Table 4. A. 1 (Appendix 4). The two PAC sequences were analysed using 
DNASTAR software to determine the position of BamHI and EcoRl restriction enzyme 
sites. The position of restriction enzyme sites and calculated expected fragment sizes 
resulting from digestion of normal genomic sequence are also presented in Table 4. A. 1. The 
position of IGF2-R exons, restriction enzyme digest fragments and the five probes, with 
respect to clones RPI-249F5 and RPI-288HI2 (and RP4-655C5), are also represented in Fig 
3.23. Restriction enzyme fragments that do not overlap with one of the exons are also 
highlighted in Fig 3.23. 
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Fig 3.20 FISH analysis of Complex 
rearrangements of chromosome 6 
found in patient 22. 
a) Red signals; RPI-71H19 (marking 
the 6q centromeric region). Green 
signal; RPI 249F5 (containing exons 
1-4 of the IGF2-R gene). A single green 
signal is seen on a chromosome marked 
by the red probe, and consistent with 
the presence of deletion, absent from 
a second smaller chromosome 
hybridising to the 6q centromeric 
probe. 
b) Red signals; RPI-71HI9. Green 
signals; RPI-655C5 (containing exons 
5-48 of the IGF2-R). Two green signals 
are seen, neither hybridising to the 
chromosome marked by the 6q 
centromeric probe. 
c) Red si gnal; RP I- 167A 14 (marking 
the 6qtelomeric region). Green 
signals; RPI-655C5. Red and green 
signals co-localiseon two marker 
chromosomes. 
Taken together the pattern of FISH 
signals is consistent with a scenario 
in which deletion of one homologue 
of 6q was accompaniedby a 
translocation that interrupted the 
IGF2-R. Duplication of the 
translocation product containing the 
distal part of 6qhas taken place and 
since the two chromosomes marked 
by 6q telomeric probes are of different 
sizes, further rearrangement of at least 
one of the markers had occured. 
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HIH 
OX 
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ýx 
Fig 3.21 Patient 22 and reference DNA 
digested with restriction enzymes 
and run on an agarose gel for 
Southern blot preparation. (1) patient 
22 sample date 21.9.98 when 50% of cells 
carried a translocation of 6q according 
to FISH analysis, (2) patient 22 sample 
date 13.2.98 when the patient was 
reported to carry a cytogenetically 
detectable deletion of 6q though no 
FISH analysis had been performed, 
(3-5) lymphoma patients with no 
evidence for 6q translocation. 
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123451234 
EcoRl BamHl 
2322 
2027 
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V- 
2345X HIII a 
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1 
' 
-564 
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Fig 3.22 Probes for Southern 
blot analysis amplified from the 
IGF2-R cDNA. Probes 1-5 before (a) 
and after (b) excising from gel and 
cleaning. 
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The bands obtained after hybridizing the blot with the six probes and the position of 
molecular weight markers can be seen in Fig 3.24 a-e. Though some of the fragments 
predicted from analysis of the sequences of RPI-249F5 and RPI-288HI2 were not visible, 
no differences were seen between the hybridisation pattern in the remission bone marrow 
samples and the leukaernic DNA samples in patient 22. Several of the predicted restriction 
fragments positioned between exons I and 10 either did not overlap with an exon or 
overlapped with only a single exon so would have been predicted to give either no signal or a 
weak signal which would be difficult to detect. Between exons 12 and 48 (covered by IGF2R 
SB probes 2-4) the exons were more closely arranged and most fragments overlapped with 
several exons resulting in bands that were easily detectable on Southern blot analysis. It was 
therefore judged that if the translocation break point interrupted the IGF2-R it was most 
likely to be positioned towards the 5' end of the gene where introns were larger and the 
likelihood of missing a rearranged fragment was greatest. The FISH data also suggested that 
the breakpoint fell within the first 10 exons of the gene. 
,,,,. 
EcoRl BamHl 
%NOW 
Fig 3.24a Southern blot of patient 22 and 
reference DNA hybridised with IGF2-R 
* 23130 SB probe 1. Lanes (I and 2) patient DNA, 
(3-5) lymphoma patients without 6q 
* 9416 rearrangements. Arrows indicate the position 
* 6557 of molecular weight marker bands. Expected 
44361 EcoRl fragments (see Table 3.17) were; 
11665,8455,7935,7335,5755,5490,3270 
and 1030, base pairs in size. Of these the 
11665 and 1030 b. p. bands could not be seen in 
either patient or reference digests. 
Expected BamHl fragment sizes were; 
13371ý13185,9680,8830,8195,5280,1725 
4 1353 and 775 b. p. Of these 9680,5280,1725 and 
4 1079 775 b. p. fragments were not seen. The pattern 
4 892 of visible bands was identical in patient 22 and 
reference digests. 
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-t -- 
123451234 
EcoRl BamHl 
Fig 3.24b Southern blot of patient 22 and 
reference DNA hybridised with IGF2-R 
SB probe 2. Expected EcoRl fragment sizes 
were; 13321,8455,7335,6065,1910 and 760 
b. p., of these, either the 8455 or 7335 b. p band 
was not present. The expected BamH I 
digest fragment sizes were 8195,5280,4320 
2875,2280,2605 and 775 b. p. Of these only 
the 5280 and 4329 b. p. bands were visible. 
Restriction digest fragment sizes appeared 
identical in patient and reference samples. 
A 23130 
Fig 3.24c Southern blot of patient 22 and 
49416 
reference DNA hybridised with IGF2-R 
46557 
S. B probe 3. Expected EcoRl digest fragment 
44361 sizes were; 13321 and 8209 
b. p. Expected 
BamHl fragment sizes were 2605 and 14080 
b. p. Bands corresponding to the expected 
fragment sizes were seen in patient and 
reference samples digested with both EcoRl 
and BamHl. 
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Fig 3.24d Southern blot of patient 22 and 
423130 reference DNA hybridised with IGF2-R 
-49416 
SB probe 4. Expected EcoRl digest fragment 
-46557 
sizes were; 8209,4035 and 2677 b. p. Expected 
BamHl fragment sizes were 17505 and 14080 
-44361 b. p. Bands corresponding to the expected 
fragment sizes were seen in patient and 
reference samples digested with both EcoRl 
and BamHl. 
-41353 
-4 1079 
4 892 
-423130 
49416 
-46557 
44361 
41353 
41079 
4892 
Fig 3.24e Southern blot of patient 22 and 
reference DNA hybridised with IGF2-R 
SB probe 5. Expected EcoRl fragment sizes 
were; 8175,6515,4035,1730,1559 and 1231 
b. p. The expected BamH I digest fragment 
sizes were 17505,16269,14080 and 41 10b. p. 
Restriction digest fragments of the expected 
sizes were seen in both patient and reference 
samples. 
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3.6.6 RACE PCR analysis of the IGF2-R (patient 22). 
RACE PCR analysis of patient 22 was conducted to investigate the possibility that the 
observed translocation of 6q resulted in production of a fusion transcript consisting of exons 
of the IGF2-R and of a second unknown gene. On the basis of the FISH and Southern blot 
analysis an assumption was made that the translocation interrupted the IGF2-R between 
exons I and 10. 
A sample of RNA from patient 22 was first run on an agarose gel confirming the presence of 
RNA but also revealing a relatively high level of contaminating DNA (Fig 3.25). 5' and 3' 
RACE ready cDNAs were then prepared using the patient RNA and also control placental 
RNA. First round PCR reactions were performed using the positive control TFR primers and 
3' and 5' RACE ready placental cDNA. Bands of the expected sizes were obtained from both 
3' and 5' RACE PCR reactions demonstrating the efficacy of the system (Fig 3.26). 
w 
1 23 
-310 
X HIH 
ýx 
Fig 3.25 Assessment of patient RNA 
Sample by gel electrophoresis. (1) 
3 ýd RNA from patient 22 (2) 3gl 1: 10 
dilution of RNA from patient 22 (3) 
3ýtg reference placental RNA. The 
high molecular weight band seen in 
lanes I and 2 suggests that the patient 
Sample was heavily contaminated with 
DNA. 
The same reactions were then performed using the patient RACE ready cDNA. No product 
of the expected size was seen for either the 5' or 3' reaction, probably reflecting the 
relatively low concentration of RNA in the patient's sample. To test the cDNA further PCR 
reactions were performed using forward and reverse G6PD and #-Actin primers. Products of 
the expected size were amplified with the #-Actin primers but not the G6PD primers, using 
5' RACE ready cDNA prepared either from patient 22 bone marrow or placental RNA (Fig 
3.27). This suggested that the SMART RACE cDNAs, while making effective templates for 
the amplification of sequences close to the 3' end of a gene, was less efficient for the 
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Fig 3.26 RACE PCR using positive 
control (TFR) primers to amplify 
cDNA made from a commercial 
placental RNA sample. (1) 3' RACE 
product showing the expected 2.9 Kb 
band and additional bands also present 
in the manufactures example image. 
(2) 5' RACE product showing the 
expected 2.6 Kb band. 
Fig 3.27 PCR using positive control 
primers to amplify patient RACE 
ready cDNA. Lanes 1-3 G6PD primers 
4-6,8Actin primers. (I and 4) H209 
(2 and 5) 3' RACE ready cDNA, 
(3 and 6) 5' RACE ready cDNA. The 
expected product was amplified with 
theflActin but not the G6PD primers. 
detection of 5' sequences. Since both 5' and 3' cDNAs were primed from the 3' poly A tail 
(see 2.14.1) this limitation was expected, and furthermore the likelihood of detecting 5' 
sequences could be predicted to be inversely related to the distance between the 3' and 5' 
ends of the gene. Since the IGF2-R is a large gene (over 9Kb) and translocation was thought 
to have occurred close to the 5' end, cloning of the 5' part of any fusion gene would be 
expected to be inefficient. For this reason priority was given to 3' RACE reactions. 
3' RACE was first attempted using the patient 3' RACE ready cDNA, the IGF2-R exon I 
primer and the universal primer mix for the first round PCR reaction. No visible PCR product 
was produced at this stage. A dilution of the first round PCR product was then used as a 
template for a second round of PCR with the nested universal primer and an exon 2 specific 
primer. The first round positive control 3' RACE product was also amplified using a nested 
TFR primer supplied with the SMART RACE kit. 
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Gel electrophoresis of the nested reaction from patient cDNA and IGF2-R gene specific 
primer resulted in a diffuse band (Fig 3.28). A heavy band of the expected size was obtained 
firom the positive control (TFR) reaction. Both patient and positive control nested reaction 
products were then cloned using the TOPO TA cloning kit. Positive colonies were selected, 
grown, and digested with EcoRl before checking for evidence of inserts (Fig 3.29). Inserts, 
of variable size, were seen in 12 of 14 positive clones obtained from nested 3' RACE of 
patient 22. All of 6 positive control colonies contained inserts of the expected size. Patient 
clones, containing inserts, were then sequenced. None of the 12 clones contained sequence of 
the exon 2 primers or any other part of the IGF2-R gene. Since the positive control reaction 
yielded cloned products of the expected size, indicating that there were no problems 
associated with the RACE PCR or cloning procedures, it was decided next to test the 
efficiency of the IGF2-R gene specific primers. 
Combinations of IGF2-R exons 1,, 29 2b (internal to primer set 2) and 3 forward primers with 
exons 10,8 and 7 reverse primers were then tested in PCR reactions using normal bone 
marrow cDNA that had already been assessed with G6PD primers. A positive PCR product 
was obtained when the exon 10,8 and 7 specific primers were used with forward primers 2b 
and 3 but not I or 2 (Fig 3.30). This finding suggested that inefficient primer hybridisation 
might have caused the failure of the earlier RACE reactions to amplify IGF2-R sequences. 
Fig 3.28 3' nested RACE PCR 
products. (I and 2) from patient 
22 cDNA using IGF2R gene specific 
primers. (3) using commercial placental 
cDNA and TFR gene specific primers. 
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The 3' RACE PCR reaction was then repeated using the patient 3' RACE ready cDNA as a 
primary template for amplification with the exon 2b primer for first round PCR and the exon. 
3 primer for nested PCR. No clear band resulted from the first round amplification but after 
the nested reaction, 3 major bands, between 600 and 1300 base pairs in size, were seen (Fig 
w 
4 
Fig 3.29 EcoRl digested clones 
of 3' nested RACE PCR products. 
Lanes 1- 14 from patient cDNA 
amplified with IGF2R gene specific 
Primers. Lanes 15-20 from positive 
control (TFR) reaction. 
4" 
1 10 11 12 
Fig 3.30 PCR of normal marrow DNA with paired IGF2R primers. 
Primer pairs were; (1) exon I and 10, (2) exon 2 and 10, (3) exon 2b 
and 10, (4) exon 3 and 10, (5) exon I and 8, (6) exon 2 and 8, (7) 
exon 2b and 8, (8) exon 3 and 8, (9) exon I and 7, (10) exon 2 and 7, 
(11) exon 2b and 7, (12) exon 3 and 7. 
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3.31). The nested PCR product was cloned as before but this time positive colonies were pre- 
screened in PCR reactions using the nested universal primer and the IGF2-R exon 3 primer 
(Fig 3.32). Colonies that gave a PCR product of over 500 bp in size were then grown, 
digested with EcoRl and run on agarose gels to check for the presence of inserts (Fig 3.33). 
0-4361 
"! Trý -2027 
low -1353 
low 
f4low -892 
0000 
ý -564 
-3 10 
X Hill 
-2027 
, 1353 
- -892 
"1 0 *avow "- -564 
-310 
HIII 
OX 
42 
-2027 
-1353 
-892 
-610 low #Aw 
0# *» 1 HIII 
ox 
Fig 3.313' nested RACE PCR 
product amplified from patient 
cDNA with IGF2R exon 2b and 
3 gene specific primers. 
Fig 3.32 PCR of positive colonies 
cloned from the patient 3' nested 
RACE PCR product. Clones with 
inserts over 500 Kb in size were 
selected for further analysis. 
Initially sequence analysis was performed on 20 clones with inserts of suitable size. Both the 
IGF2-R exon 3 specific sequence and NUP sequence joined to oligo dT sequences were 
found in pairs of forward and reverse reactions. Analysis of the intervening sequences 
revealed IGF2-R exon 3 and 4 sequence in all of the clones, in some genomic sequence 
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followed on from exon 4 or exon 5. Oligo dT primers were in some cases joined to intronic 
sequences downstream of IGF2-R exons; in others they extended into IGF2-R exon 12 or 
into unknown sequence that could not be identified on BLAST search. 
WWWWwWWWWW 
Wo 1353 
WN %W *= -892 Fig 3.33 EcoRl digests of clones 
-610 Containing 3' nested RACE products. 
-310 Colonies were pre-screened by PCR to 
check insert sizes. Sequence analysis was 
ox performed on colonies with 
inserts of 
Over 500 Kb in size. 
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Further colonies were screened by PCR and after DNA preparation and analysis of EcoRl 
digests by gel electrophoresis, 20 further clones were sequenced. As before the majority of 
clones consisted of IGF2-R exons 3 to 5 joined to either IGF2-R intronic sequence or 
unidentifiable sequences. However, two clones contained exons of a second gene, migration 
inhibitory factor-related protein 8 (MRP8 or SI OOA 8), fused to IGF2-R exon 3 sequence. The 
cloned sequences shared 100% identity with the published MRP8 sequence from base pair 
position 39 (9 of exon 2) to the 3' end of the gene. The fusion with MRP8 occurred at base 
pair 530 (nucleotide 91 of exon 3) of the IGF2-R sequence and resulted in an out of frame 
sequence 3' the break point. A single base pair deletion had also occurred at position 12 of 
the MRP8 exon 2 sequence. The sequence trace at the break point junction and for 
comparison the wild type IGF2-R exon 3and MRP8 exon 2 sequences are presented in Fig 
3.34. 
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IGF2-R MRP8 
gtgactctgt tttgagaagt gcaaccagat ctctcctgga allcaacaca 
acagtgagct gfizaccagca aggeacaaat cacagautcc agagcagcat IGF2-R 
tgccftcctg tgtgggaaaa ccctg t exon 3 
Break point 
b. p. 91-92 
Break point Thymine residue at b. p. 12 
b. p. 8-9 deleted from fusion sequence. 
gtggggc aagttccgtg ggcatcatgt tgaccgagct ggagaaagcc ttgaactcta MRP8 
tcatcgacgt ctaccacaag tactccctga taaaggggaa fftccatgcc exon 2 
gtctacaggg atgacctgaa gaaattgcta gagaccgagt gtcctcagta tatcagg 
Fig 3.34 Sequence obtained from 3' nested RACE PCR of patient 22with 
IGF2-R gene specific primers. The 5' end of the IGF2-R (highlighted in red) 
was fused to 3' sequences of MRP8 (highlighted in blue). Break points were between 
base pairs 91 and 92 of exon 3 of the IGF2-R and between base pares 8 and 9 of INN 
exon 2. Deletion of a Single nucleotide had occurred at position 12 in the AIMP8 exon 
2 sequence (highlighted in green). 
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Forward and reverse and nested reverse MRP8 specific primers from either side of the break 
point junction were then designed and shown to amplify product of the expected size from 
normal bone marrow cDNA (Fig 3.35). The IGF2-R exon 3 forward primer and MRP8 
reverse primer were then used in a PCR reaction using the patient first round 3' RACE 
product as a template. Gel electrophoresis of the resulting PCR product revealed a single 
strong band of the expected size (Fig 3.36). Direct sequencing of the PCR product confirmed 
that an IGF2-RIMRP8 fusion sequence, identical to the one obtained by nested YRACE 
PCR, had been amplified. This result demonstrated convincingly that the chimeric sequence 
was present after first round RACE PCR. 
Fig 3.35 PCR with paired forward 
and reverse MRP8 primers. (I and 2) 
primers MRP8 forward and MRP8 
reverse, (3 and 4) MRP8 forward and 
MRP8 nested reverse. (I and 3) H20 
(2 and 4) cDNA from normal marrow. 
Fig 3.36 PCR with paired IGF2R 
exon 3 forward and MRP8 reverse 
primers. template was; (1) H20 
(2) first round YRACE reaction 
product. 
so 
4p -310 
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cDNA was then prepared from patient 22 RNA using random oligonucleotide primers. After 
confirming that a product of the expected size could be amplified using G6PD primers, the 
new cDNA was used as a template for paired IGF2-R exon 2b or 3 forward and MRP8 
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reverse primers in a PCR reaction. The same primer pairs were also used in an attempt to 
amplify the fusion sequence from the patient 3' and 5' RACE ready cDNA. No visible 
product resulted from any of the first round PCR reactions. 
Dilutions of the first round product amplified with the IGF2-R exon 2b primer were then 
used as templates in nested PCR reactions using the IGF2-R exon 3 and MRP8 nested reverse 
primer. As a positive control the same primers were used to amplify a dilution of the first 
round 3' RACE reaction product from which the fusion sequence was originally cloned. Gel 
electrophoresis of the nested reaction products resulted in a number of visible bands in each 
case, the positive control yielded a single strong band of the expected size (Fig 3.37). Bands 
that appeared identical in size to that seen in the positive control, were amplified from first 
round products made from the new cDNA and the 3' RACE ready cDNA. 
Fig 3.37 Nested PCR with paired 
IGF2-R exon 3 forward and MRP8 
nested reverse primers. Templates 
(1-4) were first round PCR products 
amplified with IGF2-R exon 2b and 
MRP8 reverse primers from (1) H20ý 
(2) 3' RACE ready cDNA, (3) 5' 
RACE ready cDNA, (4) cDNA 
prepared with random oligonucleotides. 
The template for 5 (positive control) 
was the first round 3' RACE reaction 
N.: 7 product. 
In an attempt to produce a cleaner, more easily cloned PCR product, the nested PCR reaction 
was repeated using three different dilutions of the first round product amplified from the new 
cDNA, and shorter denaturation, annealing and extension steps. The positive control reaction 
was also repeated using the same program. Each nested reaction resulted in production of 
several bands including one apparently identical in size to the positive control band (Fig 
3.38). Since bands additional to the one of expected size were less prominent in these 
reactions, one of the fresh products was cloned. Of 19 positive colonies amplified by PCR all 
contained products that were either the same size or slightly smaller than the positive control 
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band (Fig 3.39). Initially three bands of each size were sequenced directly but except for the 
primer sequences none contained sequences specific for WP8 or the IGF2-R. Additional 
clones were amplified by PCR and a total of 24 sequenced, of these none provided 
supporting evidence for the presence of an IGF2-RIMRP8 fusion transcript. 
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Fig 3.38 Nested PCR with paired IGF2-R 
and MRP8 primers. Primers were IGF2R 
exon 3 forward and MRP8 nested reverse. 
Templates were (1) HA (2-4) dilutions of 
first round PCR product amplified with 
IGF2R and MRP8 specific primers from 
Patient cDNA made with random primers, 
(5) first round 3' RACE PCR product. 
Fig 3.39 PCR amplification of positive 
colonies cloned from the product of 
nested RACE PCR with IGF2R and 
MRP8 specific primers. All colonies 
Contained inserts of the expected sizes and 
were sequenced directly. 
5' RACE PCR was also performed in an effort to find evidence for a fusion sequence. 59 
RACE ready cDNA from patient 22 was amplified using the universal primer mix and either 
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IGF2-R exon 8 reverse or AIIRP8 reverse primer oligonucleotides. While amplification with 
the IGF2-R exon 8 primer failed to produce any visible product, use of the MRP8 reverse 
primer resulted in a single strong band (Fig 3.40). Direct sequencing of the AMP8 5' RACE 
product demonstrated that the band consisted of the Afl? P8 wild type sequence including the 
5' end of the gene. While failing to confirm that fusion between the IGF2-R and MRP8 had 
taken place in patient 22 bone marrow, this result demonstrated that the 5' RACE ready 
cDNA was adequate for cloning the 5' end of a suitably small gene (418 bp). The contrasting 
failure to amplify IGF2-R sequences from the same cDNA confirms that the SMART RACE 
system was less effective for the amplification of the 5' end of large genes. 
Fig 3.40 5' RACE PCR of patient 22. 
(1) Using MRP8 reverse as the gene 
specific primer (2) Using IGF2-R exon 8 
as the gene specific primer. The product 
In lane I was sequenced directly. 
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MRP8 was positioned on chromosome I band q2 1282. If translocation between the IGF2-R 
and AMP8 had occurred in the patient 22 leukaemic clone, the maker chromosomes 
containing the telomeric region of 6q would also be expected to consist partly of 
chromosome 1. Chromosome I paint and RPI-57M24 were used to re-FISH metaphase cells 
from patient 22. No evidence for rearrangement of chromosome I was seen in any cells 
examined including metaphases where RPI-57M24 fluorescent signals were clearly 
positioned on the marker chromosomes rather than on normal copies of chromosome 6 (Fig 
3.41). The fusion between IGF2-R and MRP8 therefore either arose in the course of the first 
round 3' RACE reaction or resulted from a complex rearrangement involving insertion of a 
relatively small segment of chromosome I between part of 6q and a third chromosome. 
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Fig 3.41 Example of a metaphase cell from patient 22 hybridised with a whole 
chromosome lpaint (green signal) and PAC RPI-167AI4 (red signals). From 
chromosome morphology it is clear that RPI-167AI4 is hybridising to the 
duplicated chromosome 6 translocation product, rather than to normal copies of 
chromosome 6, in this cell. Chromosome I appears to be unrearranged suggesting 
that it is not involved in the 6q translocation. 
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Chapter 4 (Discussion) 
FISH analysis of acute leukaemia patients with cytogenetically detectable abnormalities of 
the long arm of chromosome 6 was performed with the principal aim of identifying one or 
more candidate tsgs. A secondary goal, the characterization of balanced rearrangements of 
6q, developed unforeseen significance because of the high incidence of cryptic 
translocations. For the purpose of discussion, the translocations of 6q have been organised 
into three groups 1) cases of AML with breakpoints on partner chromosomes at the site of 
known oncogenes. 2) Cases of ALL or AML with breakpoints clustered within a 14 Mb 
region of q22-23 and 3) a single case of ALL with a complex karyotype involving both 
homologues of 6q and balanced and unbalanced translocations. Section 4.1 deals with the 
analysis of deleted cases, identification and investigation of a candidate tsg. Section 4.2 
covers the three groups of balanced rearrangements. 
4.1. Cases with deletion of 6q. 
Twenty four of 34 leukaemia patients or cell cell lines analysed by FISH with PACs and 
BACs displayed loss of 6q. The pattern of deletions was open to different interpretations that 
depended on the number of tsgs positioned on the long arm of chromosome 6. The CDR 
identified in this study is based on a model in which a single leukaemia associated tsg is 
located on 6q, and this rests on two assumptions. Firstly, chromosomal rearrangements that 
involve translocation with a second chromosome as well as loss of DNA sequences are less 
likely to mark the position of tsgs than are simple interstitial deletions. In these cases 
formation of a fusion oncogene, deregulation of a gene near the translocation breakpoint or 
loss of tsgs on the partner chromosome may have driven clonal expansion. Secondly, it 
seems likely that at least some simple interstitial deletions confer no growth advantage but 
rather are neutral and carried by co-existent/unknown advantageous mutations. A low level 
of deletion occurs at all parts of the genome in haematological malignancies but only those 
regions showing consistent loss are thought to harbor tsgs contributing to leukaemia 251 . 
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As outlined in 1.7 earlier analysis of patients with 6q deletions in this department led us to 
256 define two independent regions of deletion . Of the two patients that 
defined the more 
telomeric region, one was included in this study (patient 22). Further analysis of this case 
revealed that both homologues of chromosome 6 were affected by either balanced or 
unbalanced translocation. Two other patients (23 and 24; Fig. 3.2) showed loss of more 
telomeric regions of 6q but these cases also involved translocations. Of the cases 
investigated, none therefore, was shown to have a simple interstitial deletion confined to the 
more distal of the two previously identified regions. Disregarding patients 22,23 and 24, (for 
the reasons given above), the remaining 21 cases were found to bear deletions that 
encompassed all or part of the more proximal of the two earlier defined regions. Twenty of 
the 21 deletions also overlapped with each other to give a 4.5 Mb CDR in band q16. 
Notwithstanding the possibility that the assumptions made in defining the new CDR were 
wrong, published LOH and FISH studies supported the existence of a leukaemia related tsg 
within this region of 6q (Fig 3.7). Of seven published CDRs two fell entirely within our own 
region and three others overlapped with it. 
4.1.1 Selection of a candidate tsgs from within the CDR. 
The genomic region within the newly defined CDR contained 16 genes of which 7 coded for 
novel proteins of unknown function and 4 for genes that had not been characterized but were 
homologous to genes of known function. The 4 seemed unlikely to have a tumour suppressor 
role on the basis of the known function of the related genes. Of the remaining five genes 
SIM] and POU3F2 (BRN-2) encoded transcription factors known to regulate development of 
neuroendocrinal. tissues. The two transcription factors have not been reported to be expressed 
in haematological tissues though BRN-2 is also involved in melanocyte development. As 
discussed in 1.5 transcription factors regulating lineage development can also be tsgs. 
Consequently, the possibility that loss of SIMI or BRN-2 contribute to leukaemia should not 
be dismissed until their expression in haematological. tissues has been assessed. Of the two, 
SIM] seems the less likely candidate because hemizygous deletion was associated with early 
onset obesity in mice and a similar observation was made in a human bearing a translocation 
of SIM]. In neither case was malignancy reported 264 .A third gene, was recently identified 
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and shown to encode a receptor for melanin-concentrating hormone (MCH2). Like SIM] and 
BRN-2, MCH2 was expressed predominantly in the brain, but did show significant expression 
in a minority of other tissues tested including lymphocyteS265,283. In brain tissue, melanin- 
concentrating hormone is known to be involved in the control of appetite. The role of MCH2 
in haematopoietic cells though is unknown, making its potential as a tsg difficult to evaluate 
at present. 
Two other genes within the CDR, GluR-6 and CCNC were functionally promising candidate 
tsgs (discussed further in 4.1.3). Two facts argued against a role for GluR-6 in 
leukaemogenesis; 1) GluR-6 was not known to be expressed in haematopoietic cells and 2) 
mice homozygously inactivated for GluR-6 were not reported to develop malignancies 284 .A 
tumour suppressor role for CCNC was also doubtful because analysis of cases of leukaemia 
285 with deletions of 6q failed to identify any inactivating mutations in the locus 
In the absence of a single candidate gene that clearly merited further investigation above 
others in the region, we compared published deletion data with our own CDR (as described 
in 3.4.3 and illustrated in Figs 3.7 and 3.8). As a result of this analysis a single gene, GluR-6, 
was unambiguously identified as the most promising of our candidate tsgs. Furthermore, a 
CDR derived from an LOH study conducted in our department by Dr Amani Sorour in cases 
of ALL (personal communication; data not shown), overlapped with the FISH CDR to give a 
consensus region containing only GluR-6 as a candidate tsg. 
4.1.2 Expression and mutation analysis of GIuR-6. 
As described in 3.5.1 the expression of GluR-6 in haematopoietic as well as other tissues was 
investigated by RT-PCR. Using two different sets of primers one from the 5' and one from 
the 3' end of the gene, a product of the expected size was consistently amplified from normal 
bone marrow samples. Although GluR-6 transcripts were clearly more abundant in brain 
tissue, a visible product was amplified from marrow using a single round of PCR- Analysis 
of leukaemic samples and cell lines suggested that expression of GluR-6 was more abundant 
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in lymphoid than myeloid cells. Preliminary analysis also suggested that GIuR-6 is widely 
expressed at variable levels in tissues outside the CNS. 
Although any role for glutamate receptors in the haematopoietic system is currently 
speculative, the fact that GluR-6 is transcribed in lymphocytes opens up the possibility that it 
might also protect against development of leukaemia. As discussed in 1.5 both heterozygous 
and homozygous inactivation of tsgs are thought to contribute to malignancy and a common 
scenario leading to homozygous loss of function involves point mutation of one allele 
accompanied by deletion of the second. To establish whether homozygous inactivation of 
GluR-6 through this mechanism occurs in ALL, sequence analysis of the GluR-6 exons and 
flanking intronic sequences was performed in patients and cell lines known to bear deletions 
of the region containing the GluR-6 gene. Among 14 cases analysed a single base pair change 
resulting in an amino acid substitution was detected in exon 6. To date the possibility that 
this change might have been leukaemia-related, remains to be established. The base pair 
substitution was present in the patient's germ line DNA but was not seen in any of 20 
additional normal samples analysed. These findings suggest that homozygous inactivation of 
GIuR-6 through a combination of deletion and point mutation is not a common occurrence in 
ALL patients carrying cytogenetic deletions of 6q. However, a base pair change present on 
one allele in the germ line, and retained in the leukaemic sample of an ALL patient with a 6q 
deletion, was not shown to be a polymorphism. The possibility therefore remains that point 
mutations of GluR-6 result in altered protein function in rare cases of leukaemia. 
No visible product could be amplified with primers specific for GluR-6 exon 6 in one cell 
line (PEER). Exon 6 was amplified with ease in all other cases analysed and conversely, the 
other 16 exons of GluR-6 could be amplified from the PEER DNA sample. One explanation 
for the repeated failure of PCR with primers for exon 6 in a single case is that microdeletion 
of the second allele resulted in loss of all or part of the target sequences. However, this 
possibility would need to be confirmed using another approach, such as hybridization of an 
exon 6 specific probe to a Southern blot of PEER genomic DNA. Alternatively, a 
polymorphism might have reduced the efficiency of primer annealing in this case. It is worth 
emphasizing that failure of PCR occurred only with one of the two cell lines analysed and not 
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with any of the 12 patient samples. Unlike the cell lines that are monoclonal, patient samples 
would all have included some normal haematopoietic cells in addition to the leukaemic 
clones. Complete failure of PCR, resulting from biallelic deletion, would therefore be 
unlikely to occur in the patient samples and homozygous inactivation through this 
mechanism would have remained undetected. 
4.1.3 Evaluation of GIuR-6 and other candidate tsgs positioned on 6q, possible future 
studies. 
Glutamate receptors can be broadly divided into metabotropic and ionotropic sub-types. The 
ionotropic receptors function as membrane bound ligand-gated ion channels that mediate the 
majority of excitatory neurotransmission in the brain 286 . The ionotropic receptors are 
further 
divided into three pharmacologically defined classes, named after their selective agonists, N- 
methyle-D-aspartate (NMDA), oc- amino- 3 -hydroxy- 5 -methyl-4-i soxazo le propionic acid 
(AMPA) and kainate. The different ionotropic glutamate receptors are each associated with 
specific sub-units, and may be homomeric or heteromeric in composition. The sub-unit 
composition of receptors within each class can influence ligand affmity and the strength of 
ion flux induced by specific ligands. The known kainate specific receptor sub-units include 
GluR-5, GluR-6, GluR-7, KAI and KA2. 
In neurological tissues binding of glutamate receptors by their ligands results in a rise in 
intracellular Ca 2+ levels but can also transduce signals through cytoplasmic proteins. Apart 
from neurotransmission the physiological consequences of glutamate signaling include the 
regulation of growth, migration and survival of developing neuronS287-289. Stimulation of 
glutamate receptors has also been associated with the induction of apoptosis through Ca2+ 
mobilisation and through binding to the post-synaptic density protein 95 (PSD 95). PSD 95 
links NMDA or kainate receptors to a variety of signaling cascades. In the case of GluR-6 
specifically, binding of PSD 95 has been shown to lead to phosphorylation of MKK4 and 
MKK7, and to activation of JNKs and caspases followed by apoptoSiS290. PSD 95 is 
associated with synaptic junctions but has also been shown to function in T-cells 291 . The 
Drosophila homologue of PSD 95 (hDIg) is considered a tsg because inactivating mutations 
result in neoplastic overgrowth of some tissues 292 . 
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Although it was assumed that glutamate signaling is restricted to the CNS, recently it has 
become evident that cells throughout the body possess glutamate receptors 293 . 
Tissues 
already shown to express glutamate receptors include osteoclasts and osteoblasts, 
megakaryocytes, keratinocytes, pancreatic islet cells, taste buds, lung, liver, heart, kidney and 
the enteric nervous systeM294 .A number of studies 
have implicated glutamate signaling in 
haematopoietic cell function. In vitro glutamate was found to bind specific sites on T- 
lymphocyte plasma membranes and has also been shown to impair the activity of 
macrophages and lymphocyteS295-297. In carcinoma patients elevated plasma glutamate levels 
298,299 
were linked to a reduced lymphocyte response to mitogens and a high death rate 
Glutamate has also been shown to induce differentiation of HL60 cells and to be involved in 
the recall of the conditioned NK cell response, implicating glutamate signaling in a 
brain/immune system connection 300,301 . This, however, is the first study in which expression 
of a specific glutamate receptor has been demonstrated in haematopoietic tissue. 
The known functions of GluR-6 include the induction of apoptosis through a p53 
independent pathway and are therefore consistent with a tumour suppressor role. Although 
the function, if any, of this receptor in haernatopoietic cells is unknown a protein involved in 
the transduction of pro-apoptotic signals (PSD-95) that lies immediately downstream of 
GluR-6 is present in lymphocytes. While the position of deletions in various studies, clearly 
suggest that loss of GluR-6 contributes to leukaemia, mutation analysis produced only 
inconclusive evidence for homozygous inactivation. However, as discussed in 1.5 the level at 
which inactivating mutations can be detected in known tsgs in hernatological tissues shows 
considerable variation. In some cases loss of heterozygosity alone seems to be sufficient to 
promote leukaernia while in others biallelic inactivation occurs through alternative routes. 
Deletions of the p16 1NK4A/p 14 ARF locus for example are rarely accompanied by point 
mutations but more often by deletion or promoter methylation of the second allele. In this 
study homozygous inactivation through mechanisms other than point mutation of the coding 
region would not generally have been recognized, although failure of PCR for one exon in a 
cell line was suggestive for the presence of a second small intragenic deletion. 
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The GluR-6-1- mouse model provided no evidence for a tsg role for GluR-6. However, this 
cannot be considered conclusive because of differences in physiology between mice and 
men. Notably the relatively short life span of mice might mask any leukaemogenic effects of 
introduced mutations because there would be insufficient time to acquire the necessary 
additional genetic changes needed to develop recognizable malignancy. Production of double 
knock out mice, for example p53-1- GluR-6ý1 , would provide a more sensitive test of tumour 
suppressor activity. In this context, an interesting model would result from breeding 
TELIAlEl and GluR-6"- animals because deletions of chromosome 6 are probably 
associated with t(I 2; 2 1)(see 1.6). 
Against a background of only inconclusive support for an anti-leukaemic role for GluR-6 it is 
worth considering both alternative assays to test its tsg potential and other candidate genes. 
First, attention should be paid to the genes from within the CDR defined by the FISH study. 
As outlined in 4.1.1,7 genes in the region encode proteins of unknown function that may 
later emerge as interesting candidates. The transcription factors BRN-2 and SIMI should be 
assessed for evidence of expression in haematopoietic tissue before any further analysis is 
conducted. MCH2 was shown to be expressed in lymphocytes and may be worth considering 
as a candidate for further analysis although its role in haematopoietic tissue has so far not 
been investigated. 
CCNC has already been proposed as a candidate tsg because it was deleted in more than 90% 
of cases of childhood ALL with abnormalities of 6q, including a t(2; 6)(p2l; ql5) without 
deletion visible at the cytogenetic level285. Unlike most members of the cyclin family that 
positively regulate the cell cycle through Rb phosphorylation, CCNC and its associated 
kinase (cdk8) form part of the RNA polymerase 11 holoenzyme complex. Recently 
CCNC/cdk8 was shown to regulate transcription by phosphorylation of the cdk7/cyclin H 
subunits of the transcription initiation factor IIH. Phosphorylation of cyclin H was found to 
have a dominant negative effect on cell growth 302 . Furthermore, expression of CCNC is 
upregulated by the nuclear hormone vitamin D, which is known to inhibit cell growth and 
induce apoptosis 303 . Functionally therefore CCNC is an attractive candidate tsg but SSCP 
analysis of 8 cases of childhood ALL with deletion of the region failed to identify mutations 
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of the second allele 285 . As it has already been argued in the case of GluR-6, loss of 
heterozygosity or homozygous inactivation of CCNC through a mechanism other than point 
mutation of the coding sequence, may contribute to leukaemia. Further investigations into the 
potential tumour suppressor role of CCNC would be justifiable on the basis of its position 
relative to leukaemia related deletions and its apparent role in the inhibition of cell growth. 
As already discussed, the assumption that only a single leukaemia related tsg is positioned on 
6q may be wrong. If two or more tsgs are present, the CDR might result from coincidental 
overlap of deletions that encompass more proximal and distal anti-leukaemogenic genes. On 
this basis, other genes in the 6ql5-q2l region merit consideration as candidate tsgs. 
Positioned on the centromeric side of the CDR is BACH2 a B-cell specific transcription 
factor contained within PAC RPI-253B9 that in this study was deleted in 17 of the 24 
patients with 6q deletions. Treatment of lymphoid but not myeloid BCR-ABL- positive cell 
lines with the tyrosine kinase inhibitor ST1571 resulted in a 2-10 fold upregulation of BACH2 
expression 304 . This result suggested that suppression of BACH2 
function is associated with 
lymphoid transformation. Furthermore, enforced expression of BACH2 in the Burkitt's cell 
line RAJI resulted in a reduction in both the number and size of colonies when plated on 
305 methylcellulose . Southern blotting 
failed to reveal any rearrangements of BACH2 in 
lymphoma or ALL patients 304 . However, the possibility that inactivating mutations or 
epigenetic silencing of BACH2 occur in cases of leukaemia carrying cytogenetic deletions of 
the region remains untested. 
Another master regulator of B-cell differentiation BLIMP-] is positioned telomeric to the 
CDR at band q2l. BLIMP-1 is able to repress transcription through recruitment of HDACs 
and its ectopic expression was sufficient to induce differentiation of lymphoma cells to 
plasma celIS306,307. Important targets of BLIMP-1 mediated repression include c-myc and 
PAX5 both of which are upregulated in ALL as a result of translocation to antigen receptor 
loci (see 1.4 . 
)308,309. BLAp_l is flanked by PACs RPI-132E6 and RP11-5919, and was 
therefore deleted in between 15 and 18 of the patients analysed in this study. In view of its 
ability to suppress the expression of known ALL associated oncogenes, BLIMP-] would be a 
valid subject for further investigation in cases of lymphoid malignancy. 
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Several different approaches might be taken in order to establish the contributions that loss of 
candidate tsgs from the 6ql5-q2l region make to haematological malignancy. Mutation 
analysis of cases bearing deletion of 6q might reveal evidence for homozygous inactivation 
as expected in the classical tsg model. Other techniques, such as Southern blot or methylation 
sensitive PCR, would be needed to establish the existence of biallelic deletion or epigenetic 
silencing at any of these loci. Quantitative RT-PCR and Western or Northern blotting could 
be used to investigate relative levels of expression of candidate genes in leukaemic cells and 
their normal counterparts. More global assays such as genomic array, differential display or 
proteomics could address the same question and would have the advantage that large 
numbers of genes could be investigated simultaneously. 
The possibility that loss of heterozygosity of one or more genes in the region is 
leukaemogenic should also be taken into account. Evidence for such an effect might be 
obtained through functional assays. For example changes in the rate of growth or evidence 
for differentiation of ALL cell lines when transfected with a candidate gene would be 
suggestive for the rescue of loss of function. An assay of this type could also be used to 
demonstrate that point mutations truly result in loss of function. In particular, the relevance to 
leukaemia of the base pair change found in the germ line GluR-6 sequence of one patient in 
this study could be investigated. More stringent evidence for effects of haploinsufficiency 
would depend on the demonstration in animal models that loss of function of a single allele is 
sufficient to increase the rate of malignancy. 
4.2. FISH and molecular analysis of translocations. 
Reported G-banded karyotypes that include balanced rearrangements of 6q are more 
, 
25 
common among myeloid than lymphoid malignancies '. Through our department we 
obtained 4 cases of AML with balanced translocations/inversions of 6q in which partner 
chromosomes were accurately identified. A fifth case was described as add(6q) and later 
shown to be a balanced t(3; 6). Only two cases of ALL with translocations that were 
recognized on G-banding were obtained. However, a further 4 of the 25 cases of ALL 
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described as having del(6q) on G-banded analysis, were shown by FISH to involve balanced 
translocations. A further case had a translocation that also resulted in deletion of an 
interstitial part of 6q and 4 other cases appeared to be unbalanced translocations because the 
telomeric region (hybridizing to PAC RPI-167AI4) was found to be deleted on FISH 
analysis (Fig 3.2). Two cases of myeloid leukaemia had unbalanced translocations one of 
which was noted in the G-banded karyotype (case 24). Unbalanced translocations will not be 
discussed further since they have been included in the analysis of deletions. 
The high incidence of unrecognized translocations, among ALL rather than AML patients is 
likely to reflect differences in the quality of G-banding typically achieved with the two types 
of leukaemia. The number of translocations of 6q revealed by FISH alone in cases of ALL, 
suggests that their incidence may have been previously underestimated. In this study there 
were no obvious differences in presentation features or outcome between ALL patients 
bearing translocations and deletions of 6q. However, numbers analysed were relatively small 
and a larger cohort of patients would be required to determine both the true incidence and 
any clinical association with the balanced rather than unbalanced rearrangements. 
4.2.1 Cases of myeloid leukaemia with balanced translocations of 6q and break points at 
the site of known genes in partner chromosomes. 
Only one of the five translocations of 6q found in cases of AML, the t(6; 8) in patient 34, was 
found to be associated with a known fusion oncogene (FOP-FGFRI). In this case, FISH 
analysis suggested that FOP sequence fused to FGFRI was present on the derivative 
chromosome 6 only because no signal from RPI-167AI4 was observed on the derivative 8 
chromosome. As a consequence of the t(6; 8)(q27; p 11) originally cloned, both FOP-FGFRI 
and FGFRI-FOP were produced. The FOP-FGFRI fusion is thought to be oncogenic 
because its encoded protein retains the FGFRI catalytic domain, however a leukaemogenic 
role for FGFRI-FOP has not been ruled out. As a result of translocation, FOP-FGFRI is 
located on the derivative chromosome 6 234 . The rearrangement analysed in this study 
therefore appeared to result in production of the FOP-FGFRI fusion only suggesting that, 
like BCR-ABL, it can be leukaemogenic in the absence of the reciprocal fusion product"'. 
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Remaining cases did not involve a recognised recurrent translocation therefore might result 
in production of novel chimeric oncogenes or in dysregulation of known or previously 
unknown oncogenes. With the exception of the t(2; 6) and inv(6) found in patient number 32 
the breakpoints on the partner chromosomes were within a band known to contain an AML 
associated proto-oncogene. If confirmed, the involvement of a known oncogene partner in 
any of these cases, might provide an opportunity to clone a new leukaemia related gene on 
6q. 
Of the three translocations that potentially involved known oncogenes, the t(6; 11) was 
investigated and shown to interrupt the promiscuous oncogene partner AffL. The breakpoint 
on 6q clearly differed from those involving known MLL partners (AF6 and AF6q2l). Further 
molecular analysis was not, however performed in this case so the possibility that a complex 
rearrangement involving insertion of AF6 or AF6q21 (or a known MLL partner from another 
chromosome) into the 6q 15 region has not been excluded. Identification of a rare new partner 
of MLL would have been of value because comparison between different partners may help 
elucidate the precise mode of action of the fusion genes 136 . 
A 6q abnormality, described as add(6q), was demonstrated by chromosome painting to be an 
apparently balanced translocation involving band 3q26, site of another promiscuous 
oncogene partner EVIIIMDS]. The E11711IMS] locus is unusual in that the two genes can be 
expressed separately or as a single transcript. EVII encodes a transcriptional repressor that 
drives megakaryocyte differentiation 310,311 . Rare MDS, AML or CML(bc) associated 
translocations between EVII/MDS1 and AMLI, ETV6 or Ribophorin I result from 
t(3; 21)(q26; q22), t(3; 12)(q26; pl3) and inv(3)(q2lq26)/t(3; 3)(q2l; q26), respectively6l, 62,312. 
EVII is also ectopically expressed in about 5% of cases of AML without cytogenetically 
detectable abnormalities of 6q26 313 . Since EVII was known to be deregulated by different 
partner genes it seemed not unlikely that its expression was affected by the t(3; 6)(q26; q25) 
identified in this study. However, a YAC containing EVII (14e-el2), that had been shown to 
encompass the break point of 3 of 4 cases of inv(3)(q2lq26)and failed to split on 
hybridisation to the t(3; 6). This finding does not exclude the possibility that EVII expression 
was affected by the t(3; 6) because breakpoints at the locus are highly variable and may fall 5' 
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or 3' of the gene and outside the region encompassed by 14e-e 12 
62,314,315 
. Either expression 
studies, pulsed field gel electrophoresis or further FISH analysis would be required to 
eliminate EVII as a candidate gene affected by this translocation. 
A breakpoint within band 6q21 between PACs 429G5 and 661-114 was identified in the case 
of t(6; 7)(q2l; pl5). This region of 6q contains the fork head transcription factor AF6q21 
which becomes fused to 1EL in the t(6; I 1)(q2 1; q23). Band 7p 15 is recurrently involved in 
the AML associated t(7; 11)(pl5; pl5) resulting in the NUP98-HOXA9 NUP98-HOXA]l or 
NUP98-HOXA13 fusion genes 97,316,317 . The novel t(6; 7) may therefore 
be a rare variant of 
the NUP98-HOXA fusions involving AF6q21 and a member of the HOXA cluster of genes. 
However, further FISH or molecular analysis would be needed to confirm this possibility. As 
with the other cases discussed in this section, characterization of the molecular lesion 
underlying a rare translocation will have little if any direct clinical impact, but may help 
clarify the mode of action of a known oncogene partner or pinpoint a new gene involved in 
normal haematopoiesis. 
4.2.2 Cases of AML and ALL with break points clustered in the 6q22-q23 region. 
In addition to the translocations discussed in 4.2.1 a further case of AML with a complex 
karyotype that included balanced rearrangements of both homologues of chromosome 6 was 
analysed. In this case neither the translocation partner break point (2q3 1) or inversion break 
points (6p 13 and q22), were known to harbor leukaemia associated oncogenes. Though not 
identical, the translocation and inversion breakpoints on 6q occurred within the same region 
(bands q22-q23). Intriguingly, breakpoints in 5 of the 6 balanced rearrangements identified in 
cases of ALL, fell within the same region. A more detailed FISH map of the rearrangements 
of 6q22-q23 was constructed in the expectation that a new recurrent leukaemia related break 
point would be identified. Of the 7 breakpoints further analysis was not possible in two cases. 
Surprisingly of the 5 breakpoints mapped in detail, all occupied different sub-regions (see 
Fig 3.19). 
The observation of clustered yet non-identical leukaemia related breakpoints in bands q22- 
q23 of chromosome 6 prompts two different explanations. 1) Several different rare new 
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oncogene partners, perhaps all belonging to a functionally related cluster of genes, might be 
positioned in the region. 2) The rearrangements might dysregulate expression of a single 
gene (or possibly multiple genes) through long-range effects on transcription. 
The region of 6q containing the clustered breakpoints contained 91 recognised genes and 
covered just under 15 Mb, making it a relatively gene rich. Breakpoints for the 5 cases 
mapped in detail were narrowed to intervals of 1-2.5 Mb in size, in each case genes of known 
or predicted as well as of unknown function were present. Although it seems unlikely that 
five different genes involved in the pathogenesis of leukaemia would by chance be 
positioned in this relatively small region of 6q, interesting candidate oncogenes were found 
to be located within each breakpoint sub- region. 
The translocation breakpoint from the AML patient no 32 (between PACs RPI-293L8 and 
RPI-179EI3) contained a gene with homology to Protein Kinase-C inhibitor. Although in 
this instance not yet characterized, protein kinase-c inhibitors exert negative control over cell 
cycle entry and have anti-tumourogenic properties 269. Also in the region were two genes that 
were homologues of known Drosophila developmental genes. The inversion breakpoint from 
the same patient (between RP I 199H 14 and RP I-I 17D4) was positioned within a region 
containing three genes encoding cytokine receptors, IL20RA, IL-22BP and IFNGRI. As 
discussed in 1.1 dysregulation, inappropriate expression or modification of growth factor 
receptors is a characteristic of many malignancies. At least one of the three cytokine 
receptors, IFNGRI is expressed in haematopoietic tissues. 
The breakpoint of the translocation found in patient 29 (between RPI-69DI7 and RPI- 
131F15) was contained within a 2.5 Mb region encompassing several genes that could 
potentially be involved in malignancy. Notably AKAP7 is essential for the function of PKA 
that in turn inhibits lymphocyte proliferation by down-regulating cyclin D3 and inducing 
p27k'Pl expression 271 .A second gene within the region, CRISP 3, is a target for the 
transcription factor Oct2 so probably it plays a role in terminal B-cell differentiation 272 . In 
this case the translocation was recognized on G-banding and thought to involve chromosome 
19 band p13, the site of the E2A proto-oncogene. Demonstration of disruption to the E2A 
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sequence at the molecular level would present an opportunity to clone the break point and 
precisely determine which gene on 6q, if any, is involved in this translocation. 
Detailed mapping of the translocation breakpoint in patient 27 defMed a region (between 
RPI-55C23 and RPI-76H23) containing three genes involved in lymphocyte migration 
(VNNI, VNN2 and VNN3). Interruption of genes in this cluster might interfere with 
lymphocyte infiltration of the thymus and hence perturb T-cell development 274,275 . Lastly, the 
breakpoint of the translocation found in patient 28 (between RP I- 12L5 and RP I -42A6) fell 
within a region containing c-MYB, the only recognised oncogene in the 14.8 Mb region. The 
c-Myb protein is a sequence specific transactivating transcription factor expressed at high 
levels in immature hematopoietic cells 318 . c-Myb is known to play important roles in the 
growth and differentiation of haernatopoietic cells and its loss of function was shown to 
increase the rate of apoptosis of T-cells in mice. Targets for c-Myb transactivation include c- 
MYC, M-2 and a homeobox gene GBX2 319-321 . Activated 
forms of c-MYB were first isolated 
from chicken leukaemia viruses and subsequently truncating mutations of the wild type gene 
have been shown to stimulate malignant transformation in mice and to arise in human 
leukaemia 278,322,323. Over-expression of c-MYB has also been reported in cases of leukaemia 
although its activation through translocation has not been reported 
324,325 
In summary, the seemingly unlikely hypothesis that several different genes in the 6q22-q23 
region can contribute to leukaemia, was strengthened on examining the gene content of the 
break point sub-regions. The region was gene rich and contained a concentration of genes 
specifically involved in haematopoietic development. However, involvement of the candidate 
genes in these patients will remain a matter of speculation unless further FISH and/or 
molecular analysis is performed. 
As discussed in 4.2.1 the oncogene EVII may be ectopically expressed as a result of 
translocations with breakpoints falling several hundred Kb outside the locus. Other genes 
such as IL3 and GSH2 may also be deregulated as result of relatively short-range position 
effects". The mechanism by which oncogene deregulation occurs in these cases is uncertain 
but probably involves local disruption of higher order chromatin structure. The 5 breakpoints 
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defted in this study encompass a minimum distance of 5 Mb and a different mechanism 
leading to a long-range position effect would be required to bring about dysregulation of a 
single gene in the region. 
That the same gene is dysregulated by all of the translocations is a theoretical possibility 
because long-range effects of translocations on expression have been demonstrated 
experimentally in Drosophila. A mutant of the brown eye colour locus (brown) was 
expressed at less than 2% of wild type levels through association with transcriptionally 
repressive heterochromatin. The repressive effect has been termed position effect variegation 
(PEV) and could be modified by translocations. Rearrangements that moved the mutant locus 
closer to the heterochromatin enhanced the trans-inactivation of brown while those that 
distanced it from heterochromatin counteracted the PEV326. 
Human genes including some involved in haematopoietic development are also trans- 
inactivated through association with centromeric heterochromatin. The related zinc finger 
DNA binding proteins Ikaros, Helios and Aiolos are thought to act as master regulators of B 
and T-cell development327. In the interphase nucleus Ikaros family proteins are concentrated 
at the centromeric heterochromatin clusters sometimes known as chromocenters. Using the 
approach of confocal microscopy and immunoFISH a striking correlation was reported 
between repression of genes with Ikaros binding sites (in this case TdT and X5) and their 
association with the lkaros-heterochromatin complex. Active Ikaros responsive genes were 
found elsewhere in the nucleoplasm providing an elegant demonstration of the role of 
chromatin movement in the control of transcription 328 . 
Modifications to heterochromatin mediated trans- inactivation of genes involved in human 
malignancy that result from chromosomal rearrangements, have not as yet been 
demonstrated. However, position effects of this type might account for the novel cluster of 
leukaemia-associated breakpoints observed in this study. Theoretically expression levels of 
any of the 91 genes in the region, or indeed of more proximal or distal genes, could be 
influenced by the translocations. An interesting candidate for such long-range position effects 
is e-WB because its expression level varies during normal haematopoietic development and 
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the wild-type gene is sometimes over-expressed in leukaemia. Furthermore in ALL derived 
cell lines a correlation between high levels of c-MYB expression and the presence of 6q 
deletions has already been reported 324 . Two of the cell lines (RPMI-8402 and MOLT-4) 
have 
been analysed in this study and in both cases the telomeric boundaries of the 6q deletions 
were positioned 10-20 Mb proximal to the c-MYB locus. Any direct relationship between the 
deletions of 6q and high levels of c-MYB expression would therefore have to result from 
long-range position effects, although loss of trans-inactivation of the locus resulting from 
deletion of a more proximal gene is also a possibility. 
Other potential targets of position effects include the genes discussed above that lie within 
the translocation breakpoint sub-regions and also genes positioned outside the sub-regions. 
Two genes (Q9NYF8 and AlfAP3K5) that were not located within the sub-regions, encode 
genes involved in the regulation of apoptosis and therefore are potential candidates for 
dysregulation resulting from leukaemia related cytogenetic rearrangements. Though in 
principle, loss of transcription control mediated by chromocenters or other nuclear sub- 
domains might account for the cluster of translocation break points, evidence in support of 
the hypothesis would be difficult to obtain. It might be of interest to monitor expression 
levels of candidate genes, such as c-AffB, in future cases of leukaemia with rearrangements 
of 6q. The spatial relationship between candidate genes, on normal and rearranged 
chromosomes, and transcription factor associated nuclear sub-domains, such as the 
chromocenters, could also be investigated by confocal microscopy. 
4.2.3 FISH and molecular analysis of a complex rearrangement of 6q (patient 22). 
As described in 3.2.3 FISH analysis of patient 22 revealed complex rearrangements involving 
both homologues of chromosome 6. The most straightforward interpretation of the pattern of 
signals observed was that deletion of 6q, resulting from an unbalanced translocation, was 
accompanied by balanced translocation of the second homologue. As an additional 
complication one of the products of the balanced translocation appeared to have undergone 
duplication and some further rearrangements. 
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The breakpoint of the balanced translocation was mapped to a position between PACs 655C5 
and 249F5. Using Blast Search the first four exons of the IGF2-R, covering a distance of 
more than 40 Kb were positioned on 249F5 while exon 5 and other more distal exons 
(spanning approximately 90 Kb) were found on 655C5. Since evidence for a split signal was 
not seen on hybridization with either 655C5 or 249F5 to patient 22 metaphases the 
translocation break point seems unlikely to have fallen outside the gene. Disruption of the 
IGF2-R could not be confirmed on Southern blot analysis, however this was thought to be for 
technical reasons. Based on the assumption that the translocation breakpoint fell within the 
first 10 exons of the gene, RACE PCR was performed. 
With some difficulty a fusion transcript between the IGF2-R and a second gene (MRP8) was 
amplified from 3' RACE ready c-DNA prepared from patient 22 RNA. The amplified fusion 
transcript resulted in an out of frame sequence and therefore should not have produced a 
functional protein. Attempts to amplify the fusion sequence using paired IGF2-R and MRP8 
specific primers and an independently made cDNA from patient 22 were unsuccessful. FISH 
with a 6q probe lying telomeric to the breakpoint and a chromosome I paint also failed to 
provide supporting evidence for juxtaposition of the IGF2-R and MRP8 sequences in this 
case. It is possible that a small segment of chromosome I including the AMP8 locus became 
inserted next to the IGF2R as a result of a complex rearrangement involving not less than 3 
chromosomes. It is also conceivable that the difficulty encountered in confirming existence 
of the IGF2-R-AM8 fusion arose because the chimeric transcript was unstable and quickly 
degraded. However on the basis of the data obtained the possibility that the fusion sequence 
was artificially produced in the course of the RACE reaction cannot be excluded. In 
conclusion the chromosomal rearrangements of 6q were likely to have resulted in biallelic 
inactivation of the IGF2-R and possibly in loss of function of one copy of a second gene, 
MRP8. 
The IGF2-R is a multifunctional transmembrane protein that can bind the growth factors 
IGFI and IGF2 in competition with the IGFI-R. Positive growth signals are transduced 
through the IGF I -R while the IGF2-R is thought to transport excess of these mitogens to the 
lysosomes for degradation 329 . Through a second binding site the IGF2-R interacts with the 
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mannose-6-phosphate moieties of certain glycoproteins including precursor TGFO. 
Conversion of TGFP from its inactive to its active form depends on IGF2-R mediated 
trafficking to the cell surface and in many tissues, including those of the haematopoietic 
system, active TGFP transduces anti-growth signals through its receptors 330,331 . Recently the 
IGF2-R was shown to be the death receptor for granzyme B and therefore it may also play a 
role in immune surveillance. The IGF2-R has other important cellular functions but it is the 
above that have prompted expectations that it might act as a tsg. 
In fact several lines of evidence suggest that the IGF2-R does play a tumour suppressor role 
in some tissues. Most convincingly 70% of hepatocellular carcinomas display LOH for the 
IGF2R locus and of these 25% were mutated for the second allele 332 . Missense mutations of 
the IGF2-R that alter ligand-binding affinity have been identified in various solid 
tumours. 40; 41 In these cases mutations appeared to be monoallelic suggesting that 
haplo insufficiency of IGF2-R function, may be tumourigenic. Functional studies also support 
a tsg role for the IGF2-R because induced expression of the wild type gene was shown to 
suppress growth and promote apoptosis of a colorectal carcinoma cell line 333 . Transfection 
of antisense IGF2R cDNA into choreocarcinorna cells increased the rate of growth in vitro 
and also enhanced turnour growth in vivo 
334 
. 
This is the first report in which loss of function of the IGF2-R has been implicated in 
leukaemia. However, it is well known that the IGF system regulates proliferation and 
differentiation of hematopoietic cells (reviewed by Zumkeller 2002 227) . Hypersensitivity to 
IGF I has been implicated as an underlying cause of PRV and loss of imprinting of the IGF2 
locus reported in cases of AML and MDS. In vitro IGR was shown to induce both 
antiapoptotic and proliferative effects in multiple myeloma celIS335. Malignant lymphoblasts 
of childhood ALL were found to express components of the IGF system suggesting that they 
promote their own growth in an autocrine, paracrine or endochrine manner 336 . This 
last report 
is of particular relevance to the finding that the IGF2R is apparently homozygously 
inactivated in patient 22, who was a 10 year old presenting with ALL. 
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Cytogenetically detectable deletions of the region containing the IGF2-R (6q26) are not 
commonly reported in leukaemias. In this study only 6 cases (25%) would have included the 
IGF2-R compared with 20 (83%) for the most commonly deleted region. However, small 
deletions or point mutations, that would remain undetected on G-banding, might 
preferentially affect the IGF2-R locus. Deletions confined to the distal region of 6q have 
been reported to occur in lymphomas so it might be of interest to investigate the involvement 
of this tsg in a range of lymphoid malignancies 337 . Because of the 
large size of the IGF2-R, 
mutation analysis of the entire coding sequence might be viewed as impractical. In solid 
tumours mutations were found within the extracellular domain that includes the IGF and 
M6P binding sites; so analysis of exons encoding this part of the gene could be considered 
338,339 for an initial investigation 
Though unconfirmed the RACE PCR results suggest the possibility that not only the IGF2-R 
but also AV? P8 was inactivated as a consequence of chromosomal rearrangements in patient 
22. MRP8 is one of a cluster of genes positioned on chromosome I band q21 that code for 
related calcium binding proteins 282 . The calcium binding proteins appear to be involved in 
processes such as cell cycle progression and differentiation. MRP8 in particular is expressed 
in macrophages associated with chronic tissue inflammation 340 . Though 
function of MRP8 is 
not inconsistent with a role in leukaemia further investigation of this gene would not be 
justified on the basis of the data obtained in this study alone. 
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Conclusions, 
FISH analysis of cases of ALL with cytogenetically detectable rearrangements of 6q lead to 
the identification of a new CDR and candidate tsg (GluR-6). GluR-6 encodes one of a 
number of ionotropic glutamate receptor sub-units that was demonstrated for the first time to 
be expressed in haematopoietic tissue. One of 14 patients with leukaemia related deletions 
that included GluR-6 was found to carry a base pair substitution in the non-deleted allele. 
Although the base pair substitution resulted in a change in amino acid sequence, it was also 
present in the patient's remission sample so its relationship, if any to the patients leukaemia, 
is unclear. Further investigations of the involvement of GluR-6 as well as a number of other 
genes in the region (CCNC, BAC-2 and BLIMP-1) in leukaemia would be justifiable. 
Eleven leukaemia related translocations affecting 6q were also analysed. None of the 
translocation breakpoints fell within the CDR, four involved bands on partner chromosomes 
known to contain proto-oncogenes and seven clustered within approximately 15 megabases 
of 6q22-q23. On detailed analysis the clustered breakpoints were found to be non-identical 
suggesting that either multiple- oncogenes are positioned within this part of 6q or that these 
rearrangements contribute to leukaemia through a novel mechanism. Complex 
rearrangements of 6q in a single case of childhood ALL were consistent with biallelic loss of 
function of the IGF2-R. Though inactivation of the IGF2-R has been associated with several 
solid tumours this is the first evidence to suggest that it may also operate as a tsg in ALL. 
184 
Appendix 1 
Materials (not included in chapter 2). 
Chemicals were obtained from BDH unless otherwise stated. 
AGB Buffer (50X). 
242g trisma base 
57.1 ml glacial acetic acid 
100ml 0.5M EDTA pH 8.0 
made up to IL with DDW 
AHC Medium. 
1.7g bacto-yeast extract 
I Og caseine hydrolysate 
5g (NH4)2SO4 
10ml (2 mg/ml) adenine sulphate 
to 900 ml with DDW and autoclave 
before use add 10% volume of filter sterilised 20% glucose and antibiotics 
AHC Agar. 
As for AHC medium but glucose and 15g bacto-agar added before autoclaving 
Solid media is liquidised by microwave and cooled to 500C before addition of antibiotics 
Church Hybridisation Buffer. 
500ml IM Na2HP04 pH 7.2 
I Og Bovine Serum Albumin 
70g Sodium Dodecyl Sulphate 
2ml 0.5 M EDTA pH 8.0 
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Denaturing solution. 
1.5 M NaCI 
0.5 M NaOH 
Depurination solution. 
20 ml of HCI in 1 litre DDW 
DNA loading buffer. 
50% glycerol 
0.2% bromophenol blue 
0.2% xylene cyanol 
0.1 M EDTA pH 8.0 
DnD. 
IM DTT 
90% DMSO 
10 mM Potassium Acetate 
GDIS solution. 
20 ml 10% triton-X- 100 
10 ml 10% SDS 
3.33 ml 3M NaCl 
IMI ml Tris pH 8.0 
200 gl 0.5M EDTA 
to 100 ml with DDW and filter sterilize. 
GTE buffer. 
50 mM glucose 
25 mM Tris pH 8.0 
1 mM EDTA pH 8.0 
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Luria-Bertani broth (LB medium). 
I Og bactotryptone 
5g bacto-yeast extract 
I Og NaCl 
to 1L with DDW 
LB agar. 
1.5% bacto-agar in LB 
sterilized by autoclaving 
solid media liquidised by microwave and cooled to 500C prior to addition of antibiotics 
Neutralising solution. 
1.5 M NaCl 
0.5 M Trisma base pH 7.2 
PEG (20%). 
40g PEG 
29.22g NaCl 
dissolved in 100 ml DDW,, filtered and made up to 200 ml final volume. 
Phenol/chloroform/isoamyl alcohol (PCIA). 
25 ml phenol pH 8.0 
24 ml chloroform 
I ml isoamyl alcohol 
SOB. 
20g bacto-tryptone 
5g bacto-yeast extract 
0.5g NaCl 
10 ml 250 mM KCL 
adjusted to pH 7.0 and made up to IL with DDW 
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SSC (20X). 
3M NaCl 
0.3M sodium citrate 
adjust to pH 7.0 with NaOH 
TBE (5X-). 
27g Trisma base 
13.75g boric acid 
10 ml 0.5 M EDTA pH 8.3 
to 500 ml with DDW 
TE buffer. 
10 mM Tris pH 8.0 
I mM EDTA pH 8.0 
TFB. 
0.5 M MES (2-(N-morpholino) ethanesulphonic acid) adjusted to pH 6.3 with KOH 
100 mM KCI 
45 mM MnC12 
I OmM CaC12 
3mM hexaminecobaltic chloride 
2XTY. 
16g bacto-tryptone 
I Og bacto-yeast extract 
5g NaCl 
adjusted to pH 7.4 and made up to IL with DDW 
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Appendix 2 
(Oligonucleotide sequences) 
Probe Forward and Reverse Primer Product Annealing 
Name Sequences size temperature 
G6PD F- aftcatcatcatgggtgcatcg 168 b. p. 58 or 600C 
R- tgtttgcggatgtcagccactgt 
P-Actin F- tgctatccaggctgtgctat 480 b. p. 580C 
R- gatggagttgaaggtagttt 
GluR-6 (1) F- ccaggatagtgggaggcatttgg 469 b. p. 670C 
R- gccttcctcttgcagctgaagaattgc 
GluR-6 (2) F- ggcgcaccgftaaactcctgctctg 173 b. p. 650C 
R- gtagcaatgttctgtttctgttaattgtgttc 
Table 2. A. 1 G6PD, AActin and GluR-6 specific forward (F) and reverse (R) primer 
sequences used for RT-PCR analysis. 
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Exon Sequence of exon and position of primers 
catcctcatt tctacccgaa m Mggggaagt 
gggtgccgtg cgtgtgggca cagaaacacc atgaagatta ttttcccgat 
tctaagtaat ccagtcttca ggcgcaccgt taaactcctg ctctgtttac 
tgtggattgg atattctcaa ggaaccacac atgtattaag atttggtaag 
attecccatc tctcttggtt gcctggtatc cgctcccagg cagccggatg 
taaacaggcg gttcgctctg cctggcggtg ggctccgtgg attctgatct 
Product Annealing 
size temperature 
230 b. p. 650C 
2 atataaaagt atta 280 b. p. 600C tgtttattct t gtaaaattt atgatt tttc tctttctttt tgccaggtgg 
tatttttgaa tatgtggaat ctggcccaat gggagctgag 
gaacttgcat tcagatttgc tgtgaacaca attaacagaa 
acagaacatt gctacccaat actaccctta cctatgatac 
ccagaagata aacctttatg atag-ttttga agca ccaa 
aaaggtaatt gatagatttt 
ttaagagaft 
3 tgttggcaca ýg ac ctttatctcc 362 b. p. 650C tcttcagcct gtgatcagct gtctcttggg gtggctgcca tcttcgggcc 
ttcacacagc tcatcagcaa acgcagtgca gtccatctgc 
aatgctctgg gagttcccca catacagacc cgctggaagc 
accaggtgtc agacaacaaa gattccttct atgtcagtct 
ctacccagac ttctcttcac tcagccgtgc cattttagac 
ctggtgcagt ttttcaagtg gaaaaccgtc acggttgtgt 
atgatgacag cactigt aaatcagt atcttttgga gctatgcttt 
aaatatagat ýý attctta 
4 ttatacattc taatgagtgt tttctgattc 
tttgccctac tctatttttt 
atctctaata ttcttttttt tttttccatt ttaattaaag gtctcattcg 
tttgcaagag ctcatcaaag ctccatcaag gtataatctt 
cgactcaaaa ttcgtcagtt acctgctgat acaaaggatg 
caaaaccctt actaaaagaa atgaaaagag gcaaggagtt 
tcatgtaatc tttgattgta gccatgaaat ggcagcaggc 
attttaaaac aggtaacctt taaattactt caattcttgt tttc# 
,, -atga 
tettctttta 
294 b. p. 600C 
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5 gattctttat eacatcctae tatattttgt tctcacttga attactgaca 226 b. p. 600C tactgtcttt cctgaaatat gtaccttcag taattttttt ttttccttag 
gcattagcta tgggaatgat gacagaatac tatcattata 
tetttaccac tctggtaagt acttcattaa aacaaaatil tctiaatttt 
attattatga ctttttcaga tgaaaaatag gtt' 
4tgactgatt cctttgtagt tatattttaa 
C tttcagtaat ataat aacaacacaa 280 b. p. 600C taacatttgt ctttcaggac ctctttgcte ttgatgttga geectaccga 
tacagtggtg ttaacatgac agggttcaga atattaaata 
eagaaaatac ccaagtctcc tccatcattg aaaagtggtc 
gatggaacga ttgcaggcac ctccgaaacc cgattcaggt 
ttgctggatg gatttatgac ggtatgaata cccacttaaa gatcagtttg 
ttcta aatagtattg catacatatg aa- t i i 
7 tcttccetct teetccttgc aaaccatcta ccacaagttc tacaagttat 291 b. p. 65()C attgactata aatttccctt tcccttgctt ttcagactga tgetgetcta 
atgtatgatg ctgtgcatgt ggtgtctgtg gccgttcaac 
agtttcccca gatgacagtc agttccttge agtgtaatcg 
acataaaccc tggcgcttcg ggacccgctt tatgagtcta 
attaaagagg taagttagga gaagaacatc tgccttetct cttttgttgt 
caagctgaat gaagtgagat tattgtggtt tttctagcaa gtgteetttt 
actttatgtt 
8 agcaatgtaa aaa 275 b. p. 600C 
aaatgtttat tccatctttc ttcacttatt tattatcaat gtttttctat 
tcccataggc acattgggaa ggccteacag gcagaataae 
ttteaacaaa accaatgget tgagaacaga ttttgatttg 
gatgtgatca gtctgaagga agaaggtcta gaaaaggtat 
c ttatttgctt taattactaa atgaaacata tctcaaagaa a ttca ji i 
9 ll'I - attt 
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9 gtactctcta ceacgtgcct gatggacaat ttacaaagta catatgctat 226 b. p. tttatagatt ggaacgtggg atccagccag tggcctgaat 
atgacagaaa gtcaaaaggg aaagccagcg aacatcacag 
attccttatc caatcgttct ttgattgtta cc_acc-atttt ggtaagtaft 
tgcttftcca tta4iiiiijo = latag M 
aaaaggacat 
10 aagaaaagca ataattc 322 b. p. tttcttcttt ttcaatgttt tcaggaagag ccttatgtce tttttaagaa 
gtctgacaaa cctctctatg gtaatgatcg atttgaaggc 
tattgcattg atctcctcag agagttatct acaatccttg 
gctttacata tgaaattaga cttgtggaag atgggaaata 
tggagcccag gatgatgcca atggacaatg gaatggaato 
- 7ý'ý jttcgtgaac taattgatca tg taagtccc ttccctcatg atttaM 
gttgatgtat 
ttaatttgat tactgatttt ttettgtgac tgaaaatcaa ttttttctct 
ctttctttct ttcttttttt tttttttttg tttgtttctg tctacagaaa 
363 b. p. 
600C 
600C 
600C 
gctgaccttg cagttgctcc actggctatt acctatgttc 
gagagaaggt catcgacttt tccaagccct ttatgacact 
tggaataagt attttgtacc gcaagcccaa tggtacaaac 
ccaggcgtct tctccttcct gaatcctctc tcccctgata 
tctggatgta tattctgctg gcttacttgg gtgtcagtt 
! gtgctst tcta ýýcatgc tcacttttgt gatttt tti 
a 
12 ttttgcagca 
gtattctttt tti 
aatccacacc 
acaattttac 
agctctcat 
cctttgii 
aa atttaaat 
ctgtcaat taccacaggt ttagtcctta tgagtggtat 
cttgcaaccc tgactcagac gtggtggaaa 
cttgctaaat agtttctggt ttggagttgg 
cagcaaggta tacgattcag cctgctattt 
ggggtga ag 
237 b. p. 650C 
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13 aagtatctga tccccc actctctgtt 330 b. p. 650C ag2ttctizat! g ctcatgccca aagcactgtc caccaggata gtgggaggca tttggtggtt tttcacactt atcatcattt cttcgtatac tgctaactta 
gccgcctttc tgacagtgga acgcatggaa tcccctattg actctgctga 
tgatttagct aaacaaacca agatagaata tggagcagta gaggat t ggtlg 
caaccat ac ttttttcaag gtaagttctg ctggttacct aaaa= a ifi 
lija4i gattcacaaa 
14 atgtagttca tt gtgtctaa gcattatagg agcacatgga aactaaag aa taactttctc 352 b. p. 650C gtgaccaact tatatttatt ttcttcagaa atcaaaaatc tccacgtatg 
acaaaatgtg ggcctttatg agtagcagaa ggcagtcagt gctggtcaaa 
agtaatgaag aaggaatcca gcgagtcctc acctctgatt atgctttcct 
aatggagtca acaaccatcg agtttgttac ccagcggaac tgtaacctga 
cacagattgg cggccttata gactctaaag gttatggcgt tggeactece 
j at ggtaggt i tatatgtcag ctctttgttc tttgttcatt aatctgagtt gctgtaagac 
gaaaaa 
15 cattttgaaa a atct aacc tttaattatg aaatttcagg 432 b. p. 600C ttccttgaaa tacttaacat aacctctcct ttcttaggtt ctccatatcg agacaaaatt 
accatagcaa ttcttcagct gcaagaggaa ggcaaactgc atatgatgaa 
ggagaaatgg tggaggggca atggttgccc agaagaggag agcaaagagg 
ccagtgccct gggggttcag aatattggtg gcatcttcat tgttctggca 
gccggcttgg tgctttcagt ttttgtggca gtgggagaat ttttatacaa 
atccaaaaaa aacgctcaat tggaaaaggt aaatgttact tgtttcagtt 
taaatttaaa acaatttttg ttgttacaat aaaacacaaa ccaaaagagt týý 
gc tctaaattgt 
15b caagattl tgtaaatata aattgactaa 324 b. p. 600C ttaaatataa tgaattttat taagagtttt actaatttaa atgcaattat acatgctaac 
agctcaaaga tttaaatttt cattttcagg aatcttctat ttggttagtg 
ccaccatacc atccagacac tgtttagtaa tcttttgaaa cttactaaaa 
gaggttttta ataatggtta gtatccttgt gcctttcttt tttctttttg tagtctgtta 
tattaatgtg gagaaacatt tttatýýýýýýtatttaa 
ttctccttct 
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16 tgttgaggat gattttaata ttgatcttgg acagttacag tttatgtatc ttgtaatatt 301 b. p. 600C taatttttct gtgttcttct gtagaggtec ttctgtagtg ccatggtaga 
agaattgagg atgtccctga agtgccagcg tcggttaaaa cataagccac 
aggccccagt tattgtgaaa acagaagaag ttatcaacat gcacacattt 
aacgacagaa ggttgccagg taaagaaacc atggeataaa gctgggaggc 
caaacaccca agcacaaact gtcgtctttt tccaaacaat ttagccagaa 
tgtttcctgt ggaaatatgc 
Table 2A. 2 Sequence of exons (bold type) and flaking intronic regions of GluR-6. The positions 
of forward and reverse primers used to amplify each exon for sequence analysis are highlighted 
in grey. * The position of the second set of exon 6 primers is highlighted. *The position of nested 
primers used to amplify exon II are marked in a lighter shade of grey. 
194 
Probe Name Forward and Reverse Primer Nucleotide Exons 
Sequences position encompassed 
IGF2R SB 1F- tagggatcccgcagtccgggcccggcg 
R- tagggatccggtgcagtcaacctcccct 1- 1628 
IGF2R SB 2F- taggaattccagcggatgagcgtcataaac 
R- taggaattcggtttctgcctcacagccag 1360-3239 10-22 
IGF2R SB 3F- taggaattctgtctgcggcacaatgcctg 
R- taggaattccttgtacaccagctgcaggac 3047-5095 22-34 
IGF2R SB 4F- taggaattcgcgtggcaaggccaacaag 
R- taggaattcacgagactccgttgtggaccag 4839-6216 34-40 
IGF2R SB 5F- taggaattctgggaggccacaagtcttcagt 
R- taggaattcgaagcatcatcgagtggaagtcftat 5982 - 9091 40-48 
SP6 F- ttccaagaccccgagtcaatgcctaaaacc 
Table 2A. 3 Paired oligonucleotide sequences used to amplify probes for Southern blot 
analysis of the IGF2-R. 
Primer Sequence 
SMARTII AAGCAGTGGTAACAACGCAGAGTACGCGGG 
5'-CDS (T)25N-iN [where N=A, C, G, or T; N- i =A, G or C] 
3'-CDS AAGCAGTGGTAACAACGCAGAGTAC(T)3oN-iN 
Table 2. A. 4 Primer sequences used for first strand c-DNA synthesis for SMART RACE 
PCR. 
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Primer Sequence 
Long Universal primer ctaatacgactcactatagggcaageagtggtaacaacgcagagt 
Short universal primer ctaatacgactcactatagggc 
Nested universal primer aagcagtggtaacaacgcagagt 
IGF2R exon 1 agcagtcgcgcgccgttagcctc 
IGF2R exon 2 acatctgtggaagtgtggatattgtcc 
IGF2R exon 2b tacatgggaagctgttgataccaaaataat 
IGF2R exon 3 tgagaagtgcaaccagatctctcctg 
IGF2R exon 7 tgcctcttccctcacgtaactcagg 
IGF2R exon 8 tctatggagacatcctgctgctcgc 
IGF2R exon 9 tgctttgacttgagaggtatcgctctt 
IGF2R exon 10 tgaaaccctgagctgcattcatcacc 
MRP8-F gtctcttgtcagctgtctttcagaag 
MRP8-R tatcaccagaatgaggaactcctgga 
MRP8 nested-R ctgcaccatcagtgttgatatccaac 
Table 2A. 5 Oligonucleotide sequences used for SMART RACE PCR analysis. 
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Appendix 3 
(Characteristics of Genes on 6q) 
Gene Ensemble I. D. Transcript Number of Size of Genomic 
size (b. p. ) exons region (Kb) 
POU3F2 ENSGO0000132419 1329 1 1.329 
FBXL4 ENSGO00001 12234 1353 6 43.44 
Q9BXE6 ENSGOOOOO 164415 372 1 0.372 
Novel ENSGO0000146273 771 1 0.771 
Q9B552 ENSGO0000146267 1512 6 68.49 
NMO17421 ENSGO0000132423 1335 7 24.81 
Q9POCO ENSGO0000132424 2422 11 23.85 
Novel ENSGO0000152263 1381 8 38.99 
Q9BRUI ENSGO0000123552 1387 8 33.17 
CCNC ENSGOOOOOI 12237 2145 12 26.27 
PRDM13 ENSGOOOOO 11223 8 2187 4 7.72 
Q9BXA8 ENSGO0000152034 1020 5 35.21 
Sim I ENSGO00001 12246 3995 11 274.8 
L043738 ENSGO00001 12214 5748 39 496.44 
Q9H5A2 ENSGO00001 12254 336 3 8.89 
GluR-6 ENSGOOOOO 164418 2727 17 670.0 
Table 3A. 1 Transcript length, number of exons and size of genomic region covered by genes 
positioned within the CDR derived from acute leukemia patients with cytogenetic deletions of 
6q. Genes are listed according to position in a centromeric to telomeric orientation. 
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Gene Structure and function of gene 
POU3F2 
FBXL4 
Q9BXE6 
Novel 
Q9B552 
NMO17421 
Qgpoco 
Novel 
Q9BRUI 
Also known as Brain Specific homeobox/POU domain protein 2 
(BRN-2) or Nerve system specific octamer-binding transcription 
facter N-OCT 3. Member of 8 member POU domain protein 
family. 
Putative protein fragment of unknown function with no other known 
family members. 
Function unknown, no other known family members. 
Oxidoreductase, member of 2 member oxidoreductase family. 
Hypothetical 56 KDA protein fragment of unknown function with no 
Other known family members. 
Hexaprenyldihydroxybenzoate methyltrannsferase. 
Function unknown, no other known family members. 
Ubiquitin carboxy terminal hydrolase 16 (Ubiquitin processing 
protease). Member of ubiquitin carboxy terminal hydrolase 
family. 
Hypothetical 32.7 KDA protein of unknown function with no other 
family members. 
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CCNC Cellular cyclin, binds to and activates cyclin dependent kinase 8 that 
phosphorylates a sub-unit of RNA polymerase 11. Positive regulator 
of cell cycle transition. 
PRDM13 PR-domain zink finger protein 13, no other known family members. 
Q9BXA8 Melanin concentrating hormone receptor 2 (MCH2) 
G protein-coupled receptor, expressed predominantly in the brain 
and thought to be involved in the regulation of food intake and 
Energy balance. 
Sim I Homologue of (Drosophila) single minded 1. bhlh transcription 
factor, involved in embryogenesis. 
L043738 RNA helicase (fragment), member of U5 small ribonuclear protein 
Family. 
Q9H5A2 Novel protein of unknown function. 
GluR-6 Glutamate receptor 6 sub-unit, also known as GRIK 2, member 
of ionotropic glutamate receptor family. Prominent role in 
neurotransmission. 
Table 3A. 2. Description of the genes contained within the CDR derived from FISH analysis 
of cases of acute leukemia with cytogenetic deletion of 6q. 
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Gene Ensemble I. D. Transcript Number of Size of Genomic 
size (b. p. ) exons region (Kb) 
HEY2 ENSGO0000135547 2533 5 11.55 
Novel ENSGO0000146375 2535 12 67.82 
Q9NQES ENSGO00001 11912 303 3 1.11 
Q9NQE9 ENSGOOOOO 111911 2536 5 22.69 
Q9NQFO ENSGO0000066651 2079 14 52.79 
Novel ENSGOOOOO 152872 320 4 66.54 
Q9BXY4 ENSGO0000146374 2390 5 78.39 
Q9NTX6 ENSGOOOOO 118 518 2146 4 21.49 
Q9NTX5 ENSGO0000093144 2123 6 53.70 
043158 ENSGO0000009718 6302 4 10.60 
Q9UGCI ENSGOOOOO 118 509 2022 6 42.50 
Novel ENSGO0000152884 915 5 13.14 
Novel ENSGOOOOO 164460 300 3 103.03 
PTPRK ENSGOOOOO 152894 2844 18 524.90 
Q9UN81 ENSGOOOOO 164481 1014 1 1.014 
LREI ENSGOOOOO 164481 3825 1 3.825 
LAMA2 Not available 9534 67 400.0 
Q96564 ENSGO0000146376 3297 14 64.93 
Q96JM7 ENSGO0000146381 4101 22 
Novel ENSGO0000164483 590 4 30.86 
Q96PX5 ENSGOOOOO 164484 1503 1 1.503 
EPB41 L2 ENSGO0000079819 4290 19 117.16 
AKAP7 ENSGOOOOO 118 507 978 7 136.39 
ARG1 ENSGOOOOO 118 520 1447 8 
CRSP3 ENSGOOOOO 112282 5215 29 41.48 
Q9NTTS Not available - - - 
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Novel ENSGOOOOO 154269 1931 13 62.47 
OR2A4 ENSGO0000135570 930 1 0.930 
095046 ENSGO0000135570 2331 1 2.331 
ENPPI ENSGOOOOO 112264 3511 25 83.19 
Novel ENSGO0000164486 327 1 0.327 
Novel ENSGO0000146384 381 1 0.381 
CTGF ENSGO00001 18523 1047 5 1.91 
Q9Y4U3 ENSGO0000079931 2950 11 79.00 
STX7 ENSGO0000079950 1588 9 43.58 
GPRI02 ENSGO0000146385 1029 1 1.029 
Q96RI8 ENSGO0000135569 1035 1 1.035 
014804 ENSGO0000135569 1011 1 1.011 
GPR58 ENSGO0000146378 918 1 0.918 
Q96RJO ENSGO0000146399 1017 1 1.017 
VNNI ENSGOOOOO 112299 3106 7 32.4 
VNN3 ENSGO0000093134 1711 7 11.97 
VNN2 ENSGOOOOO 112303 2004 7 14.03 
N_M052831 ENSGO0000146409 2367 14 29.18 
RPS12 ENSGOOOOO 112306 501 6 3.00 
Q9UN80 ENSGOOOOO 154272 3825 1 3.825 
Q9UN81 ENSGO0000145152 1014 1 1.014 
Q9NTR7 ENSGO00001 12319 1842 17 82.18 
Novel ENSGO0000153889 471 1 0.471 
Q9BXE6 ENSGO0000164473 372 1 0.372 
TCF21 ENSGO00001 18526 1254 2 3.12 
TBPL-I ENSGO0000028839 558 6 6.91 
Q96MR8 ENSGO0000146411 1329 4 27.7 
SGK ENSGO00001 18515 2354 12 5.6 
Novel ENSGO0000153894 204 1 0.204 
ALDH8A1 ENSGOOOOO 118 514 2536 7 32.7 
HBSIL ENSGO00001 12339 2046* 17 88.37 
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L MYB ENSGO00001 18513 3676* 16 37.86 
Q9NXTI ENSGO0000135541 5267* 26 208.27 
Novel ENSGO0000164478 372 1 0.372 
Novel ENSGOOOOO 164479 132 1 0.132 
Q9BZ40 None available 1266 11 90.00 
Q9BZ38 ENSGO0000146410 1152 5 11.86 
Q9NYF8 ENSGO0000029363 5538* 13 31.27 
MAP7 ENSGO0000135525 2238* 17 204.55 
MAP3K5 ENSGO0000008177 4137 29 234.4 
PEX7 ENSGO00001 12357 1448 10 91.34 
Novel ENSGO0000146391 885 2 1.9 
IL20RA ENSGOOOOOO 16402 3485 7 45.00 
Q96A41 ENSGO0000164485 2754* 7 29.69 
ENSGO0000146394 561 1 0.561 
IFNGRI ENSGO0000027697 2096 7 21.93 
Novel ENSGO0000146392 768 1 0.768 
TNFAIP3 ENSGO00001 18503 4425 9 15.86 
Q9H230 ENSGO00001 12378 1875 3 16.59 
Novel ENSGOOOOO 164422 327 4 42.43 
Q9GZYI ENSGOOOOO 118 531 405 1 0.405 
Novel ENSGOOOOO 164423 344 4 0.344 
Q9ULH6 ENSGO00001 12379 5421 24 74.96 
C6orf34 ENSGO0000051620 1197 4 9.16 
Q9P2JO ENSGO0000135540 4023 3 9.47 
Novel ENSGOOOOO 151992 687 4 124.92 
Q9Y430 ENSGO0000024862 1245 6 19.55 
NM016557 ENSGOOOOO 118 519 1858 1 1.858 
REPS I ENSGO0000135597 2435 19 43.05 
Q9PIF3 ENSGO0000146386 818 3 14.6 
Q9UB 19 ENSGOOOOO 112403 5614 4 45.69 
Novel ENSGOOOOO 164440 2055 10 46.37 
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14287 ENSGO0000151997 
Q9CO63 ENSGOOOOO 151998 
Novel ENSGOOOOO 164443 
471 1 0.471 
660 9 51.29 
153 1 0.153 
Table 3A. 3 Transcript length, number of exons and size of genomic region covered by genes 
positioned within the region of 6q containing a cluster of leukaemia related translocation 
break points. Genes are listed according to position in a centromeric to telomeric orientation. 
* more than one splice form of this gene, size and exon number presented are for the largest 
transcript. 
Gene Structure and function of gene 
HEY2 
Novel 
Q9NQES 
Q9NQE9 
Q9NQFO 
Novel 
Q9BXY4 
Hairy/enhancer of split related (Drosophila) with YRPW motif 2. 
BHLH protein Expressed during embryogenesis 
Unknown function 
Novel protein similar to Drosophila L82. 
Novel protein similar to protein kinase C inhibitors. 
Novel protein similar to S po. 
Function unknown 
Thrombospodin type 1, member of 3 member family. 
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Q9NTX6 
Q9NTX5 
043158 
Q9UGCI 
Novel 
Novel 
PTPRK 
Q9UN81 
LREI 
LAMA 2 
Q96564 
Q96JM7 
Novel C3HC4 type zinc finger (ring finger) protein. 
Uncharacterised hypothalamus protein. 
Function unknown. 
Function unknown. 
Function unknown 
Function unknown 
Protein-tyro sine phosphatase, receptor type kappa. Involved in the 
Regulation of cell contact and adhesion, growth control, tumour 
Invasion and metastasis. 
Function unknown 
Contains a reverse transcriptase domain, member of a 300 member 
LINE I reverse transcriptase family. 
Laminin alpha 2, also known as merosin. Mutations are the cause of 
congenital merosin-deficient muscular dystrophy. Thought to mediate 
the attachment, migration and organization of cells into tissues during 
embryonic development. 
RhoGAP containing protein, function unknown. 
Function unknown. 
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Novel Function unknown 
Q96PX5 Function unknown 
EPB41 L2 Erythroid membrane protein band 4. I-like 2, also known as generally 
expressed protein 4.1 (4.1 G). Major structural element of the 
erythrocyte membrane skeleton which stabilizes spectrin-actin 
interaction. Also associates with the nuclear mitotic apparatus. Widely 
expressed. 
AKAP7 A-kinase anchor protein 7. Targets the cAMP-dependent protein kinase 
(pka) to the plasma membrane. 
ARGI Arginase I (liver type arginase), essential component of the Urea cycle. 
CRISP3 Cofactor required for Sp I transcriptional activation subunit 3, vitamin 
D3 receptor interacting protein. 
Q9NTTS Phosphodiesterase I nucleotide pyrophosphotase 3 (PDNP3). 
Novel Ectonucleotide pyrophosphatase / phosphodiesterase 1 (ENPP 1), plasma 
membrane glycoprotein PC 1. 
OR2A4 Olfactory receptor like protein 
095046 Meningioma expressed antigen 6/11, transcription factor. 
ENPPI Ectonucleotide pyrophosphatase / phosphodiesterase 1, may have a role 
In regulation of n-glycosylation. 
Novel Function unknown 
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Novel Function unknown 
CTGF Connective tissue growth factor precursor, also known as hypotrophic 
Chondrocyte-specific protein 24 and insulin-like growth factor-binding 
Protein (IGFBP8). Promotes proliferation and differentiation of 
Chondrocytes. 
Q9Y4U3 Monooxygenase X. 
STX7 Syntaxin 7, mediator of endocytic trafficking. 
GPRI02 Trace amine receptor. 
Q96R 18 Trace amine receptor. 
014804 Trace amine receptor. 
GPR58 Trace amine receptor. 
Q96RJO Trace amine receptor. 
VNNI Vascular non-inflammatory molecule I (VANIN 1), involved in the 
recycling of pantathenic acid. Expressed in spleen, thymus, peripheral 
blood lymphocytes and small intestine. 
VNN3 Vascular non-inflammatory molecule 3 (VANIN 3), thought to be a 
hydrolase involved in the control of lymphocyte migration into tissues. 
VNN2 Vascular non-inflammatory molecule 2 (VANIN 2), involved in the 
homing of bone marrow cells to the thymus. May regulate beta-2 
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integrin-mediated cell adhesion, migration and motility of neutrophils. 
NM052831 Function unknown 
RPS12 40S Ribosomal protein S12. 
Q9UN80 Line I reverse transcriptase, member of 300 member family. 
Q9UN81 Function unknown. 
Q9NTR7 Eyes absent homologue (Drosophila) 4 (EYA 4), member of four 
Member family. Mutations are cause of late onset deafness. 
Novel Line I reverse transcriptase, member of 300 member family. 
Q9BXE6 Function unknown 
TCF21 Transcription factor 2 1, also known as Podocyte expressed I (POD- 1), 
Epicardin or Capsulin. 2 members in family. 
TBPL-I TATA box binding protein like protein 1, also known as TATA box 
binding protein-related factor 2 or Stud protein. Ubiquitously expressed 
DNA binding protein. 
Q96MR8 Similar to glucose transporter type 2, member of 2 member solute 
carrier family. 
SGK Serum /glucocorticoid-regulated kinase (serine/threonine-protein 
Kinase), member of 23 member family. 
Novel Function unknown, has a bipartite nuclear localization signal. 
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ALDH8A1 Aldehyde dehydrogenase family member 8 Al (13 members in family) 
HBSIL HBS I (S. Cerevisiae)-like protein, member of 17 member Elongation 
factor I alpha family. Contains GTP binding elongation factor and ATP 
/GTP- binding site motif A domains. 
L-MYB MYB proto-oncogene protein (C-MYB), expressed at high levels 
in early lymphocyte development and reported to be deregulated, as a 
result of translocation or mutation, in leukemia. Member of, 3 member 
family. 
Q9NXT1 Function unknown, contains SH3, RecA bacterial recombination 
protein and G-protein beta WD-40 repeat domains. 
Novel Function unknown. 
Novel Glyceraldehyde 3 phosphate dehydrogenase, member of, II member 
family. 
Novel Glyceraldehyde 3 phosphate dehydrogenase, member of, II member 
family. 
Q9BZ40 High affinity cAMP-specific 3 ', 5'-cyclic phosphodiesterase (Roliprim 
Insensitive phosphodiesterase type 7) 
Q9BZ38 Novel protein, function unknown. 
Q9NYF8 BCL-2- associated transcription factor. 
MAP7 Microtubule associated protein 7, predominantly expressed in epithelial 
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cells. 
MAP3K5 Mitogen activated protein kinase, kinase, kinase 5 (MEKK5) also 
Known as Apoptosis signal regulator kinase I (ASK). Member of 2 
member serine/threonine protein kinase family. Overexpression induces 
apoptosis. 
PEX 7 Peroxisomal targeting signal 2 receptor (PTS2 receptor) also known as 
peroxin. Plays an essential role in peroxisomal protein import. Defects 
in PEX 7 are the cause of rhizomelic chondrodysplasia punctata type 1. 
Novel UDP glucuronic acid/UDP N acetylgalactosamine transporter (UDP 
GLCA/UDP GALNAQ, member of 3 member family. 
IL20RA Class 11 cytokine receptor 2CYTOR 7 also known as interleukin 20 
receptor alpha. 
Q96A41 Soluble cytokine class 11 receptor also known as interleukin 22- 
binding protein. 
PRO1828 Function unknown 
IFNGRI Interferon- Gamma receptor alpha chain precursor (IFNGR1), member 
Of class 11 cytokine receptor family. 
Novel Protein kinase C binding protein Rack 17 has bHLH dimerisation 
Domain. 
TNFAIP3 Tumor necrosis factor, alpha-induced protein 3, also known as Zink 
Finger protein A20. Inhibitor of tnf-induced gene expression and 
apoptosis. Has a role in the function of the lymphoid system. 
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Q9H230 I P53-induced protein PIGPC 1. 
Novel I Function unknown. 
Q9GZYI I UC28 protein. 
Novel I Function unknown 
Q9ULH6 I KIAA 1244 protein (fragment), function unknown. 
C6orf34 I Putative heme binding protein. 
Q9P2JO I KIAA 13 57 protein (fragment), function unknown. 
Novel I Function unknown. 
Q9Y430 I Hypothetical protein fragment, function unknown. 
NM_016557 CC Chemokine receptor type 11 (C-C CKR-11) also known as 
chemokine receptor-like I (CCRLI). Member of 15 member 
family. 
REPSI I Function unknown 
Q9PIF3 I Hypothetical protein. 
Q9UB 19 1 Homologue of Drosophila Head case. 
Novel I Specific response 5 (member of 5 gene family) 
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Q14287 
Q9CO63 
Novel 
Member of 300 member LINE I reverse transcriptase family. 
LYST-interacting protein (LIP5) 
Member of 3 member ATP synthase B chain, family. 
Table 3A. 4 Function of genes positioned within the region of 6q containing a cluster of 
leukaemia related translocation breakpoints. 
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